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The mode of action of the novel hypoglycaemic agent,Wy 23675,has 
been compared with that of the sulphonylurea,tolbutamide,and that of 
the biguanide,phenformin#
Wy 23675 has been shownflike tolbutamide,to stimulate insulin 
release,but it has also been shown to have an insulin—indeoendant 
hypoglycaemic activity# Wy 23675 lowers blood glucose levels in both 
normal and alloxan-diabetic rats in contrast to phenformin,which does 
not affect blood glucose levels in the normoglycaemic rat#
Wy 23675 has been shown to stimulate glucose utilisation in vivo 
indepenc^it of any effect on insulin release,whereas tolbutamide is 
only active when it can stimulate insulin release# Phenformin 
stimulated glucose utilization in vivo.but only in hyperglycaemic 
conditions#
Phenformin stimulated glucose utilization by hemidiaphragms at a 
lower concentration when they were prepared from alloxan-diabetic rats 
than from normal rats# Phenf ormin caused a decreased glycogen content 
and an increase in lactate production in the hemidiaphragm,suggesting 
an increase in glycolysis and a possible inhibition of lactate oxidation# 
Phenf ormin,in high concentrations,stimulated glucose utilization by 
adipocytes prepared from normal and alloxan-diabetic rats#
Wy 23675 stimulated glucose uptake into isolated hemidiaphragms 
and adipocytes prepared from normal and alloxan-diabetic rats# In 
hemidiaphragms fWy 23675 caused an increase in glycogen synthesis with 
no effect on lactate or pyruvate production# The measured increase din 
glucose uptake could not be solely accounted for by the measured 
increase in glycogen content,suggesting!-an: increase in glucose 
oxidation# The possibility that Wy 23675 could activate pyruvate 
dehydrogenase is discussed#
Both phenformin and Wy 23675 inhibited gluconeogenesis from lactate 
pins pyruvate and from dihydroxyacetone,but not from xylitol in 
hepatocytes prepared from fasted#normal or alloxan-diabetic rats#
(i)
these drugs to inhibit gluconeogenesis than did hepatocytes from 
alloxan-diabetic rats or hepatocytes from fasted,normal rats which 
were stimulated by glucagon#
The pattern of hepatic metabolite levels following phenformin 
treatment of alloxan-diabetic rats showed a negative cross-over 
between 3-phosphoglycerate and dihydroxyacetone phosphate# Measurement 
of appropriate metabolite ratios showed a more reduced state in the 
cytosol and mitochondria and these redox changes are discussed#
Wy.23675 treatment resulted in a negative cross-over between malate 
and phosphoenolpyruvate indicating a possible effect on the enzyme 
phosphoenolpyruvate carboxykinase,although this was hot supported in 
a preliminary in vitro experiment#
(ii)
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This thesis compares the hypoglycaemic effects of a novel agent,
Wy 23675,with those of the two main clinically used groups of oral 
hypoglycaemic agents - the sulphonylureas,as represented by tolbutamide, 
and the biguanides,as represented by phenformin.
Drugs can cause a lowering of blood glucose levels by a variety of 
mechanisms. They may act indirectly by stimulating insulin release or they 
may cause an increase in glucose utilization and/or inhibit gluconeogenesis. 
They may also act by preventing the absorption of glucose from the gut or 
by lowering the renal threshold for glucose so that glucose is cleared in 
the urine.
Insulin
Insulin has profound effects on carbohydrate,protein and fat metabolism 
in liver,muscle and adipose tissue. The net result of these effects is a 
reduction in blood glucose,amino acid and free fatty acid levels and an 
increase in glycogen,fat and protein synthesis.
<
Insulin Effects In The Liver.
In the liver,insulin affects carbohydrate metabolism by inhibiting 
*
catabolic processes and stimulating glycogen synthesis (1). Insulin can 
suppress gluconeogenesis,but only in circumstances where it is stimulated. 
For example,insulin has no effect on basal rates of gluconeogenesis from 
different substrates in isolated hepatocytes,but it does inhibit the 
glucagon stimulation of gluconeogenesis (2,3)* Similarly,insulin has no 
effect on the basal activities of the key enzymes involved in gluconeogenesis 
and glycolysis Ceg: glueokinase,phosphofructokinase,pyruvate kinase,fructose 
bisphosphatase (4)],but does counteract the effects of glucagon on these 
enzymes [eg: insulin counteracts the inhibition of pyruvate kinase by 
glucagon (5)3. It has also been shown that insulin reverses all glucagon- 
induced changes in metabolite levels involved in gluconeogenesis,which 
suggests a similar site of action (5)* Also,in alloxan-diabetic rats, 
where rates, of gluconeogenesis are markedly elevated,insulin has inhibitory j
carboxylase,phosphoenolpyruvate carboxykinase,fructose bisphoaphatase 
and glucose-6-phosphatas e) and increases the levels of glycolytic enzymes 
(eg: glueokinase,phosphofructokinase and pyruvate kinase) (8)# Thus,the 
effects of insulin in the liver are to decrease glucose production#
Insulin Effects In The Muscle#
In muscle,glucose transport is the principle rate-limiting step for 
glucose utilization;insulin accelerates this process (9-13)# Insulin 
stimulates glycogen formation in muscle and is able to do so even when 
bound to dextran and unable to enter the cell (1*0# The effect of insulin 
on glucose transport has been separated from its effect on glycogen 
synthesis (15) • Insulin stimulates glucose oxidation to carbon dioxide, 
glycogen synthesis and glycolysis (l6);the effects on glycolysis being 
independant of the effect on glucose transport (17,18)# Insulin appears 
to stimulate the synthesis of all proteins in muscle (19), It stimulates 
the incorporation of amino acids into protein (20,21) and this effect is 
independant of the stimulatory action on the transport of certain amino 
acids (22,23) - insulin stimulates the incorporation of all natural amino 
acids into protein,including those formed intracellular jfy (2*0 # insulin 
reduces plasma amino acid levels,in part at least,through suppression of 
their release from muscle (25)# Thus,in muscle insulin stimulates glucose 
uptake and utilization and protein synthesis,and reduces proteolysis and 
amino acid release.
Insulin Effects In Adipose Tissue#
In adipose tissue,insulin enhances glucose transport (26,27) and 
increases carbon dioxide production from glucose as well as the synthesis 
glyceride-glycerol,fatty acids and glycogen (27) ~ this is independant of 
its effect on glucose transport (28-30). Insulin stimulates amino acid . 
transport into fat cells (31) and increases their incorporation’ into * 
proteins (32)# As well as stimulating glycerol and fatty acid synthesis,
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stimulation of pyruvate dehydrogenase (33-35). Thus,the effects of insulin 
in adipose tissue are to enhance glucose uptake and utilization,to promote 
glycerol and fatty acid synthesis,while inhibiting the stimulation of 
lipolysis,and to increase amino acid incorporation into protein.
Mechanism Of Insulin Action.
The mechanism by which insulin exerts its biochemical effects remains 
unclear. Several insulin-responsive enzyme systems have been linked to the 
regulatory influence of cyclic adenosine-31,5*-monophosphate (cAMP) - for 
example,glycogen synthetase and phosphorylase in muscle (36,37)*liver 
(3^,39) and adipose tissue (^-0 ,^1),and the hormone-sensitive lipase in 
adipose tissue (^2,^3). Thus,insulin may act by altering intracellular . 
levels of cAMP. Support for this concept comes from reports showing that 
insulin inhibits the rise in cAMP due to submaximal concentrations of : 
hormones opposing insulin action - for example,catecholamines and glucagon 
in the liver (kk~k6) and adipose tissue (^ -7,^ 8), It has also been shown 
that insulin inhibits adenylate cyclase in plasma membranes of liver
(^9*50) and stimulates phosphodiesterase in liver and fat cell homogenates
*
(31-59). However,other groups have found that under certain conditions 
insulin had no effect (60-63) or increased (6*f) cAMP in adipocytes while 
inhibiting lipolysis. Also,in muscle cAMP levels have been observed to 
remain constant (63) or increase (66) in the presence of insulin,while 
glycogen synthetase activity was stimulated. Recent evidence suggests that 
the effects of insulin on hepatocyte glucose output can be dissociated 
from effects on intracellular cAMP. It has been reported that insulin 
decreases basal glucose output in liver slices incubated in a high K+ 
medium with no effect on cAMP (67). Also,in isolated hepatocytes insulin 
antagonized the increased rates of gluconeogenesis due to adrenaline (68), 
which has been demonstrated to act on this process by a cAMP-independant 
mechanism (69,70), Insulin action on gluconeogenesis has been shown to 
be unaffected,while its effects on cAMP were abolished in the absence of
4
whereas the antilipolytic action does not.
More recently,a unified hypothesis of insulin action involving 
intracellular Ca++ flux has been proposed (72-75), Basically,it proposes 
that the primary action of insulin is to trigger the release of plasma 
membrane-bound Ca into the cytoplasm,which results in a rapid rise in 
intracellular free Ca++ followed by an increased uptake into mitochondria !
and,perhaps,endoplasmic reticulum stores. The increased cytoplasmic and f
mitochondrial Ca++ concentration is purported to mediate the actions of !
j
insulin on membrane transport and intracellular enzymes,which stimulate j
glycogenesis and lipogenesis and decrease lipolysis and glycogenolysis, i
In support of this concept,it has been shown that several' effects of ‘ ji
insulin or agents that mimic its actions in muscle require Ca++ in the j
j
medium (76-80)|increased Ca++ flux has been observed in various conditions j 
mimicking insulin action (73*81-85);and insulin has been shown to have j
direct effects on Ca++ flux (86-92), However,this model cannot explain j
all the actions of insulin. For example,it seems that the response of j
+ + Icertain insulin-sensitive enzyme s/stems to Ca is in the opposite j
direction to that of insulin (93-97)* I
s
\
\
Sulphonylureas j
The hypoglycaemic effects of the sulphonylureas were originally j
thought to be entirely due to the stimulation of insulin release from j
the pancreas (98-101), This conclusion is supported by studies which 
showed that there was an increase in the 1 insulin-like * activity of
r ,
pancreatic venous blood following intravenous injection of tolbutamide 
- Goetz and Egdahl (99) assayed this activity by the hypoglycaemic :
response in mice, Pfeiffer et al (100) found that three hours after j
I *'
administration of tolbutamide to calves the extractable insulin content j.
{
of the pancreas was reduced by about 75% \ Hoot (101) observed similar |
[■
L ■
changes in the dog, j
humans (102-105),cats (106),or dogs (107-109)* Similarly,sulphonylureas 
do not reduce blood glucose concentrations in alloxan-diabetic rats (1IQ- 
113),rabbits (11*0 ,or dogs (115)*
Direct effects of sulphonylureas on the pancreatic JB-cells have been 
shown, The cells lose their granules under the influence of these agents 
(116) and the amount of insulin recoverable from the pancreas falls in 
parallel with the degranulation (117)* Furthermore,electron microscope 
studies have shown that the /3-cell granules are contained in membranous 
sacs which move under the influence of the sulphonylureas to the cell 
membrane,where they expel their contents into the pericellular fluids 
by a process called emiocytosis (118),
However,although acute treatment with sulphonylureas does clearly 
cause an elevation of plasma insulin levels (119-121),it has been shown 
that chronic oral therapy with sulphonylureas can reduce blood glucose 
levels without increasing absolute circulating insulin levels (122-125)* 
It has also been shown that plasma glucose concentration can be lowered 
by sulphonylureas without a rise in plasma insulin concentration when 
given acutely to dogs (126), Also the hypoglycaemic response to an 
increase in plasma insulin due to the administration of sulphonylureas is 
preceded by a lag period,and it continues after insulin values have 
returned to basal levels (119)* These results cannot be explained by an 
inhibition of glucagon release as sulphonylureas have no effect on this 
(127),although there is some evidence to suggest that they can inhibit 
catecholamine release (128), Loubatieres et al (129) have put forward 
the proposal that the effects are due to a ’secretagogue amplifying’ 
effect of the sulphonylureas,
Sulphonylurea Effects On Glucose Absorption From The Gut And On The
Renal Threshold For Glucose,
Sulphonylureas have been reported by some workers to have no effects
on (130-132) and by others to inhibit (133) glucose absorption from the
6
responsive diabetics is accompanied by decreased glucosuria (13^,135)#
Other Effects Of Sulphonylureas#
Very few other direct positive effects of sulphonylureas other than 
those on the pancreas have been reported,which could contribute to their 
hypoglycaemic effects# Tolbutamide,in varying concentrations,has been 
reported to increase (136),inhibit (137),and to have no effect on (138-14-0 ) 
glucose uptake by diaphragms from normal rats# Some workers have found that 
glycogen synthesis was increased (14-1) and others that it was decreased 
(14-2,14-3) by sulphonylureas#
Glucose uptake by adipose tissue (14-4-) and brain (14-5) has not been 
found to be affected by sulphonylureas,but it has been claimed that the
• 14-incorporation of C from isotopic glucose into fatty acids was inhibited 
(14-6)# Several workers have reported antilipolytic effects on adipocytes 
(14-7-152) and this action could lower blood glucose levels by decreasing 
the available plasma free fatty acids for oxidation by muscle,thus 
increasing muscle glucose oxidation and lowering of blood glucose levels 
(133).
In the liver,sulphonylureas cause a rise in glycogen content (154-), 
although this is dependant upon the presence of some intrinsic or extrinsic 
insulin (153). Sulphonylureas have been shown to diminish glucose release 
from the liver both in vitro (156) and jLn vivo (157). Tolbutamide has also 
been shown to inhibit the conversion of fructose to glucose in the livers 
of diabetic subjects (104-)# Sulphonylureas inhibit intrahepatic triglyceride 
lipase (158,159) : this hormone-sensitive enzyme is thought to contribute ' 
to the regulation of gluconeogenesis,perhaps by regulating the flow of, 
energy and regulatory acetyl CoA units from stored fatty acids,so that’ 
inhibition of the lipase could contribute to blood sugar lowering through< 
inhibition of gluconeogenesis# Sulphonylureas have also been shown to 
limit the movement of substrate anions across the inner membrane of 
hepatic mitochondria (160,161) and other workers (162) have concluded
7 :
greatly dependant upon anion movement into and out of mitochondria,such 
an action of sulphonylureas in the liver could help to reduce blood 
glucose levels.
Sulphonylureas have been shown to affect transmembrane 
Ca++ fluxes in several tissues (133*135) ; these effects,as with insulin, 
may play a part in the hypoglycaemic activity of these agents.
In summary,sulphonylureas elevate plasma insulin levels when given 
acutely,but are capable,with chronic administration,of reducing blood 
glucose concentrations without affecting plasma insulin levels. Most of 
the in vitro effects of sulphonylureas require the presence of insulin, 
so that their jLn vivo capability of reducing blood glucose concentrations 
without affecting plasma insulin levels is probably due to an ability to 
potentiate some of the metabolic effects of insulin.
Biguanides.
Guanidine was shown to be hypoglycaemic following a rise in its
concentration in the blood stream in 1918 (163)* Various chemical
»
modifications of the molecule were attempted and it was shown that a 
free guanidine group was necessary for the hypoglycaemic effect (l6*f).
The general formula for all the hypoglyaemic derivatives of guanidine is:-
N— C.
R^
The biguanides are the only guanidine derivatives which have been 
significantly used in the treatment of diabetes. Phenformin,which was 
first synthesized in 1929 has been studied in man (165) and was introduced 
in the U.S.A. for the treatment of diabetics some thirty years later.
The other biguanides most commonly used in the treatment of diabetes are 
buformin and metformin. However ,with the recent awareness of -’the 
lacticacidosis associated with biguanides,phenformin has now been 
withdrawn from the United States market and their use elsewhere appears
: 8
G H„ NH-G-NH-G -NH
n T  2 2 ii n 2
Buformin
N -butylbiguanide
Metformin 
1 1N ,N -dimethylbiguanide
CHt NH NH
3
Very large doses of biguanides are necessary to lower blood glucose 
levels in normal rats and man (166,167),whereas relatively small doses
are required to lower blood glucose levels in diabetic man (168-172) and 
in experimentally-induced diabetic animals (167,173*17*0 #
Biguanides tend to become concentrated in certain organs in the body* 
Rats given radiolabelled phenformin have nearly all the radioactivity in 
the digestive tract and liver and almost the whole dose is excreted by 
the kidneys within 2k hours (175,17^)# However,these results do not 
necessarily indicate a selective concentration of the active drug,as almost 
all the radioactivity in the rat liver can be attributed to metabolic 
products of the biguanide (176)#
There is considerable species variation in the extent of the metabolis 
of phenformin and this is largely reflected in its degree of hypoglycaemic 
activity. Phenformin is almost completely metabolized in the rat liver, 
mainly to p-hydroxyphenformin glucuronide (177-179),while in the 
guinea-pig,an animal which is very sensitive to the hypoglycaemic effects 
of phenformin,the extent of its metabolism in the liver is very much less
(180.181). p-Hydroxyphenformin is not an active hypoglycaemic agent
(177.182) and Cook et al (180) have shown that guinea-pigs treated with 
3 ,*f-benzpyrene,an inducer of microsomal hydroxylation,had a decreased 
hypoglycaemic response to phenformin. They also showed that rats treated 
with Lilly l89*f-7,&n inhibitor of hepatic microsomal hydroxylation,had an 
enhanced hypoglycaemic response to phenformin (180). Similarly,phenformin
9
metabolism of phenformin in the rat liver plays an important role in its 
relative lack of hypoglycaemic effect in the rat.
Biguanides And Insulin.
Unlike the sulphonylureas,the biguanides do not stimulate insulin 
release from the pancreas (185-185)# However,there is some evidence that 
the presence of insulin is necessary for some o£ the effects of biguanides 
such as the increased peripheral uptake of glucose (167,186-188). In 
contrast to this suggestion other workers have shown that biguanides can 
increase glucose uptake into isolated muscle without the addition of 
insulin (189,190)# Biguanides have also been shown to possess hypoglycaemi 
activity in both alloxan-diabetic (167,173*17*0 and pancreatectomized 
animals (191*192). Thus,insulin is probably relatively unimportant to 
the hypoglycaemic effects of the biguanides.
Effects Of Biguanides On Intestinal Glucose Absorption.
Biguanides have been shown to markedly inhibit the absorption from 
the intestine of glucose,amino acids,lipids,ions and water (193-20*0 #
As biguanides have also been shown to accumulate in the intestine (175*176 
it has been suggested that part of their hypoglycaemic action may be 
through inhibition of intestinal glucose absorption. Gardner and Langslow 
(20*0 have shown that phenformin is tightly bound within the mucosal 
cells of the intestine and have suggested this as the site of action of 
phenformin on intestinal glucose absorption. Other workers (205*206) 
have shown a reduction in intestinal ATP and this could account for the 
inhibitory effects of biguanides on intestinal glucose absorption.
However,since several other biguanides inhibit oxidative phosphorylation 
yet have no hypoglycaemic properties (207) this may be irrelevant to 
the hypoglycaemic effect of phenformin. While diminished glucose 
absorption would restrict the increase in blood glucose concentration 
following a meal,it would not account for a hypoglycaemic effect in the
10
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Effects Of Biguanides On Mitochondrial Respiration And On Gluconeogenesis, 
Biguanides are potent inhibitors of mitochondrial respiration and 
oxidative phosphorylation (189,190*208-215), Thus,the concept was introduc 
that biguanides could inhibit gluconeogenesis by reducing cellular supplies 
of adenosine triphosphate - ATP (189,190*209), However,this hypothesis is 
very tenuous for several reasons:-
1, The correlation between potency as respiratory inhibitors in vitro and 
hypoglycaemic activity in vivo is very poor (20?).
2, The concentrations of biguanide required for respiratory inhibition are
several orders of magnitude greater than those observed in tissues with
the usual therapeutic doses in vivo (178,207,216-219),
3, The theoretical ratio of high energy phosphate required- to glucose'
produced is 6:1 , 2:1 , and 1.2:1 for gluconeogenesis from lactate,
dihydroxyacetone and xylitol,respectively. Thus,the observation that 
phenformin decreases the rate of gluconeogenesis from both lactate 
and dihydroxyacetone to about the same extent and has no effect on 
gluconeogenesis from xylitol (181) suggests that the effect of
phenformin on gluconeogenesis is not directly related to energy 
requirements.
Other workers have found that the inhibition of gluconeogenesis by 
biguanides does not correlate with a measured drop in ATP levels' (220). i 
5* Inhibition of gluconeogenesis in liver (221-223) and stimulation of ! 
glucose uptake into skeletal muscle (22*0 has now been observed in' ■} )
j
vitro at concentrations of biguanide too low to be associated' with' ' !
inhibition of mitochondrial respiration. j
6. In the intact animal or in the patient,biguanides in therapeutic j
%
doses do not restrict hepatic oxygen uptake (225) or overall carbon I
' J ;
dioxide production from glucose (226,227), On the contrary,Unger et al j
I:
(228) have reported a stimulation of tissue respiration,while metformin j 
has not been found to inhibit tissue respiration even at high doses' |
(229),
normal rats (230) and man (226,227) and there is direct evidence of 
increased glucose uptake by muscle,as shown by human forearm studies 
083,186) . Losert et al (230) have reported an increased oxidation of 
glucose to carbon dioxide and an increase in blood lactate concentrations. 
Searle and Cavalieri (227) report an increase in glucose turnover in 
normal human sujects due to increased gluconeogenesis from lactate# They 
suggested that the increased gluconeogenesis was due to the increased 
lactate availability,following the increase in glucose utilization# They 
found no decrease in blood glucose levels in the normal man (227,231), 
while biguanides did lower blood glucose levels in diabetic man (168-172)# 
They explained this by suggesting that in normal man the increased 
peripheral glucose utilization was compensated for by increased gluconeo­
genesis from lactate,while in diabetic man gluconeogenesis was already 
maximally stimulated and could not be further increased by the increased 
availability of lactate,thus leading to a fall in blood glucose levels in 
diabetic,but not normal man# However,this hypothesis can be critized on 
several grounds:-
1* The pigeon has bepn shown to be sensitive to the hypoglycaemic effects 
phenformin,but in vitro pigeon muscle appears to be unaffected by 
phenformin (232) ; so it is unlikely that theories for the peripheral 
action of phenformin could explain its hypoglycaemic effects in the 
pigeon#
2# Phenformin has been shown to inhibit gluconeogenesis in both high 
concentrations (180,181,190,209,221,233*^237) &nd at concentrations 
associated with therapeutic administration of the drug (221-223) ; the 
latter concentrations being too low to be associated with inhibition 
of mitochondrial respiration# Furthermore,it has been shown that 
.phenformin can inhibit gluconeogenesis by livers from diabetic rats 
at lower concentrations than those required for normal rats and 
Connon (238).has suggested that this may offer an explanation for the
12
being inactive in normal rats and man#
3. Recent work by Dietze et al (239) has shown an inhibition of hepatic 
gluconeogenesis in normal volunteers following five days pretreatment 
with phenformin (3 x 50mgs daily)# However,they also showed an increase 
in hepatic venous concentration ratio of p-hydroxybutyrate:acetoacetate, 
indicating the possibility of interference with oxidative phosphorylatio 
Iyngsoe (240) has also shown a decreased gluconeogenesis in normal 
starved subjects treated with phenformin# These results support tfce 
in vitro findings of inhibition of hepatic gluconeogenesis#
Effects Of Biguanides On Adipose Tissue#
Biguanides tend to favour weight loss and have been shown to have a 
beneficial effect in human obesity (241-243),so there has been considerable 
interest in their effects oja fat metabolism. These effects on weight loss 
could not be attributed to anorexia (242,24-3)#
Phenformin therapy in obese diabetics has been shown to result in 
reduced plasma levels of free fatty acids,cholesterol and triglycerides 
(244-249)# In vitro,phenformin and other biguanides have been shown to 
inhibit lipolysis (147*149,230,231)• However,for the most part,the 
antilipolytic effect of phenformin has only been demonstrated with 
concentrations of the drug,which are higher than those normally observed 
following treatment# Thus,the clinical significance of this action is 
probably limited#
Most workers report inhibitory effects of biguanides on lipogenesis 
(252-236) and these effects have been observed in concentrations similar 
to those seen in the plasma with therapeutic administration of the drug 
(255)# However,some workers report an increase in glucose uptake and 
utilization (256-260),while others have shown that phenformin depressed 
glucose uptake and utilization (251*261,261).
These conflicting results and the often high doses of biguanide 
required to achieve them,makes the analysis of biguanide action in adipose 
tissue and its importance in terms of their hypoglycaemic effects difficul
lipolysis,could lead to an improved glucose tolerance# .However,as has 
been discussed,the antilipolytic action of phenformin only occurs in 
vitro with high concentrations of the drug.
Mechanism Of Action Of Biguanides#
The mechanism of action of biguanides at the cellular level has been 
investigated in some detail by several groups of workers# As has already 
been stated,it was proposed that biguanides act by inhibiting 
mitochondrial respiration and oxidative phosphorylation (189,190,208-215) 
However,for the reasons given earlier it is very unlikely that this 
concept can explain the hypoglycaemic actions of biguanides#
More recently,both Schafer (263) and Davidoff (264) have proposed 
theories to explain the actions of biguanides based on their binding to 
membranes#
Schafer's theories are based on the fact that most processes,which 
are sensitive to the biguanides,are either directly localized in 
membranes or involve membrane-linked reactions as rate-limiting steps# 
Biguanides have a positive charge and Schafer has shown that,in 
binding to membranes,they cause a positive shift in the electrostatic 
surface potential (265*266-268),leading to an inhibition of proton 
translocation (235,266,268). This may be of significance in 
gluconeogenesis on the flux of substrate anions across mitochondrial 
membranes,as anion uptake is driven by the electrochemical gradient of 
protons across the membrane via coupling to the energy-linked uptake of 
inorganic phosphate (269-271)
Davidoff has shown that low concentrations of biguanides enhance 
Ca++ uptake in a concentration-dependant manner (272) and he has 
suggested $hat enhancement of Ca++ uptake is the basis of biguanide 
inhibition of gluconeogenesis (264)# Biguanides,in low therapeutic 
closes,only lower blood glucose levels in situations where the net 
glucagon/insulin signal to the liver is markedly in favour of glucagon 
Cie: diabetes (169) or prolonged starvation (273)1• The proposed
subcellular basis for the inhibition of the glucagon signal to the 
liver is through an alteration in Ca++ binding to mitochondrial and, 
perhaps,other membrane systems,including the plasma membrane and the 
endoplasmic reticulum (264).
Other Hypoglycaemic Agents. I
There are several other hypoglycaemic agents,which are worthy of a j
brief mention in this introduction because of their different modes of
: £
action# These include the indole and quinoline derivatives,dichloroacetate,*
nicotinate,hypoglycin and pent-4-enoate,and diphenyleneiodonium#
Indole And Quinoline Derivatives #
Of the indole and quinoline derivatives,both quinolinic acid and
3-mercaptopicolinate have been extensively investigated. These agents j
are believed to exert their hypoglycaemic effects through inhibiting
the enzyme phosphoenolpyruvate carboxykinase (PEPCK) and thus inhibiting 1
Ii
gluconeogenesis (275-278). Both quinolinic acid (274-) and 3-mercapto- ]
picolinate (275) have been shown to have hypoglycaemic effects in 
starved and diabetic animals,but to have little effect on blood glucose 
levels in normal,fed animalstthis is an indication that they inhibit j
gluconeogenesis,since the process operates minimally in the post- j
absorptive state. I
Ditullio and coworkers (274) showed that 3-mercaptopicolinate j
inhibited gluconeogenesis in perfused livers from lactate,pyruvate and 
alanine,but had no effect on the rate of gluconeogenesis from fructose 
or dihydroxyacetone. These results indicated that the site of inhibition 
was probably at the rate-limiting step controlled by pyruvate carboxylase, 
PEPCK and pyruvate kinase. A cross-over plot,calculated from the 
metabolite concentrations in freeze-clamped perfused livers,indicated |
the phosphoenolpyruvate carboxykinase reaction as a possible site of |
inhibition (276,277). Similar results have been obtained with quinolinic j 
acid (275,278).
A possible mechanism for the inhibition of phosphoenolpyruvate
carboxykinase has been proposed (279) based on the ability of these 
compounds to bind to Fe++ (or Mn++),which are in turn bound to and 
activate PEPCK# The presence of the agent at the metal—ion binding 
site interferes in some way with the catalytic site of PEPCK,
Dichloroacetate#
Diehlorcacetate has been shown to be hypoglycaemic in normal,fasted 
rats (280,281) and in alloxan-diabetic rats (282-286),but not in normal, 
fed rats (282-284)# It increases glucose oxidation and inhibits fatty 
acid oxidation in diaphragm muscle of diabetic rats (283,284) and 
increases glucose,lactate and pyruvate extraction but decreases fatty 
acid oxidation in perfused heart (287,288)# Whitehouse and coworkers 
(281,288) have shown that dichloroacetate activates pyruvate dehydrogenas 
(PDH),probably due to inhibition of pyruvate dehydrogenase kinase,and 
have proposed this as the mechanism of action of dichloroacetate#
Blackshear and coworkers (286) have shown that dichloroacetate 
causes a decrease in the accumulation of lactate,pyruvate and alanine in 
the blood of functionally hepatectomized diabetic animals# These findings 
are consistent with activation of extrahepatic PDH and support the view 
that dichloroacetate causes hypoglycaemia by decreasing the net release 
of gluconeogenic precursors from extrahepatic tissues (280,281)#
Nicotinate#
Nicotinate has been shown to be hypoglycaemic in fasted,normal and 
alloxan diabetic rats (289-292),in mice (293) and during infusions into 
man (294-296)# This lowering of blood sugar is combined with an increased 
respiratory quotient indicating an increased oxidation of carbohydrates 
(297,298)# However,nicotinate has also been shown to have no effect on 
blood glucose levels in man (299) and to actually increase them (300, 
304)# The diversity of these results seems to come from the different 
experimental conditions used,but it does seem likely that nicotinate 
affects glucose tolerance by more than one mechanism#
Dzedin et al (303) have suggested that the stimulatory effect of 
nicotinate on blood glucose levels is at least partially dependant on,g
catecholamines;they showed that the hyperglycaemic effect of nicotinate 
in rabbits was reversed to a hypoglycaemic €ffect if the animals were 
pretreated with sotalolfan adrenergic p-receptor blocking agent#
Nicotinate is believed to lower blood glucose levels by virtue of its 
antilipolytic activity (306-312)# Randle and coworkers (313,314) have 
demonstrated that the increased oxidation of fatty acids which results 
from a rise of plasma free fatty acids brings about the inhibition of 
glucose metabolism (they showed an inhibitory effect of free fatty acids 
and ketones on the uptake and phosphorylation of glucose in isolated 
muscle preparations)# The increase in free fatty acid oxidation brings 
about a rise in acetyl CoA formation and an inhibition of several 
enzymes of the glucose metabolic pathways#
Mechanisms have been proposed for the inhibitory effects of diabetes
$
and of free fatty acid oxidation on pyruvate dehydrogenase,phcjphofructo- 
kinase and hexokinase (315-320)# Fatty acids and diabetes have been shown 
to increase the ratio of acetyl CoA to CoA in the perfused heart (321) 
and such an increase has been shown to inhibit the oxidation of pyruvate 
to acetyl CoA by pyruvate dehydrogenase (318,322)# The increased 
acetyl CoA/CoA ratio may also lead to increased citrate formation through 
citrate synthase# Citrate is an inhibitor of phosphofructokinase and 
elevated levels of citrate have been shown to be induced by fatty acid 
oxidation and by diabetes (319,320,323)# The inhibitory effects of free 
fatty acids and diabetes on glucose phosphorylation have been attributed 
to the inhibition of hexokinase by glucose-6-phosphate# The concentration 
of glucose-6-phosphate is increased in muscle as a result of inhibition 
of phosphofructokinase (314)# Thus,an increase in the acetyl CoA/CoA 
ratio can cause an inhibition of glucose phosphorylation,glycolysis 
and pyruvate oxidation# This mechanism could explain both the decreased 
glucose utilization following the rise of plasma free fatty acids by a 
fat infusion and the improved glucose tolerance following the lowering 
of plasma free fatty acids during perfusion of an antilipolytic agent, 
such as nicotinate#
Hypoglycaemia is caused by hypoglycin (L-2-amino-3-methylenecyclo- 
propylpropionic acid) the toxic principle of the Jamaican ackee fruit, 
Blighia sapida (324-326), The structurally related compound,pent-4-enoate 
has also been shown to cause hypoglycaemia in many species. Both compoun
systems (327-358), It has been suggested that hypoglycin and pent-4-enoat 
inhibit gluconeogenesis secondary to their inhibition of fatty acid 
oxidation,such that glucose is the only major metabolic fuel and when 
glycogen is exhausted,hypoglycaemia ensues (339)# Plasma free fatty acids 
have been shown to be elevated after hypoglycin (340) or pent-4-enoate 
(341) administration to rats. Also hypoglycin poisoning is associated 
with fatty livers (342),when presumably free fatty acids are supplied 
from adipose tissue stores in excess of the amounts that are oxidized 
to carbon dioxide and ketone bodies,and are therefore converted to 
triglycerides,Methylenecyclopropylacetate CoA (methylenecyclopropyl- 
acetate is the active metabolite of hypoglycin) inhibits the maximum 
rate of oxidative generation of acetyl CoA from palmitoy1-carnitine by 
isolated rat liver mitochondria (331),
Billington and coworkers (338,3^3) have proposed that the accumulatio 
of high concentrations of several acyl OoA esters in the mitochondrial 
matrix will interfere with gluconeogenes is by inhibiting the activation 
of pyruvate carboxylase by acetyl CoA, In support of this proposal, 
Williamson and coworkers (336) and Toews and coworkers (344) have 
produced evidence with crossover plots of liver metabolite levels in 
the presence of pent-4-enoate that showed pyruvate carboxylase was 
inhibited.
However,there are other effects of these agents whose contribution 
to their hypoglycaemic action is not yet defined. For example,it has 
recently been demonstrated that the administration of hypoglycin to rats 
can severely inhibit both gluconeogenesis and glucose utilization (343, 
346), There is,however,no quantitative information about the effects of 
hypoglycin or pent-4-enoate on fatty acid oxidation in vivo*nor on the
interfere with p—oxidation and gluconeogenesis in a variety of in vitro
effects of pent-4-enoate on glucose metabolism in vivo (346), Both 
hypoglycin and pent-4-enoate also cause profound hypothermia in small 
animals,which will decrease the absolute rates of metabolism compared 
with control animals (338), However,there are no measurements of the 
effects of hypoglycin or pent-4-enoate on oxygen consumption in animals 
maintained in thermoneutral conditions,so that the contribution of the 
hypothermia to their metabolic effects is not clear,
Diphenyleneiodonium,
Diphenyleneiodonium causes extreme and irreversible hypoglycaemia in 
several animal species (347,348) associated with a potent inhibition of 
gluconeogenesis (348,349)# High doses of diphenyleneiodonium were also 
shown to cause a stimulation of whole body glucose utilization and lactate 
production,but this was not apparent with lower doses where hypoglycaemia 
was still observed (348), Diphenyleneiodonium has been shown to decrease 
the [ A T P ) / ( A D P ] r a t i o  and to decrease the [NAD+J/[NADH] ratio 
(348,349)# These results suggest that diphenyleneiodonium inhibits 
gluconeogenesis by virtue of its ability to inhibit mitochondrial oxidation 
Holland and Sherratt (330-332) / showed that diphenyleneiodonium inhibits 
State 3 and dinitrophenol-stimulated oxidation of succinate and glutamate 
by isolated mitochondria. They proposed that these inhibitory effects of 
diphenyleneiodonium were a consequence of the compulsory exchange of 
chloride ions for hydroxyl ions across the inner mitochondrial membrane, 
which they found diphenyleneiodonium caused in their experiments (34,9)# 
However,their in vitro experiments required high concentrations of 
diphenyleneiodonium and Holland and coworkers (348) were unable to show 
this effect in latter iu vivo work. It seems likely that diphenyleneiodon 
-ium has a direct action on mitochondrial metabolism as it causes marked 
inhibition of glutamate-malate oxidation in mitochondria (348), Further 
evidence comes from the fact that diphenyleneiodonium inhibits NADH 
oxidation in submitochondrial particles and the oxidation of NADH—linked 
substrates added in vitro to intact mitochondria (348),
Concluding Remarks,
Thus,there is a wide variety of mechanisms by which a hypoglycaemic 
agent can lower blood glucose levels. Very little was known about the 
hypoglycaemic agent,Wy 23673,when the present study was started,so that 
initially in vivo comparisons were made with other hypoglycaemic agents. 
These studies were followed by in vitro studies with hemidiaphragms, 
isolated adipocytes and isolated hepatocytes and,finally,a measurement 
of liver metabolite levels. The results of this work are reported in 
this thesis.
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The iigures in this section illustrate the errects or Wy ^5075 on Diooa 
glucose and plasma insulin levels;and compares these effects with those 
of the standard oral hypoglycaemic agents,tolbutamide (a sulphonylurea) 
and phenformin (a biguanide),used in this study# The results illustrate 
the following effects of these agents:-
1# Oral or intravenous administration of Wy 23675 and tolbutamide results 
in hypoglycaemia in the normal rat;phenformin has no effect.
2. Oral administration of Wy 23675 and tolbutamide elevates plasma insulin 
levels in the normal rat;phenformin has no effect,
3. Intravenous administration of Wy 23675 in low dosesfwhich are still 
markedly hypoglycaemic,has no effect on plasma insulin levels;intravenous 
administration of tolbutamide elevates plasma insulin levels,
4-, Inhibition of insulin release by diazoxide does not markedly effect the 
hypoglycaemic action of Wy 23675,while it inhibits that of tolbutamide,
5# Wy 23675,tolbutamide and phenformin are hypoglycaemic in the glucose- 
loaded rat,
6. Tolbutamide further elevates glucose-stimulated plasma insulin levels 
in the glucose-loaded rat,while neither phenformin nor Wy 23673 have any 
further effect.
7. Thus,these results indicate that Wy 23675,tolbutamide and phenformin 
have dissimilar modes of hypoglycaemic action.
.FAKhY STUDIES ON THE HYPOGLYCAEMIC AGENT, WY 25675.
The hypoglycaemic agent,Wy 23675,has been under investigation at 
Wyeth Laboratories,Taplow as a potential antidiabetic agent since 1973,
following the discovery of its hypoglycaemic action. During 1975 it was j
j
appreciated that the toxicity of Wy 23675 precluded its development as j
it
a therapeutic agent for clinical use; however,its novel chemical structure! 
and possible novel mode of action have made it worthy of further j
investigation. Furthermore,it is related in structure to other compounds j
developed by Wyeth Laboratories,which have shown a similar insulin- 
independant hypoglycaemic activity,but without, the poor therapeutic ratio j
exhibited by Wy 23675# Examples of these compounds include mazindol and 
ciclazindol (l-*f).
i
In structure Wy 23675 is chemically dissimilar to existing drugs, j
which are in clinical use as hypoglycaemic agents (Figure 1(i).)« The 
most commonly used groups of orally-administered hypoglycaemic agents 
are the sulphonylureas and the biguanides. Mechanistically,the former 
are thought to act primarily by an action on the pancreatic JB-cells 
(although studies with chronic administration of sulphonylureas have 
indicated extra-pancreatic effects such as direct action on the liver or 
peripheral potentiation of the glucose-lowering effectiveness of insulin) 
and the latter through an action other than stimulation of insulin 
release from the pancreatic jB-cells (5)# It was important to consider to 
what extent the mechanism of Wy 23675 could be attributed to an insulin- 
independant action.
Chemistry.
Wy 23675 was originally developed as a structural analog of another 
Wyeth compound (Wy 23117) being investigated for its antidepressant 
potential. This series of compounds had previously shown marked .
hypoglycaemic activity; and in Wy 23675 this was very marked,which led j
i
to its being considered as a potential antidiabetic agent.
together with that of a biguanide (phenformin) and a sulphonylurea 
(tolbutamide) for comparison#
Methods.
1# General#
Rats used throughout the study,unless otherwise stated,were Charles 
River CD strain,weights 180-220 gms# They were fed on rat pellets (Qxoids 
*f1B) and kept in cages of k in rooms at 22*C with a 12 hour light/dark 
cycle. Drugs administered by the oral route were made up in 0#5% hydroxy- 
propylmethyl cellulose in 0#9% saline (HPMC) vehicle in a dose volume of
1 ml/100 g# body weight# Drugs administered by the intravenous route were 
made up in 0#9% saline in a dose volume of 0#1 ml/100 g# body weight; all 
intravenous injections were made into the tail vein#
2 # Mat ©rials «
Wy 23675 was synthesized by Wyeth Laboratories,Maidenhead,Berks# 
Tolbutamide was supplied by Hoechst Pharmaceuticals,Hounslow,Middx# 
Phenformin was supplied by Winthrop Laboratories,Surbiton,Surrey# 
Diazoxide was supplied by Allen 8c Hanburys Ltd,Ware,Herts#
3# Blood sampling method#
Blood samples were taken throughout the study by cutting the tip off 
the tail of unanaesthetized rats,held in Perspex cylinders with a groove 
cut down the top to allow the tail to pass through,and gently massaging 
it# 0#5 ffll-K of blood was collected into fluoride pots for determinations 
of blood glucose by the ferricyanide method - Teehnicon Autoanalyser 
Method N~l6b# (Blood glucose determinations were made by the staff of 
the Clinical Chemistry Section at Wyeth Laboratories,Taplow)•
*f# Plasma insulin determinations#
Plasma insulin levels were estimated by a competitive binding radio­
immunoassay method on 0#3 mis of blood samples obtained from the tails o 
rats as above and centrifuged in a Beckman microfuge for b minutes# The 
Lepetit radioimmunoassay kit for insulin,which was used,relies upon the
reaction between the insulin to be measured and a standard amount of
antibody,to form an antibody-insulin complex# The concentration of
antibody has been selected to restrict the amount of insulin allowed to
combine,so that following reaction,some fraction of the insulin
originally present remains in the uncombined or 'free* form. Therefore,
as the total amount of insulin present in the system increases,so the
ffreef fractionwill increase,and conversely the proportion of insulin
^ound* to the antibody will decrease.
A tracer amount of radioactive-labelled insulin introduced into the
reaction mixture reflects the distribution of unlabelled and labelled
insulin between the free and bound forms# The distribution of radioactiv
insulin following the reaction thus provides an easy measurement,which
indicates the amount of unlabelled insulin in the system#
A standard response curve or calibration curve is plotted showing
the counts recorded from the unbound insulin fraction against the known
concentrations of unlabelled insulin introduced into the standard
incubation tubes. Insulin concentrations in blood samples are estimated
by comparison with the standard response curve#
The Lepetit kit differs from others principally in the means employe
to isolate the free from the antibody-bound labelled insulin following
reaction# The Lepetit kit relies upon the adsorption of free insulin
onto activated charcoal,the antibody-bound radioactivity remaining in
the supernatant solution# In contrast a radioimmunoassay kit for insulin
from the Radiochemical Centre,Amersham involves a double antibody
technique,where separation of free from bound insulin fractions is by
adsorption of the insulin-bound-antibody complex onto a second antibody
forming an insoluble complex# The free insulin remains in the supernatan
125which is discarded,and the bound complex is counted for I-insulin. Th 
overall time for the assay using the Radiochemical Centre kit is longer, 
as longer incubation period is required between the insulin and insulin— 
antibody.
Effects oa Elood Glucose and Plasma Insulin Levels
YJy 23675 has been shown to have oral hypoglycaemic activity in the
2k—hr fasted,fed,glucose-loaded and alloxan-diabetic rat (Table 1)! and in 
the normoglycaemic mouse,dog and Patas monkey (Wyeth Laboratories, 
unpublished results). The results for Wy 23675 in the rat are compared 
with results from similar experiments with tolbutamide and phenformin in 
Table 1. Tolbutamide had hypoglycaemic effects in all situations where it 
was able to stimulate insulin release (ie: 2k-hr fasted,fed and glucose- 
loaded rats),but not where .-insulin release could not be stimulated (ie:the 
alloxan-diabetic rat). Phenformin lowered blood glucose levels in the 
fasted,glucose-loaded and alloxan-diabetic rat,but not in the normal,fed 
rat.
Figure 1(ii) illustrates the oral hypoglycaemic acivity of'Wy 23675 
as compared with that of the sulphonylurea,tolbutamide,in normoglycaemic, 
fed rats. The hypoglycaemic effect of Wy 23675 occurs over a narrower 
dose range than that of tolbutamide,first becoming apparent at about 0.04 
mmol/kg p.o. and almost maximal by 0.k mmol/kg p.o.. Tolbutamide appears 
to be less potent than Wy 23675 at low doses,but its maximal hypoglycaemic 
activity is markedly greater than that achieved with Wy 23675. The 
biguanide,phenformin,showed no hypoglycaemic effects in the normoglycaemic 
fed rat at doses up to 0.8 mmol/kg p.o. (results at Wyeth Laboratories,not 
shown,6),
Wy 23675 administered by the oral route to normoglycaemic fed rats 
stimulates insulin release (Fig. 1(iii).)fwhereas given intravenously at 
lower doses,it has no effect on plasma insulin levels,but retains its 
hypoglycaemic action (Fig. 1(iv).). YJhen animals were pretreated \^ ith 
diazoxide,in order to suppress insulin release from the pancreas(7,8), 
the oral administration of Y/y 23675 still provoked a hypoglycaemic 
response despite the lack of stimulation of insulin release (Fig, 1(v).). 
In glucose-loaded rats,the increase in plasma insulin concentration is 
not further stimulated by the simulataneous oral administration of 
Wy 23675 until after *f0 minutes,whereas the increase in blood glucose 
levels is considerably diminished by YJy 23675 by 20 minutes (Fig. 1(vi).). 
Hov/ever,it is possible that oart of the early hyoogiycaemic action of
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of insulin already released by the glucose-load. At 60 minutes after
treated with glucose alone and glucose plus Wy 23675 may be related in 
part to the persistence of hyperinsulinaemia in the Wy 23675-treated rats. 
However,taken.together'Figures. 1(iv),1(v),and 1(vi) provide good evidence 
for an insulin-independant hypoglycaemic action of Wy 23675.
The actions of Wy 23675 differ from those of both tolbutamide and 
phenformin. The hypoglycaemic action of tolbutamide is accompanied by 
increases in plasma insulin levels for both oral (Fig. 1(vii).) and 
intravenous administration (results not shown,but similar to Fig, 1(vii),) 
When diazoxide blockage of insulin release is complete,tolbutamide has no 
effect on blood glucose levels (Fig. 1(viii).). Progressive increases in 
doses of tolbutamide,which overcome the diazoxide-blockage of insulin 
release,result in a progressively greater hypoglycaemic effect. In the 
glucose-loaded rat,tolbutamide lowers raised blood glucose levels in 
relation to its ability to stimulate plasma insulin levels further 
(Fig, 1(ix).);this is unlike Wy 23675 (Fig. 1(vi).),
Phenformin,on the other hand,does not markedly affect plasma insulin 
levels and,unlike Wy 23675 or tolbutamide,has no effect on blood glucose 
concentrations in the normoglycaemic rat (Fig, 1(x),). In glucose-loaded 
rats,phenformin lowers blood glucose levels without affecting plasma 
insulin levels (Fig, 1(xi).).
Effects on Growth Hormone and Glucagon Levels.
The possibility that the insulin-independant hypoglycaemic action of 
Wy 23675 is mediated by other hormones affecting carbohydrate metabolism 
has been considered. No effects of Wy 23675 have been measured on plasma 
growth hormone levels at doses at which it is hypoglycaemic; and 
hypophysectomy has been shown to have no effect on the hypoglycaemic 
action of V/y 23675 (results not shown).
Tests for Glycosuric Effects.
The possibility that V/y 23675 lowered blood glucose levels by 
increasing the loss of glucose in urine has been investigated, xwenty—j-our
treatment,the difference in blood glucose concentration between the rats
nour iastea rats were given a glucose-load combined with a hypoglycaemic 
dose of Wy 23675 and left in rat metabolism cages with free access to 
water for 5 hours,during which the urine was collected. The group given 
Wy 23675 were not significantly different to the control group with 
respect to either total urine volume or urine glucose produced.
Toxicity Studies.
The possibility that the hypoglycaemic action of Wy 23675 could be 
an indirect consequence of general toxicity has also been considered. 
However,rats dosed with Wy 23675 (0.2inmol/kg p.o.) twice-a-day for 31 
days developed no tolerance to its hypoglycaemic action and no effects 
were seen on the mean rat gro:vth rate or on histological examination of 
selected tissues (adrenals,testes,lungs,heart,kidney or liver) or on 
serum chemistry (albumin,globulin,total protein,lipids,cholesterol, 
alkaline phosphatase,aspartate transaminase,alanine transaminase,sodium 
or potassium), (results not shown).
Pharmacokinetic Studies.
Studies of the plasma kinetics of Wy 23675 in Pat as monkeys have 
revealed that peak plasma concentrations of Wy 23675 are reached within 
2 hours of an oral dose of the drug. Following intravenous administration 
of Wy 236759plasma levels remained fairly steady over a ten hour period. 
Furthermore,it was found that plasma levels after intravenous dosage 
were similar to oral levels after correcting for the different dosages.
An in situ gut absorption study was considered to offer a more direct 
means of establishing that the drug was rapidly absorbed. An isolated 
intestinal loop cannulated at both ends in an anaesthetized monkey 
showed that within 10 minutes of introducing Wy 23675 into the isolated 
gut section,the concentration had fallen b£ 9O%0
Thus,Wy 23675 is rapidly absorbed and only minimally,if at all, 
metabolized during its passage through the gut. Following an oral dose 
of 0.2 mmol/kg,plasma concentrations of Wy 23675 were 0.12 mM and 0.16 mM 
in two different Patas monkeys.
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PHENFORMIN ON BLOOD GLUCOSE AND. PLASMA INSULIN LEVELS IN NORMAL RATS.
Figure No. Title
1(i) Structure and Physical Properties of Wy 23675.
1(ii) Effects of Wy 23675 and Tolbutamide on Blood Glucose Levels
Two Hours after Oral Dosing*
1(iii) Effect of Oral Administration of Wy 23675 on Peripheral Blood 
Glucose and Plasma Insulin Levels,
1(iv) Effect of Intravenous Administration of Wy 23675 on Periphere
Blood Glucose and Plasma Insulin Levels.
1(v) Effect of Oral Administration of Wy 23675 on Peripheral Blood
Glucose and Plasma Insulin Levels in Diazoxide-Treated Rats, 
1(vi) Effect of Oral Administration of Wy 23675 on Glucose-Stimulat
Insulin Release.
1(vii) Effect of Oral Administration of Tolbutamide on Peripheral 
Blood Glucose and Plasma Insulin Levels.
1(viii) Effect of Oral Administration of Tolbutamide on Peripheral
Blood Glucose and Plasma Insulin Levels in Diazoxide-Treated 
Rats.
1(ix) Effect of Oral Administration of Tolbutamide on Glucose-
Stimulated Insulin Release.
1(x) Effect of Oral Administration of Phenformin on Peripheral
Blood Glucose and Plasma Insulin Levels.
1(xi) Effect of Oral Administration of Phenformin on Glucose-
Stimulated Insulin Release,
♦Table 1,
EFFECTS OF TOLBUTAMIDE,PHENFORMIN AND \IY 23673 ON BLOOD GLUCOSE LEVELS IN 
24-ER. FAS TIED, FED, GLUC CS E-LOADED AND ALLOXAN-DIABETIC FATS.
Groups of 6 female rats (l80-220gm) were dosed orally with the drugs 
(0*2 mmol/kg) and blood samples were taken for glucose measurement at 
0,1,2 and 3 hrs afterwards. Fasted rats were deprived of food for 2k hrs 
prior to the experiment. Glucose-loaded rats were simultaneously dosed 
orally with glucose ( to mmol/kg') and with drugs. Alloxan-diabetic rats 
were treated with alloxan(0.7ra®ol/kg i#p) ,following a 24-hr fast,7 days 
prior to the experiment when animals were found to be frankly diabetic 
(as judged by glucosuria). Statistical significance was determined by 
Student's t-Test : * p<0.03 ; ** p<0.01 ; *** p(0.001
Zero time control blood glucose levels x^ rere:- 
24-hr, fasted : 3»03 mmol/1.
Fed : 4.24 mmol/1.
Glucose-loaded • 5«20 ramol/l. (1 hr after glucose-load). 
Alloxan-diabetic : 19*41 mmol/l.
Drug
Change in Blood Glucose Levels (mmol/l.) from Zero Time 
Point "Relative to Control at the Following Times :-
1 hr. 2 hr. 3 hr.
,24-hr. Fasted Pats,
Tolbutamide -0.99*** -1.82*** -1.16**
Phenformin -O.83** -0.61 -0.77**
Wy 23673 -1.54*** -2.59*** -2.20***
.Fed Pats•
Tolbutamide -1.43*** -1.71*** -1.60***
Phenformin .0.17 0 .22 -0.50
Wy 23675 -1.16*** -1.87*** —1 # 43* * *
.Glucose-loaded Pats.
Tolbutamide -2.52** : -4.26** -3 .71+***
Phenformin -2.34 -2.60** . -0 .78
Wy 23675 -2.03** -3.90*** -1.92***
.Alloxan-diabetic Pats,
Tolbutamide 1.34 -2.44 0 .76
Phenformin -5.41* -6.72*
Wy 23675 -9.72* -11.66** -7.2if*
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Wy 23675
HO
Diphenyl-(1,k,5 § 6~tetrahydro-2~pyrimidyl)-methanol 
Empirical formula: C^H^gN^O 
Molecular weight: 266 
Melting point:
Chemical purity: 99%+ on TLC.
Wy 23675 is a white crystalline solid,virtually odourless with 
slightly bitter taste.
Phenformin
Tolbutamide
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Wy 23675 is a hypoglycaemic agent of novel structure and with a mode 
of action apparently different from those of the two major groups of 
oral hypoglycaemic agents,the sulphonylureas and the biguanides,as 
represented by tolbutamide and phenformin,respectively. It is apparent 
from the results on blood glucose and plasma insulin levels,that Wy 23675 
has a hypoglycaemic action which is independant of,although it can 
stimulate,insulin release.
It is interesting that Wy 23675 causes the release of insulin when 
administered by the oral route,while in low doses,it does not affect
plasma insulin levels by the intravenous route,although it is still
hypoglycaemic. These results suggest that VJy 23675 does not have a direct
effect on the pancreas to stimulate insulin release. There are three
possible ways by which Wy 23675 could stimulate insulin release when
administered by the oral route but not by the intravenous route.
First,a metabolite of Wy 23675 could be formed during its passage 
through the gut and it is this metabolite which stimulates insulin release. 
This suggestion is unlikely in view of the pharmacokinetic studies with 
Wy■23675 described in this chapter.
Secondly,Wy 23675 may cause a neurogenic effect on insulin release, 
mediated through the vagus nerve. Histological studies have shown that 
fibres from the right vagus nerve innervate the pancreas in man,dog,cat 
and rabbit (17)* Plexuses of such fibres surround the islets,and filaments 
from these peri-insular networks penetrate the islets and follow the 
vessels between the cells. In 1927 LaBarre (18),using the method of 
pancreatoduodenal-jugular anastomosis in the dog,demonstrated a fall in 
blood glucose of the recipient following an electrical stimulation of the 
right vagus nerve of the donor. Frohman and coworkers (9) have shown 
that stimulation of the right and left vagus leads to a rapid rise in 
serum insulin levels and that atropine inhibits this effect. They ha^e 
also shown that,following vagotomy,a fall in portal vein insulin levels 
occurs,but that the glucose-mediated insulin release and net glucose 
utilization are not affected by vagotomy. Isolated tissue work at Wyeth
although it does cause some potentiation of acetyl choline. Thus,the
possibility of Wy 23675 stimulating insulin release through vagal effects
cannot be eliminated. However,the pattern of insulin release caused by
Wy 23675 is different from that caused by vagal stimulation. Frohman et
‘ I
al (9) have shown that,in the dog,vagal stimulation results in a prompt j
but short-lived peaking of plasma insulin release before 5 minutes j
S
despite the persistence of stimulation. They conclude that only a portion j 
of releaseable insulin appears to be under vagal control, In contrast, j 
Wy 23675 results in a gradual and sustained release of insulin over a 
period in excess of one hour,so it seems unlikely that there is a vagal 
involvement in Wy 23675 stimulation of insulin release.
The third possibility is that Wy 23675 could,when given orally, j
stimulate the release from the gut of an insulin-releasing factor. The 
existence of such a factor was suggested at the beginning of this century, 
shortly after the discovery of secretin,when acid extracts of the duodenum 
were used in the treatment of diabetes mellitus (19)# It was suggested 
th&t crude secretin contained two active principles^incretin*,stimulating 
the internal secretion of the pancreas,and 1 excretin1,stimulating the 
exocrine pancreas (20,21). More recently,it has been shown that serum 
insulin levels increased much more after oral administration than after 
intravenous injection of the same amount of glucose,despite a smaller 
increase in blood glucose levels (22,23). Similarly,intraduodena}, 
administration of amino acids has been shown to induce a greater rise in 
serum insulin than intravenous infusion despite lower serum levels for the 
individual amino acids in the former (2^). Many gastrointestinal factors 
(secretin,gastrin,gastric inhibitory polypeptide-GI?,vasoactive intestinal
'N
polypeptide-VIP) have been shown to be capable of stimulating insulin 
0*f, 25-29),but the enteric factor responsible for greater insulin releasej 
after oral glucose ingestion or intraduodenal infusion compared with an j 
intravenous glucose infusion has yet to be identified. Of the different 
candidate hormones,GIP fulfills all the criteria necessary for the role
glucose and fat (10-13) and to be insulinotropic in the presence of 
hyperglycaemia (13-16). The possibility that Wy 23675 stimulates the 
release of an insulih-release-stimulating factor from the gut,such as 
GIP,has not been looked into.
Thus,Wy 23675 appears to have a hypoglycaemic activity,which has an 
insulin-independant component,is unrelated to growth hormone levels,and 
independant of any toxic effect.
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.Chapter 2. Siimma-rvt 
The.tables in this section summarize the results of experiments designed, 
to illustrate the *in vivo* effects of selected hypoglycaemic agents on 
glucose utilization as distinct from glucose production. The results 
illustrate the following effects of these agents
1. Insulin increased the rate of glucose utilization and lowered blood 
glucose levels in both normal and alloxan-diabetic rats.
2. In the normal rat,oral administration of tolbutamide and Wy 23675 
elevated plasma insulin levels,stimulated glucose utilization and lowered 
blood glucose levels;phenformin had no effect.
3* Intravenous administration of Wy 23675 in low doses in the normal rat 
had no effect on plasma insulin levels,but stimulated glucose utilization 
and lowered blood glucose levels while intravenous administration of 
tolbutamide stimulated both plasma insulin levels and glucose utilization, 
and. lowered blood glucose levels#
*f. Inhibition of insulin release by diazoxide did not markedly affect 
Wy 23673-stimulation of glucose utilization or lowering of blood glucose 
levels,but inhibited these effects of tolbutamide.
3. In the alloxan-diabetic,Wy 23675 and phenformin stimulated glucose 
utilization and lowered bihod glucose levels;tolbutamide had no effect. 
None of these agents had any measurable effect on plasma insulin levels. 
6. In all cases,the effects of these agents on glucose utilization 
paralleled their effectiveness in causing hypoglycaemia,indicating that 
glucose utilization id. part of the mechanism by which these agents 
induce a fall in blood glucose levels.
■introduction.
Radiolabelled glucose has been used both to measure the rate of 
glucose utilization and the disposal of glucose carbon to selected 
tissues and end-products (1-29)# These studies used (U-^C)-glucose, 
which meant that measurements of radiolabelled glucose in the blood
Zj.
included not only the original (U- C)-glucose injected,but also newly 
-synthesized glucose labelled with C due to substrate recycling.
Baker et al took this into account by including recycling from a non­
glucose compartment in their 3-pool model (3),but this technique 
requires a careful and fairly complex analysis of the results. Vrba/et 
al (8-12,1^-16) did not have this problem as they were analyzing end 
products which represented large pools in the body,so that the tracer 
became sufficiently diluted that negligible loss of it accompanied the 
outflow of natural material from the pool. In this way the pool became 
an effective *sink* and a plateau value of tracer was reached and it was 
this value that Vrba et al measured.
Careful selection of tracer can eliminate the need for complex (and 
theoretical) kinetic models when measuring rates of glucose utilization:-
Labelling of the glucose molecule.
1h
1.— C-labelling of the glucose molecule results in the label occurring in
all the glycolytic intermediates,In the intermediates of the citric
ih
acid cycle and in carbon dioxide. The C label also appears in newly- 
formed glucose due to substrate recycling;this results in lower values 
for glucose utilization than actually occur,as the amount of labelled 
glucose left in the plasma pool is augmented by the newly formed
Zf.
labelled glucose (30). Thus C-labelled glucose presents problems in 
measuring glucose utilization.
2. ^H-labelling of the glucose molecule is possible for each of the six 
carbon atoms and the fate of the label depends upon the position of 
the carbon atom to which it is attached.
(i). (^H-2)-Glucose,
on the second carbon atom of the glucose molecule (C2) is lost
-H-C 1 (1) H-4-0H
H+ + CH" T^C-OH I (2) ?<OH *HOH
• - ho-4-h o r^yPhos?hohexoseJs. no-f^"o 
H-C-QH I (4-) isomer as e H-y-Q*r
H-fc — 1 (5) H-C
H-C-OPO^ (6) H-f-OPO^
k H
Glucose-6-P Fructose-6-P
There is a hydride shift between C2 of glucose-6-P and C1 of 
fructose-6-P and,during this process,the hydrogen exchanges extensivel 
with the protons of the medium. In a single transfer,part of the H
from position 2 of glucose—6—P would appear in position 1 of 
fructose-6-P and part in water. Glucose -6-P and fructose-6-P are 
reversibly isomerized as shown above# In each isomerization (in either 
direction) one-half of the hydrogen in position 2 of the aldose and 
position 1 of ketose will be exchanged with the protons of the medium. 
After a single isomerization cycle of glucose-6-P to fructose-6-P and 
back,the content at position 2 of glucose will be reduced to 25%.
The activity of phosphohexose isomerase is,in general,much higher than 
the rates of other reactions of the hexose phosphatases and the 
phosphate esters will be turned over several times before leaving the 
pool. With high isomerization rates all the H is lost from C2 of 
glucose-6-P and C1 of fructose-6-P (30).
Katz and Dunn (30) have shown that,using (^ H-2)-glueose,appreciable 
3activity from H was apparent in water 1-2 minutes after i.v. injection
ahd they found maximal activity in all experiments after 80-100 mins,
which remained essentially constant thereafter. The fraction of H
estimated to be in liver glycogen at 100 mins after injection ranged
from 0.5-1#0%,while muscle glycogen contained at most 0.5# ^H. Thus,
Katz and Dunn(30) proposed the use of (^H-2)-glucose to correct for the
under-estimate of the rate of glucose utilization caused by recycling
of C between glucose and its catabolic products arising in the
14-periphery from the use of (U- C)-glucose. The basic assumptions 
underlying this approach were that all catabolism occurs in the 
periphery,that tritium serves as an irreversible tracer for glucose, 
and that no detritiation occurs in the liver. ^  g
on C3 or C5 of glucose is lost during the isomerization between 
dihydroxyacetone-P and glyceraldehyde-3-P (32,4*1). on C3 of glucose 
appears 6n dihydroxyacetone-P and on C5 of glucose appears on 
glyceraldehyde-3-Pa
' 5
C j* (4-) Triosephosphate H-C-OH
H+ + OH" (3) < i50iaera.se *  5=° ' *HOH
H-g-OPO^ (6) H-C-OPO^
Glyceraldehyde-3-P Dihydroxyacetone-P
In the isomerization of glyceraldehyde-3-P to dihydroxyacetone-P there 
is a hydride shift from the second carbon atom of glyceraldehyde-3-P to 
the first carbon atom of dihydroxyacetone-P,and during this process the 
hydrogen exchanges extensively with protons of the medium. Thus,^H from 
the C2 of glyceraldehyde (equivalent to H on C5 of glucose) is lost to 
water during this isomerization.
3-P,^H from the C1 of dihydroxyacetone-P (equivalent to the on C3 of j
Similarly,in the isomerization of dihydroxyacetone-P to glyceraldehyde- ? 
5 yi 
glucose) is lost to water: j
? H.<P i
•H-C-OH (3) Triosephosphate C j
H* + CH" C=0 (2)  >  H-C-OH *HOH
H-C-OPOjHg (1) H-C-0P05H2 |
lI
Dihydroxyacetone-P Glyceraldehyde-3-P |
(iii).(^H-4-)-Glucose and any left on (^H-3)-Glucose. j
After the conversion of dihydroxyacetone-P to glyceraldehyde-3-P by j
glyceraldehyde-3-P dehydrogenase,the C1 of glyceraldehyde-3-P represents^
3 .•
both C3 and C4* of glucose. H in this position of glyceraldehyde-3-P is f
- i
lost during its oxidation: {
ioH (2-5) T + ^ ^ g ^ a l d e h y d e - ^  m d .h + H+ j
H-^-OPO^Hg (1,6) H^PO^ dehydrogenase H-f-OPO^Hg
or ;
Glyceraldehyde 9
-3-P C-OPO H2 !
H-9-0H ^ NADH + *H |
h-|-opo3h2 j
1,3-Diphosphoglyceric 
acid
on C1 and C6 of glucose is retained on C3 of phoshphoenolpyruvate 
and pyruvate as shown below:
!00H I^ruvate kinase
C-OPO H2 (2,5) ADP 
A  3 2 (1,6) Mg /K
H
pOOH
► 9=0
*B-9-H
H
ATP
Phosphoenolpyruvate I^ rruvate
This is,however,rapidly lost by exchange with protons,catalyzed by 
alanine-2-oxoglutai*ate transaminase(42),an enzyme with high activity in
liver and muscle (32)#
3The loss of H from C3 of pyruvate occurs during the series of reactions
in which pyridoxal phosphate functions as the coenzyme in the transfer
of an amino group to the keto acid acceptor (pyruvate) to form alanine:
CHpPO. Hp 0Ho P0kE-,
COOH ( 3 , 4 )  d  J [  0  COOH ^
H HO CHj
p=N-CH=/ 'N-H
*H-C-H \ = H
HO CH^
lyruvate I^rridoxamine-P
® > = \  
-CH^ 7T-H
10^ CH^
CH PO. H
10CB
H2P04H2COOH
* Y - H  VS
f  H HO XJH
H+ + 0 K ~ * *  HOH
H-C-N=CH
+ *H0H
H-C-NH
H-C-H
Alanine
C H ^ O ^
IVridoxal-P
3 3( H-2)-glucose was chosen for this study as the. H was irreversibly lost 
at a very early stage of glucose metabolism (in the isomerization of 
glucose-6-P and fructose-6-P),which meant that glucose utilization could 
be measured »in vivo* without including a measurement of newly formed 
glucose#
This chapter compares the effects of insulin,tolbutamide,phenformin 
and Wy 23675 on glucose utilization (as a separate measure from any
rats# This enables a link to be made between the in vivo results reported 
in Chapter 1 and in vitro work reported in future chapters,as it permits 
a determination in vivo of whether or not the drug being investigated is 
affecting tissues involved in glucose utilization#
materials
Insulin (protamine zinc) was obtained from Macarthys Pharmaceuticals Ltd# 
Romford,Essex# Alloxan monohydrate was obtained from Koch-Light 
laboratories,Colnbrook,Bucks# The sources of other drugs were given 
earlier (Chapter 1)#
Radiolabelled compounds were obtained from the Radiochemical Centre, 
Amersham,Bucks# Micellar Scintillator NE 260 was obtained from Nuclear 
Enterprises Ltd#,Sighthill,Edinburgh#
Methods
Treatment of Animals#
Rats were male Charles River CD strain (180-220 gms) maintained as 
described earlier (Chapter 1)# Animals were fed ad libitum or fasted for 
24 hours prior to the experiment as indicated.
Radiolabelled glucose (10 juCi) was injected into the tail vein of 
the unanaesthetized rat in 0#2mls of 0,9% saline# Blood samples were 
taken from the tail at selected times before and after injection and 
analyzed for blood glucose and plasma insulin levels (see Chapter 1)#
The administration of drugs is described in the text for each experiment# 
Alloxan-diabetic animals were treated with alloxan monohydrate (0$/nnwt_/kg 
intraperitoneally),following a 24 hour fast,7 days prior to the 
experiment with radiolabelled glucose when animals were frankly diabetic 
(as judged by glucosuria)#
Treatment of Samples#
For the measurement of radiolabelled glucose in blood,samples were 
collected from the tail vein into heparinized microfuge tubes and 
centrifuged in a Beckman Microfuge for 4 minutes at room temperature#
100 jil# of the supernatant was freeze-dried in an apparatus consisting 
of a flask with a single outlet connected to an Edwards High Vacuum Pump 
ES 50 via two collecting tubes "bathed in liquid nitrogen. The residue 
containing radiolabelled glucose was redissolved in 3 x 1 ml distilled 
water,mixed with 16 mis of Micellar Scintillator NE 260 (NE 260) and 
counted for 10 minutes in a Packard Tricarb Liquid Scintillation
Spectrometer#
Presentation of Results#
The rate of utilization of a substrate can be calculated,following 
a single injection of radioactive tracer,by determining the decline in 
specific radioactivity of the substrate in blood with time from the 
equation:-
Rate of Utilization =_______ Dose Injected_____________________ _
Area under Specific Activity/Time Curve to Infinity
The conditions necessary for this equation to be valid include the
absence of isotopic effects;the replacement of substrate utilized by
non-labelled material which passes through the blood;the absence of
extensive substrate recycling during the experiment;and the maintenance
of the system in a steady state (ie: the rates into and out of pools and
the pool sizes remain constant)#
The experiments described here do not conform to steady state
conditions as they involve the effects of drugs which lower blood glucose
concentrations,causing changes of the rates into and out of pools as well
as pool sizes#
Heath and Barton (4-3) have suggested using the total quantity of 
label in the plasma glucose pool rather than the specific activity#
Using the specific activity (dpra/mmol glucose) to calculate the rates of 
glucose utilization involves including the value for pool size,and this 
is only valid when this value remains constant# By using the total 
quantity of label in the pool the need for a constant pool size is 
eliminated and so can be applied to non-steady state conditions:- 
Quantity of Label in Pool = Specific Radioactivity (dpm/maol glucose)
x Glucose Concentration (mmol/ml) x Volume 
of Pool (mis)#
or Quantity of Label = Radioactivity (dpm)/ml of Plasma x Volume of
Plasma Pool (mis)#
The quantity of total radioactivity in the plasma pool was calculated 
on the basis of a glucose volume of distribution equal to the plasma
volume which,in a 200 gm rat,is 7#97 mis (44), (For practical 
considerations the quantity of label is normalized to 1*0 at zero time). 
It is not possible to calculate a rate of glucose utilization for 
most of the experiments described in this chapter,since it varies from 
moment to moment in the non-steady state conditions* Therefore,in each 
experiment,the quantity of radiolabelled glucose in the plasma pool in 
drug-treated rats is compared with that in untreated controls#
a). Preliminary Results to Justify the Methodology,
(i). Freeze-Drving Techniques for Separating Radiolabelled Glucose from 
Plasma*
To check on the losses of labelled glucose during the freeze-drying 
process, 100 jul samples of rat plasma containing 0,01 p.Ci (^H-2)-glucose 
were frozen in 3 ml. plastic vials and then freeze-dried. These vials 
were then washed three times with distilled water (1 ml.) and counted in 
16 mis. NE 260. Further 100 pi. plasma samples containing 0*01 pCi 
(H-2)-glucose (the controls) were added directly to 16 mis 'NE 260 with 
3 mis. of distilled water in each and counted. The results showed that 
relatively little loss of counts from (H-2)-glucose occurred during the 
freeze-drying process. The average percentage .^oss on 3 experiments was 
8*6% compared with controls.
To check that none of the H^O (formed by the metabolism of ( H-2)- 
glucose in the rat) was left in the 5ml, plasiric vials following freeze- 
drying,100 pi, samples of rat plasma containing 4 pCi. H^O were freeze- 
dried and the vials washed with 3 mis. distilled water,which was counted
■2
in 16 mis. NE 260, Control 100 fil. plasma samples containing 4 juCi, H^O 
were counted in 16 mis. NE 260 with 3 mis, distilled water. Residual 
counts present after freeze-drying represented only 0,11?o (average of 
3 experiments) of the total counts recorded from the controls,which were 
not freeze-dried.
It was concluded that the freeze-drying process was effective in 
separating (^H-2)-glucose from in rat plasma,
(ii). (^H-2)-glucose as a Measure of Glucose Utilization,
Plasma levels of (^H-2)-glucose should decrease asymptotically to
zero during the course of glucose metabolism in the rat. Figure 2(i),
■2
shov/s a time-course for the decline in plasma ( H-2)-glucose after a 
single injection at zero time. Radioactivity declined virtually to zero 
by 150 minutes,which suggests that tritium from ( H-2)-glucose was not 
recycled into newly-formed glucose. If this were the case as with
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the blood for periods greater then 6 hours after administration (3). It 
appears that the use of (H-2)-glucose as a valid measure of irreversible 
glucose disposal in the body is justified,
b)» The Effects of Agents on Glucose Utilization in Normal,Fed Rats,
The experiments described in this section illustrate the effects of 
insulin,tolbutamide,phenformin and Wy 23675 on plasma insulin and blood 
glucose concentrations and on glucose utilization in normal,fed rats. 
Glucose utilisation is represented by the quantity of radiolabelled 
glucose remaining in the plasma pool at selected time points,(Thus,the 
smaller the numerical value,the greater is the glucose utilisation). For 
reasons already discussed,no quantitative value for glucose utilization 
can be calculated for most of these experiments,so that comparisons have 
been made between control and test groups and significant changes in 
glucose utilization are discussed in qualitative terms only.
Insulin was shown to lower blood glucose levels and to enhance 
glucose utilisation as compared with the control group (Table 2(i),), 
Tolbutamide administered orally elevated plasma insulin levels and 
subsequently lowered blood glucose concentrations and stimulated glucose 
utilisation (tables 2(ii). and 2(ix).), Fhenformin had no effect on 
plasma insulin levels,blood glucose levels or glucose utilization 
(Table 2(iii),). This contrasts with the effects of Wy 23675 which,like 
tolbutamide,elevated plasma insulin levels,lowered glucose levels and 
stimulated glucose utilization (Table 2(iv),). However,unlike tolbutamide 
there was no evidence that Wy 23675 markedly elevated plasma insulin 
levels prior to its effect on glucose utilization. When Wy 23675 was 
administered by the intravenous route,it no longer elevated plasma 
insulin levels,but did still lower blood glucose concentrations and 
stimulate glucose utilization (Table 2(v),). Tolbutamide,administered 
by the intravenous route,still markedly elevated plasma insulin levels 
and subsequently lowered blood glucose concentrations and increased 
glucose utilization (Table 2(vi),).
c). The Effects of Tolbutamide and Wy 25675 on Glucose Utilization in 
Diazoxide-Pretreated Bats.
In order to further investigate the role that stimulation of insulin 
release plays in the effects of tolbutamide and Wy 23675 on blood glucose 
concentrations and glucose utilization,some experiments were carried out 
using diazoxide to block insulin release.
Oral administration of diazoxide was shown to cause a marked decrease : 
in plasma insulin levels followed by an elevation of blood glucose
: t
concentrations and a decrease in glucose utilization. These latter effects: 
can probably be attributed to the lowered plasma insulin levels. The I
effects of tolbutamide and Wy 23673 were observed in diazoxide-pretreated i 
rats. Wy 23675 lowered blood glucose concentrations and stimulated 
glucose utilization despite having no effect on plasma insulin levels
(Table 2(viii)•),while tolbutamide,in a dose that had no effect on plasma |
I
insulin levels in the diazoxide-pretreated rat but which was hypoglycaemic|
■ f
in the normal rat,had no effect on blood glucose levels or glucose |
• . ■'■ ' I
utilization (Table 2(x).). I
d). The Effects of Agents on Glucose Utilisation in Alloxan-Diabetic. |
Fasted Pats. |
* S"
The experiments described in this section illustrate the effects of | 
insulin,tolbutamide,phenformin and Wy 23675 on blood glucose levels and |
' f
glucose utilization in alloxan-diabetic,fasted rats. A comparison of \
normal,fasted with alloxan-diabetic,fasted rats revealed an apparently § 
reduced rate of glucose utilization in the alloxan-diabetic rats (Table / 
2(xi).). However,,as the normal and alloxan-diabetic rats had constant 
glucose pool sizes during this comparison,calculations were made to 
determine the rates of glucose utilization. The method of calculation ^ 
used followed that of Heath and Barton (*f3) to calculate the area under L 
a plot of.the quantity of (^H-2)-glucose in plasma (normalized to 1.0 at J 
zero time) against time. The mean rate coefficient of glucose utilization | 
was then calculated from the equation:-
IT-
Mean Rate Coefficient _ ________  Dose Injected (1.0)  j
of Glucose Utilization" Area, under Quantity of (^H-2)-glucose in Plasmagj
.v. Time Curve Q Z §
Thus,the mean rate coefficient of glucose utilization for the normal
rats was calculated to be 0.262 nin and for the alloxan-diabetic rats 
—1
it was 0.303 min • The mean blood glucose concentrations during the 
experimental period were 3*58 mmoll/l# for the normal rats and 13.51 mmol/-'
' . s  . J
for the alloxan-diabetic rats. Taking Metcoff and Favour*s figure of 
7*97 mis. for the plasma volume of a 200 gm. rat (*f4),this gives a total 
of 0 .029 mmoles of glucose in the plasma pool of the normal rats and
0.12*f mmoles of glucose in the plasma pool of the alloxan-diabetic rats. 
When multiplied by the appropriate rate constants these figures give a 
mean rate of glucose utilization of 0,011 mmol/ain for the normal rats 
and 0.038 mmol/iain for the alloxan-diabetic rats ; an increase over the 
normal rats by 3•3-times.
Insulin was shown to lower blood glucose concentrations and to 
enhance glucose utilization in fastedtalloxan-diabetic rats (Table 
2(xii).), Tolbutamide,in contrast to its effects in the normal rat where
it was able to elevate plasma insulin levels,had no significant effects jii
on either blood glucose concentrations or glucose utilization in fasted, |
!
alloxan-diabetic rats (Table 2(xiii),), Phenformin lowered blood glucose j
. . . I
Iconcentrations and elevated glucose utilization (Table 2(xiv).), Wy 23675 1 
was similarly able to lower blood glucose concentrations and stimulate 
glucose utilization (Table 2(xv),). The effects of both phenformin and 
Wjr 23675 were apparent in the absence of any measureable effect on plasma 
insulin levels in alloxan-diabetic rats.
e)» The Effects of Futile Cycling in the Measurement of Glucose u
Utilization. |
7 1
(*?H-2)-glucose was used to measure glucose utilization in these
experiments in the belief that the following basic assumptions,made by J
I
Katz and Dunn (30),were correct
(i). All catabolism occurs in the periphery.
(ii). serves as an irreversible tracer for glucose.
(iii). No detritiation occurs in the liver.
85 |
“ M i7fw|iw.bii cu djjuui-i.t)xi«u a xux'vnei' paper reconsiaerxxig
the posi.ti.on of the *^ H label on glucose for the in vivo estimation of
glucose utilization in rats in the light of the fairly recently accepted
knowledge concerning substrate recycling (33-57)*
Substrate recycling or •futile cycling* is the cyclic transformation
of metabolites in a pathway in which the net balance is the hydrolysis of
ATP to ADP and Pi (36)# The purpose of these futile cycles is,as yet,
unclear j indeed,until recently,their very existence was a subject of
some controversy® However,it appears that some of these cycles provide the
cell with a valuable regulatory mechanism* This is particularly apparent
when recycling occurs at the level of a metabolite,such as glucose-6-P,
which participates in the control of metabolic flow#
The purpose of the glucose/glucose-6-P recycling appears to be to
allow major changes in glucose uptake or output controlled by the
concentration of substrate only,instead of involving a complex control
mechanism(36)# Newsholme and Start (*fO) have pointed out that a small
change in glucose concentration of k-6 mM is sufficient to produce a
•' ' * 
complete change of direction of glucose metabolism in the liver#
Van Hoof et al(38) have pointed out that there is likely to be
recycling in the liver between glucose and glucose-6-P during net hepatic i
glucose synthesis and that this would invalidate the use of (^H-2)-glucose ;
for the determination of glucose turnover,as tritium would be released
without any actual utilization of glucose# Hue and Hers (39) have shown I
*5 .lit / : f
a more rapid decline in the 13/ C ratio in glucose after injection of \
(^H-2,U-^\j)-glucose than after (^H-3,TJ-^C)-glucose or (^H-6,U-^^C^- |
glucose# These ratios would be the same if no tritium was lost in futile I
;. i
cycling# *
■2 ^
Thus,the use of(^H-2)-glucose to measure glucose utilization will
'Ikavoid the problem that arises with the use of (U- C)-glucose (namely,
*1 kthat the C will be resynthesized into newly formed glucose and thus
give a false picture of glucose utilization),but will give an artificially ~
high measurement of glucose utilization due to the release of tritium 
during futile cycling of glucose and glucose-6-P# 0 p
3( H-2)-glucose was derived from hepatic recycling and 85-90% from
catabolism in extrahepatic tisaues. They showed that the use of (^H-2)-
glucose would cause an over-estimate of the rate of replacement by
about 20%,but would over-estimate the recycling of by a factor of
two as compared with (^H-3)- or (^H-6)-glucose# 0n the other hand,futile
cycles accounted for only a very small fraction of detritiation from 
3 3( H-3)- or ( H-5)-glucose* For this reason,they have suggested the use 
of glucose labelled with tritium in one of these positions,rather than 
position 2,to measure glucose utilization in the rat in vivo *
Because the use of (^H-2)-glucose gives false measurements,many of 
the experiments,reported in this section,will have an over-estimate of ! 
the rate of glucose utilization. -However,it' is not the basic rate that 
is of prime interest in these experiments so much as the changes that ,
occur with the drugs investigated* Each such test result is run against *
a control,so that the change brought about by the drug can be measured j
with respect to it. For this reason,the over-estimate of the rate of J
■ s
glucose utilization caused by the futile cycling between glucose and f
glucose-6-P and the loss of tritium from (^H-2)-glucose is not important I
$
' ' i
provided the drugs do not directly affect the futile cycling* It only |
becomes important to the results of this investigation if the hormones §
; I
or drugs being investigated act to increase or decrease futile cycling* *
If,however,they act on one of the enzymes involved in the futile cycle |
to cause an increase or decrease in net flow of substrate through the t
x r
cycle,then any H lost from the labelled substrate,above or below the
level of the controls,would reflect an increase or decrease in substrate
flow*
•z
As several workers (32,39) now recommend the use of ( H-3)-glucose
•z .
to measure glucose utilization fin vivo* rather than ( H-2)-glucose,
3several experiments have been repeated using ( H-3)-glucose and the
3
results compared with those obtained from experiments with (^H-2)-glucose.,
a direct comparison of the rates of glucose utilization as measured
3 3by ( H-2)-glucose and ( H-3)-glucose was made in normal rats (Table
2(xvi),). As these rats were din a ’steady state*,calculations were made
to determine values for glucose utilization (these were carried out as
described ealier in the comparison of normal and alloxan-diabetic rats)*
The mean rate of glucose utilization in the rats using (^H-2)-glucose
was 0 .013 mmol/din and in the rats using (^H-3)-glucose was 0,011 mmol/
min. Thus,the use of (H-2)-glucose over-estimated the rate of glucose
utilization by approximately 18$ - this is in line with the findings of
*z
Katz et al (32). However,further work with ( H-3)-glucose has shown that 
insulin and Wy 23675 have similar qualitative effects on glucose 
utilization in both normal and alloxan-diabetic rats whether this was 
measured with (^H-2)-glucose (Tables 2(i),2(iv),2(xii),2(xv)•) or with 
(^H-3)-glucose (Tables 2(xvii),2(xviii),2(xix),2(xx).). Thus,the fact
■z
that ( H-2)-glucose over-estimates the rate of glucose utilization does 
not alter the validity of the findings concerning the qualitative effects 
of the drugs on glucose utilization.
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#Chapter 2#
#THE USE OF RADIOLABELLED GLUCC6E TO MEASURE THE EFFECTS OF SELECTED
AGEHTS ON GLUCOSE UTILIZATION IN THE NORMAL AND ALLOXAN-DIABETIC HAT
* IN VIVO»#
Figure No, Title
2(i) •In Vivo* Loss of (^H-2)-glucose from the Blood of the Normal
Rat with Time#
32(ii) Effect of Insulin on the Quantity of ("n-2)-glucose Remaining 
in the Plasma Pool#
Table No# Title
32(i) Effect of Intramuscular Insulin on Glucose and ( H-2)-glucose
Levels in Blood of the Normal Rat#
2(ii) Effect of Oral Tolbutamide on Glucose,Insulin and (^H-2)-glucose
Levels in the Blood of the Normal Rat#
*Z
2(iii) Effect of Oral Phenformin on Glucose,Insulin and ( H-2)-glucose 
Levels in the Blood of the Normal Rat#
•z
2(iv) Effect of Oral Wy 23675 on Glucose,Insulin and (^H-2)-glucose
Levels in the Blood of the Normal Rat#
3
2(v) Effect of Intravenous Wy 23675 on Glucose,Insulin and ( H-2)-
Glucose Levels in the Blood of the Normal Rat#
2(vi) Effect of Intravenous Tolbutamide on Glucose,Insulin and
(5H—2)— glucose Levels in the Blood of the Normal Rat#
■z
2(vii) Effect of Oral Diazoxide on Glucose,Insulin and ( H-2)-glucose 
Levels in the Blood of the Normal Rat#
2(viii) Effect of Oral Wy 23675 on Glucose,Insulin and (^H-2)-glucose
Levels in the Blood of the Diazoxide-Treated Rat#
2(ix) Effect of Oral Tolbutamide on Glucose,Insulin and ( H-2)-
glucose Levels in the Blood of the Normal Rat#
2(x) Effect of Oral Tolbutamide on Glucose,Insulin and (^H-2)-
glucose Levels in the Blood.of the Diazoxide-Treated Rat#
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Table No, Title
2(xi) Effect of Alloxan Pretreatment on Glucose and (^H-2)-glucose
Levels in the Blood of the Normal Rat,
2(xii) Effect of Intramuscular Insulin on Glucose and (^H-2)-glucose
Levels in the Blood of the Alloxan-Diabetic Rat.
2(xiii) Effect of Oral Tolbutamide on Glucose and (^H-2)-glucose Levels
in the Blood of the Alloxan-Diabetic Rat.
2(xiv) Effect of Oral Phenformin on Glucose and C^H-2)-glucose Levels
in the Blood of the Alloxan-Diabetic Rat,
2(xv) Effect of Oral Wy 23^75 on Glucose and (^H-2)-glucose Levels in
the Blood of the Alloxan-Diabetic Rat,
z  z
2(xvi) Comparison of the Use of (H-2)-glucose and (H-3)-glucose to 
Measure Glucose Utilization in Normal,Untreated Rats *in Vivo1.
Z
2(xvii) Effect of Intramuscular Insulin on Glucose and ( H-3)-glucose 
Levels in the Blood of the Normal Rat.
z
2(xviii)Effect of Ctral Wy 23675 on Glucose,Insulin and ( H-3)-glucose
Levels in the Blood of the Normal Rat.
z
2(xix) Effect of Intramuscular Insulin on Glucose and ( H-3)-glucose 
Levels in the Blood of the Alloxan-Diabetic Rat.
z
2(xx) Effect of Oral Wy 23^73 on Glucose and rH-3)-glucose Levels in
the Blood of the Alloxan-Diabetic Rat.
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IN VIVO LOSS OF (^H-2)-GLUCOSE FROM BLOOD OF NORMAL RAT WITH TIME
Six male rats (190-210 g) were injected intravenously with 10 jiCi 
(H-2)-glucose in 0*2 ml volume® 0*3 ml blood samples were taken 
from the tail at 30,60,90,120,130 and 180 mins after injection and 
centrifuged in a Beckman Microfuge® 100 jxls of plasma from each 
sample was freeze-dried in 5 ml plastic vials® These were then washed 
three times with distilled water (1 ml) and counted in 16 mis NE 260®
\
\
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.EFFECT OF INTRAMUSCULAR INSULIN ON GLUCOSE AND (^H-2)-GLUCOSE LEVELS
IN BLOOD OF THE NORMAL RAT.
Rats were injected with 10 pCi (H-2)-glucose i.v. and either 0«1 mis of 
protamine zinc insulin (4 units/rat i,a.) or 0«1 mis saline i.m. (controls) 
at zero time. 0*3 mis blood samples were taken at the time intervals shown 
and used for glucose analysis and for measuring (*H-2)-glucose. Values 
represent the mean of 6 animals with the standard error shown in brackets. 
The quantity of total radioactivity in the pool was calculated as described 
in Methods and normalized to that theoretically present at the time of 
injection (10 jiCi=22x10°dpm)# Statistical differences between control and 
insulin-treated groups were examined by Students t-Tests
* p<0*05 *** p<P*001
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(—0,22)
7904-1 
(-6321)
86022
(±8339)
6299570
(±503784)
>855953
(±664618)
i 4.24
:±o.o6)
4.90
(±0.11)
Bk^ok
(-7119)
83324
(±9711)
6719029
(±567384)
6640923
(±773964)
5 4.18
: £ o . i ? )
5 .12
(±0 .22)
72167 
(I7001)
> 7 5 7
(±8146)
5751710
(±557980)
>958133
(±649236)
7 4.46
:±o,i7)
4.84
(±0.17)
62^69
(±5936)
66199
(±2319)
4978779
(±473099)
5276060
(±184824)
9 k 0ko 4.68
(±0.22)
65395
(±6533)
51211
(±4616)
5211982
(±504740)
4081577
(±367895)
30 >.57
;io.i7)
k0bo
C-0.22)
8450
(±621)
4905
(±316)
671871
(±49494)
>90929
(±25185)
6o >.29
["0,22)
3*7^*
Cto.11)
3062
(±419)
742
(±211)
244041
(±33394)
* 59137
(±16817)
90 4,4o
: ± o . i 7 )
2,6k**
Ct0.11)
‘ 1023 
(±89)
■135
(±19)
*81533
(±7093)
10760
(±1514)
(continued)
\
Tiae after 
(3h-2)- 
Glucose 
(mins)
Quantity Normalized to 
'1*0 at Zero Time
Control Insulin
0 1*000 1*000
1 0*286 0*312
(-0.023) (±0*030)
3 Q*305 0*302
(-0*026) (±0*033)
3 0*261 0*271
(±0*023) (±0 .030)
7 0*226 0*240
(±0*022) (±0 .008)
9 0*237 0*186
(±0 *030) (±0 .017)
30 0*031 0*018***
(±0*003) (±0*002)
60 0*011 0.003***
(±0*002) (±0.001)
90 0.004 0.001***
(±0*001) (±0.001)
Table 2(ii)
«EFFECT OF ORAL TOLBUTAMIDE ON GLUCOSE,INSULIN AND (^H-2)-GLUCOSE LEVELS
IN BLOOD OF THE NORMAL EAT,
Rats were injected with 10 jaCi (^H-2)-glucose i.v. and were dosed orally 
with either tolbutamide(0.2mmol/kg) or HPMC ( 1 ml/100 gm body weight ) at 
zero time. Blood samples were taken at the time intervals shown and used 
for plasma insulin and glucose analysis and for measuring (^H-2)-glucose. 
The quantity of radioactivity in the glucose pool was calculated as 
described in Methods and normalized to 1*0 at the time of injection. The
results are expressed as the mean - the standard error for 6 animals.
Statistical significance was determined by the Student*s t-Test :
* p<0*03 ? ** p<0*01 ; *** p<0*001
(NM = not measured ; Tolb. = Tolbutamide group)
Time after 
(3h-2)- 
Glucose 
(mins)
Change in Plasma 
Insulin relative to 
Zero Time (uUnits/ml)
Blood Glucose 
levels 
(mmol/1)
Quantity of (7h-2)- 
Glucose Normalized to 
1*0 at Zero Time
Control ToUb. Control] Tolb. Control Tolb.
0 4.73 5.01 1*000 1*000
(±0 .28) (±0 .11)
1 NM NM 4.90 4.84 0.331 0.323
:±o.i7) (±0.33) (±0.033) (±0.033)
3 NM NM 5.12 5 .0 6 0.312 0.322
(±0.22) (*0.44) (±0.033) (±0.033)
5 NM NM 5.01 4.73 0.27A- 0.295
(±0.22) (±0.22) (±0.026) (±0.033)
7 NM NM 4.84 4.90 0.2A-1 0.263
(±0.28) (±0.28) (-0.027) (±0.030)
9 5 90** 4.84 4,4o 0.232 0.223
(20 (=21) (±0.06) :±0.17) (±0.028) (±0.021)
30 -2 4,62 ,3.80* 0.035 0.027*
(-7) (±11) Cio.11) : ± o . 33 ) (-0.002) (±0.003)
60 10 6o* 4.95 2.97** 0.018 0.010*
(-8) (±15) (±0.28) (±0.44) (±0.003) (±0,002)
90 NM NM 4.79 2.53** ' 0.007 0.003**
(±0.22) :±0.39) (±0.001) (±0.001)
At zero time,the plasma insulin levels were 41 (-6) and 35 (-5)nU/m± 
for the control and tolbutamide groups,respectively#
Table 2(iii)
.EFFECT OF ORAL PHENFORMIN ON GLUCOSE,INSULIN AND (^H-2)-GLUCOSE LEVELS
IN BLOOD OF THE NORMAL RAT.
•z
Rats were injected with 10 jnCi ( H-2)-glucose i.v. and were orally dosed 
with either phenformin(0*2mmoVkg)or w±±h HPMC (1 ml/1 0 0 gm body weight) 
at zero time. Other details are as in Table 2(ii). The results are 
expressed as the mean - the standard error for 6 animals. Statistical 
significance v/as determined by Student*s t-Test - no significant 
differences were found between the control and phenformin.groups in this 
experiment. (NM = not measured).
Time after
(5h-2>-
Glucose
Change in Plasma 
Insulin relative to 
Zero Time (uUnits/ml)
Blood
Lev
(mmol
Glucose
els
L/l)
Quantity of (3h-2)- 
Glucose Normalized to 
1.0 at Zero Time
(mins) Control Phenformin Control Phenf. Control Phenformin
0 - - 4.35
(±0 .28)
4,51 
(±0.11:
1.000 1.000
1 NM NM 4.51 ■ 
(±0 .17)
4.35
(±0.391
0.313
(£0.030)
0.297
(±0 .032)
3 NM NM 4.57
(±0 .22)
4.57
(±0.¥f]
0.322
(£0.032)
0.314
(£0.030)
3 NM NM 4.29
(±0.17)
k.8k
(±0.33)
0 .292
(£0 .021)
0 .282
(£0.023)
7 NM . NM 4.73
(±0.33)
^ .1 8
(±0.28)
0*238
(-0.031)
0.277
(£0.020)
9
(-7)
20
(±12)
4.46
(±0.39)
4.29
(±0.39)
0.234
(£0.021)
0.220
(±0.024)
30
A)' I3(±8)
4.35
(±0.17)
4.24
(±0.39)
0.043
(±0.008)
O.O36
(±0.008)
60
(-11)
2
(±4)
4.62
(±0.22)
4.51
(±0.22)
0.010
(±0.002)
0.011
(±0.003)
90
j
NM HM 4.60
(±0.33)
4.62
(±0.17)
o.oo4
(±0.001)
0 .0 05 
(±0.001)
At zero time,the plasma insulin levels were 37 (-3) and 31 (-7) fx V /m l
for the control and phenformin groups,respectively.
Table 2(iv)
.EFFECT OF ORAL WY 23675 ON GLUCOSE,INSULIN AND (3H-2)^GLUCOSE LEVELS IN
IN THE BLOOD OF THE NORMAL RAT.
Rats were injected with 10 jiCi (H-2)-glucose i.v, and were orally dosed 
with either Wy 23675(0*2nmol/kg) or wi±h HPMC ( 1 ml/100 gm body weight) 
at zero time. Other details are as in Table 2(ii), The results are 
expressed as the mean for 6 animals with the standard error in brackets. 
Statistical significance was determined by Student*s t-Test:
** p{0*01 ; *** p<0,001 (NM : not measured)
Time after
(3H-2)-
Glucose
Change in Plasma 
Insulin relative to 
Zero Time (jiUnits/ml)
Blood Glucose 
Levels 
(mmol/1)
Quantity of (^H-2)- 
Glucose Normalized to 
1.0 at Zero Time
(mins) Control Wy 23675 Control Wy23675 Control Wy 23675
0 - - 5*12
:-o.33)
4,79
(±0.22)
1.000 1.000
1 NM NM 4.95 
;±0.22)
4.90
(-0.22)
0.353
(±0.032)
0.337
(±0.029)
3 NM NM 5 .1 7
:-o.39)
5 ,06
(±0.28)
0.313
(-0.031)
0 .3^6
(£0.030)
5 NM NM 4.8^ -
'.-0.28)
4.79
(±0.17)
0.335
(io.030)
0.322
(£0.032)
7 NM NM 5 .0 6
:±o.i7)
4.90
(-0.3 9)
0.300
;£o.o31f)
0.313
(£0.032)
9
(Sl7)
P(ii8)
4.90
:±0.22)
4.73
(±0.28)
0 t 290
[£0.031)
0.25^
(£0.021)
30 2
(-7)
61**
(£11)
4.73
(±0.22)
4,02
(-0.33)
0.036  
[±0.003)
0.022**
(±0.002)
60 P(-12)
80**
(-17)
4 .90
:±o.i.7>
3.08***
(io.28)
0.019
[±0.002)
0.003***
(±0.001)
90 NM NM
I
5 .0 6 2,86***
(-0.39)
0.005
[£0.001)
0.001***
(£0.001)
At zero time the plasma insulin levels were 32(£*f) and 35 (-6) i^TJ/ml
for the control and Wy 23675 groups,respectively.
Table 2(v)
.EFFECT OF INTRAVENOUS WY 25673 ON GLUCOSE,INSULIN AND (3H-2)-GLUCOSE
LEVELS IN BLOOD OF THE NORMAL RAT,
Rats were injected with 10 uCi (^H-2)-glucose i.v. and were injected i.v. 
with either Wy 23675(0«.08nmiO:l/kg)3r with 0.9% saline (0.1 ml/100 gm body 
weight) at zero time. Other details are as in Table 2(ii). The results 
are expressed sis the mean - the standard error for 6 animals. Statistical 
significance was determined by Student’s t-Test: -
* p<0,05 ; ** p<0,01 ; *** p^O.001 (NM : not measured)
Time after
(3h-2)-
Glucose
Change in Plasma 
Insulin relative to 
Zero Time (*xUnits/ml)
Blood Glucose 
Levels 
(mmol/1)
Quantity of (3h-2)- 
Glucose Normalized to 
1.0 at Zero Time
(mins) Control Wy 23675 Control Wy 23675 Control Wy 23675
0 - - 4.79
(±0 .28)
5 ,06
(±0.17)
1.000 1.000
1 NM NM 4.90
(±0.39)
4.84
(±0 .22)
0.302
(-0 .030)
0.323
(±0.031)
3 NM NM 5 .0 6
(*0.17)
4.95
(±0.17)
0.297
(±0.032)
O.32O
(±0.030)
5 NM NM 4.84
(±0 .2 2)
4,79
(±0.33)
0.298
(±0 .028)
0.287
(±0.031)
7 NM NM 4.90
(±0.39)
4.68
(±0 ,22)
0.263
(±0.029)
O.23I
(±0.027)
9
(±57)
X5
(-15)
4.57
(±0.33)
3.96
(±0.28)
0.219
(±0.031)
0.180
(±0.022)
30 12 
(-21)
24
(±1*0
4.84
(±0.22)
3.25**
(±0.33)
0.038
(±0.004)
0.024*
(±0.003)
60 11
(-11)
17
(±8)
4.90
(±0.39)
2.42***
(±0.28)
0.010
(±0.001)
0.004***
(±0.001)
90 NM NM 4.73
(±0.28)
?,o4***
(±0.44)
0.004
(±0 .001)
0.001***
(±0.001)
At zero time,plasma insulin levels were 41(±2) and 37 (-3) for the
control and Wy 23675 groups Respectively.
Table 2(vi)
.EFFECT OF INTRAVENOUS TOLBUTAMIDE ON GLUCOSE,INSULIN AND (^H-2)-GLUCOSE
LEVELS IN THE BLOOD OF THE NORMAL EAT.
Rats were injected with 10 ;uCi (^H-2)-glucose i.v. and were injected i.v. 
with either tolbutamide (Q.OBinmol/kgfcr with 0*9% saline (6.1 ml/100 Sm 
weight) at zero time. Other details are as in Table 2(ii). The results 
are expressed as the mean for 6 animals with the standard error of the 
mean in brackets. Statistical significance was determined by Student’s 
t-Test: * p(0.05 ; ** p<0.01 ; *** p<p.001 (NM : not measured)
(Tolb. = Tolbutamide)
Time after Change in Plasma Blood Glucose Quantity of (3h-2)-
(3h-2)- Insulin relative to Levels Glucose normalized to
Glucose Zero Time (uUnits/ml) (mmol/1) 1-0 at Zerc Tims------
(mins) Control Tolb. Control Tolb. Control Tolb.
0 '' 4* 90 ^•73 1.000 1.000
(io.17)(±0.22)
1 NM NM 3 .0 1 4*90 0.319 0.303
(-0.33)(=6.33) (±0.032) (±0.030)
3 NM NM 4 .79 +.79 0.322 0.327
(±0.28)(±0.39) (±0.032) (±0.037)
5 NM NM 4 .90 f.84 O.3OO 0.295
(±0 .22)(±0.28) (±0.032) (±0.022)
7 NM NM 4 .68 4.68 0.277 0.234
(io.22) (±0 .28) (±0.028) (±0.029)
9 10 105* 4 .95 4 .29 0.244 0.215
(-10) (-31) (±0.22) (±Os33) (±0.032) (±0.022)
30 17 85** 4.73 3.47* 0.037 0.023**
(±7) (ii8) (*0.33) (±0.39) (±0.002) (±0.003)
60 4 62** 4.68 2.81 * * * 0.021 0,008***
(±5) (±14) (^0.22) (=0.33) (±0.001) (±0.001)
90 NM NM 5.01 2.48*** 0.008 0.003***
(±0.28) (±0.33) |(±0.001) (±0.001)
At zero time,plasma insulin levels were 32 (±7) 27 (±5)ntfa±±s/m± ±or
the control and tolbutamide groups,respectively.
Table 2(vii)
.EFFECT OF ORAL DIAZOXIDE ON GLUCOSE,INSULIN AND (-^H-2)-GLUCOSE LEVELS
IN THE BLOOD OF THE NORMAL RAT.
Rats were injected with 10 uCi (3H-2)-glucose i.v. and were orally dosed 
with either diazoxide(1.6mmol/kg) or with HPMC (lml/100 gm body weight) 
at zero time. Other details are as in Table 2(ii). The results are 
expressed as the mean for 6 animals with the standard error of the mean 
in brackets. Statistical significance was determined by Student*s t-Test 
* p^O.05 ? ** p<0.01 ; *** p<0,001 (JIM : not measured)
Time after
(3h-2)-
Glucose
Change in Plasma 
Insulin relative to 
Zero Time (iiUnits/ml)
Blood Glucose 
Levels 
(mmol/1).
Quantity of (3h-2)- 
Glucose normalized to 
1.0 at Zero Time
(mins) Control Diazoxide Control Diazox. Control Diazoxide.
0 - - 4-.62 
^ 0.17)
4 .5?
(±0;28)
1 .000 1.000
1 NM NM 4 .73
[±0.22)
4.29
(±0.28)
0.323
(±0*033)
0.318
(±0.037)
3 NM NM 4.57
:±o.28)
4.62
(±0.11)
0.319
(±0.036)
0.323
(±0.031)
5 JIM NM <*.35 ■ 
[±0.22)
4.84
(±0.33)
0.298
(±0.031)
0.318
(±0.033)
7 NM NM >.57
[-0*22)
4,73
(±0.17)
0.279
(±0.030)
0.298
(±0.033)
9 5
«5)
-12*
(±5)
if.68
:±o.i7)
5.01
(±0.33)
0.254-
(±0.027)
0.277
(£0,028)
30 1
.(±3)
-28**
(-6)
4 .2 9
(±0.28)
5.61*
(±0.44)
0.037
(±0.004-)
0.04-8
(±0.004-)
60 1
(±2)
-31***
(±6)
4.55
(±0.38)
7,3?***
(±0.55)
0.021
(±0,002)
0.037**
(±0.003)
90 NM NM -
.
4.57
(±0.22)
7-98*** 
(±0.61)
0.009 
(±0.001) ]
0.017***
(±0.001)
At zero time,plasma insulin levels were 39 .(**0 and 40 (-6) jiUnits/ml
for the control and diazoxide groups,respectively.
Table 2(viii)
.EFFECT OF ORAL WY 23675 ON GLUCOSE,INSULIN AND (3H-2)-GLUCOSE LEVELS IN
THE BLOOD OF THE DIAZ OXIDE-TREATED RAT.
All rats used were dosed with diazoxide(1.6mmol/kg p.o.) 1 hour prior to 
the intravenous administration of (^H-2)-glucose (10 juCi) and oral 
dosing with either Wy 23675(0.2nmiol/kg)or with HFMC (1 ml/100 gm body 
weight) at zero time. Other details are as in Table 2(ii). The results 
are expressed as tne mean for 6 animals with the standard error of the 
mean in brackets. Statistical significance was determined by Student's 
t-Test: * p^0.05 ; ** p<0.01 ; *** p^O.001 (NM : not measured)
Time after
(3h-2)-
Glucose
Change in Plasma 
Insulin relative to 
Zero Time (iiTJnits/ml)
' Blood Glucose 
Levels 
(mmol/l)
Quantity of (3h-2)- 
Glue os e Normaliz ed to 
1.0 at Zero Time
(mins) Control Wy 23675 Control Wy23675 Control Wy 23675
0 - - 7.59
(-0.60)
8.03
(±0.5 0)
1.000
-
1.000
1 NM NM 7.81
(±0.44)
8.36 ' 
(±0 .61)
0.337
(±0.034)
0.318
(±0.032)
3 NM NM 7*54
(±0.55)
8,03
(±o.44)
0.326
(±0.032)
0.322
(±0.033)
5 NM NM 8.03 
(±0.72)
8.14
(-0.39)
0.318
(±0.038)
0.302
(-0 .039)
7 NT-1 NM 8.31
(±0.61)
7.65
(^0.35)
0.297
(±0.050)
0.289
(±0.022)
9 1 -7 8.14 7.59 0.283 0.263
(±7) (±4) (±0.39) (-0.39) (±0.030) (±0.027)
30 4 -5 8 .4 7 6.66* 0.0 5 2 - 0.031**
(±5) (±7) (±0.72) (±0.28) (±0 .006) (±0.003)
60 1 1 8 .69 4.90*** 0.038 0.019**
(*8) (±7) (±0.5 0) (±0.33) (±o.oo4) (±0.002)
90 NM NM 8.56
(±0.60)
5.-12**
(±0.72)
0.020
(±0.002)
O.007***
(±0.001)
At zero timefplasma insulin levels were 6 (±4) and 9 (-7) |iTJnits/ml for 
the control and Wy 23675 group,respectively.
Table 2(ix)
.EFFECT OF ORAL TOLBUTAMIDE ON GLUCOSE,INSULIN AND (^ -H»2)-GLUCOSE. LEVELS
IN THE BLOOD OF THE NORMAL FAT,
Rats were injected with 10 fiCi (^H-2)-glucose i.v. and were orally dosed 
with either tolbutamide(0.05mmol/kg) or with HPMC (1 ml/100 gm, body 
weight) at zero time. Other details are as in Table 2(ii), Results are 
expressed as the mean for 6 animals with the standard error of the mean 
in brackets. Statistical significance was determined by Student’s t-Test: 
* p/0,05 ? ** p/0,01 ; *** p/0,001 (NM : not measured)
(Tolb, = Tolbutamide)
Time after
(3H-2)-
Glucose
Change in Plasma 
Insulin relative to 
Zero Time (uUnits/ml)
Blood Glucose 
Levels 
(mmol/1)
Quantity of (^K-2)- 
Glucose Normalized to 
1,0 at Zero Time
(mins) Control Tolb, Control Tolb. Control Tolb.
0 - J'50
(±0.33)
5 ,28
(-0.39)
1,000 1.000
1 NM NM 5.39
(±0.39)
5.50
(±0.33)
0.3^2
(±0.032)
0.322  
(to.032)
3 NM NM 5.61
(±0.56)
5.39
(±0.28)
0 .330
(±0.037)
0.319  
(to.032)
3 NM NM 5.17
(±0.22)
5.'17 
(±0.28)
0.311
(±0 ,033)
0.308
(±0.030)
7 NM NM 5 .2 8
(±0.33)
^.73
(±0.22)
0 .300
(±0 .030)
0.287
(±0.032)
9 -12
(±8 )
61**
(-21)
5.50
(±0.22)
k.&k
(±0.33)
0 .272  
(to.027)
0,2*f1
(to.025)
30 8
(±9)
70**
(=12)
5.3^
(±0.33)
b.b6*
(±0.28)
0 .037
(±0.002)
0.028*
(±0.003)
60 12
(*3)
*f1
(-18)
5.17 
(±0.39)
^.07*
(±0.17)
0V019 
(to.001)
0.012**
(±0.002)
90
_------------ -- .....
NM' NM 5 .2 8
(±0.33) (±0.2 2)
0 .009
(±0.001)
0 ,005***
(±0.001)
At zero timetplasma insulin levels were 40 (*2) and 36 (±*0 jiUnits/ml 
for the control group and tolbutamide groupfrespectively.
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Table 2(x)
.EFFECT OF ORAL TOLBUTAMIDE ON GLUCOSE,INSULIN AND (^H-2)-GLUCOSE LEVELS
IN THE BLOOD OF THE DIAZOXIDE-TREATED HAT,
All rats used were dosed with diazoxide(1.6mmol/kg p.o.) 1 hr prior to the 
intravenous administration of (3h-2)-glucose (10 jiCi) and oral dosing with 
either tolbutamide (O.Q5mmol/kg)or with HPMC (1 ml/100gm body weight) at 
zero time* Other details are as in Table 2(ii). The results are expressed 
as the mean ± the standard error for 6 animals. Statistical significance 
was determined by Student*s t-Test - no significant differences were 
found between the control and tolbutamide groups. (NM : not measured)
(Tolb, = Tolbutamide)
Time after
(^H-2)-
Glucose
Change in Plasma 
Insulin relative to 
Zero Time (iiUnits/ml)
Blood Glucose 
Levels 1 
(mmol/l)
Quantity of (3h-2)- 
Glucose Normalized to 
1#0 at Zero Time
(mins) Control Tolb. Control Tolb. Control Tolb.
0 - 7.98
(-0.5 0)
8.31 - 
(±o.6i)
1.000 1.000
1 NM NM 8.47
(-0.55)
8,14
(±0.55)
0.298
(±0.031)
0.317
(to.031)
3 NM NM 7.81
(±o.44)
8,64
(±0.61)
0.312
(±0.033)
0.298  
(to.032)
5 NM NM 8.75
(-0.77)
8,42
(±0.39)
0.286 
(to.028)
0.291
(to.029)
7 NM ' NM 8.97
(±0.72)
8.53
(±0.72)
0.259 • 
(to.026)
0.263  
(to.030)
9 -6
(±7)
2
(±7)
8 .80
(-0,66)
8.80
(±0.55)
0.234  
(to.026)
0.230  
(to.028)
30 -7
(±3)
1
(±11)
8 #20 
(±0.66)
8,31
(±0.50)
0.049
(±0.005)
0.051~ 
(to.006)
60 2
(±5)
5
(±5)
8.64
(±0.44)
8.47
(±0.44)
0.034
(to.oo4)
0.035
(to.003)
90 NM NM 8.42
(±0.39)
8,25
(±0.61)
0.024
(to.003)
0.028
(to.004) ------------------.
At zero time,plasma insulin levels were 7 (~4) s-ad 4 (*3) jiUnits/ml for
the controland tolbutamide groups,respectively#
Table 2(xi)
♦ EFFECT OF ALLOXAN PR SIR BATMENT ON GLUCOSE AND (?H-2) -GLUCOSE LEVELS IN
THE BLOOD OF THE NORMAL RAT.
Alloxan-diabetic rats were treated as described in Methods and were used 
8 days afterwards# Both control and alloxan-diabetic rats were fasted for 
2k hrs prior to the experiment and were then injected with 10 p.C± (^H-2)- 
glucose i#v# (zero time)# Other details are as in Table 2(ii)# The results 
are expressed as the mean for 6 animals with the standard error of the 
mean in brackets. Statistical significance was determined by Student’s 
t-Test: ** p<0.01 ; *** p<9#001.
Time after
(3h-2)-
Glucose
•Blood Glucose Levels 
(ramol/l) . ..
Quantity of (2H-2)-glucose 
in Plasma normalized to 1.0 
at Zero Time
(mins) Control Alloxan Control '.Alloxan
6 3r58
(20.28)
15.51***
(io.99)
1.000 1.000
1 3.91 - 16.23*** 0.312 .0.343
(io.39) (ii.2i> (i0.^ )32) (20.052)
3 *£•02 15.07*** 0.306 0.319
(id.28) (io.61) (to.030) ; (io.039)
5 3^74 15.84*** 0.28^ ,0 .526
(2o ,5o ) (il.;12) (±0.029) (io.o4D
7 3.63 16.3 4*** 0.;2?0
(±0.026)
0 .314
(id.33) (io.99) (io.038)
9 3 .80 16;61*** 0 .23V- 0 .274
(io.22) (io.94) (±0.026) (id.032)
30 3.47 16.01*** 0.022 o.OM***
(io.44) (ii.3 2) (±0.001) (±0.003)
60 3.63
(io.33)
15.90*** 0.011 0.036***
(ii.54) (±0.001) (±0.003) -I
90 3.25 16.3 4*** 0.005 0.030**
(io.39) (ii.1 0) (±0.001) (±0.006)
At zero time,plasma insulin levels were 39 (±5) jatfnits/ml tor the controls 
but were below the sensitivity of the radio-immunoassay in the alloxan- 
treated rats#
Table 2(xii)
.EFFECT OF INTRAMUSCULAR INSULIN ON GLUCOSE AND (?H-2)-GLUCOSE LEVELS IN
THE BLOOD OF THE ALLOXAN-DIABETIC RAT.
Rats,alloxan-diabetic for 8 days (see Methods),were fasted for 2k hrs 
prior to the experiment and were then injected with 10 jiCi (^H-2)-glucose 
i.v. and with either protamine zinc insulin (4- units/rat i.m. or with 0»9% 
saline (0.1 m3/100 gm. body weight i.m) at zero time. Other details are 
as in Table 2(ii). The results are expressed as the mean for 6 animals 
with the standard error of the mean in brackets. Statistical significance 
was determined by Student’s t-Testj * p<0.05 ; ** p<0.01 ; *** p<0.00l
(NM : not measured)
Time after
(3h-2)-
Glucose
Blood Glucose Levels 
(mmol/1)
Quantity of (*H-2)-glucose 
in Plasma normalized to 1.0 
at Zero Time —
(mins) Control Insulin Control Insulin
0 17*93
(il.49)
18.92
(ii,7D
1.000 1.000
1 18,65
(-1.16)
17.66
(-1.49)
0.322
(io.031)
0.325
(io,037)
3 18.76
(-1.05)
18.48
(il.2D
0.332
(io.034)
e;3o4
(io.o4o)
5 18.10
(.-1.65)
19.20
(-1.76)
0.318
(io.032)
0.315
(io.032)
7 16.94
(il.54)
17.05 
(-1.49)
0.305
(io,p42)
0.279
(io.030)
9 17.16
(ii.05)
15.79
(il.32)
0.287
(io.034)
0.222
(io.053)
30 17.93
(ii.76)
11.72*
(ii.6o)
0 .052
(io.oo6)
<04028*
(io.007)
60 18.32
(io.99)
7.92***
(ii.;i6)
O.O^f
(io.005)
0,011***
(io.001)
90 17.55
(ii.49)
9.19**
(ii.6o)
0,031
(io.005)
0 ,005***
(io.001)
Table 2(xiii)
.EFFECT OF ORAL TOLBUTAMIDE ON GLUCOSE AND (3H-2)-GLUCOSE LEVELS IN THE
BLOOD OF THE ALLOXAN DIABETIC RAT,
Rats,alloxan-diabetic for 8 days (see Methods)#were fasted for 24- hrs 
prior to the experiment and were then injected with 10 jaCi (3h-2)-glucose 
i.v# and were orally dosed with either tolbutaraide£>#2 mmol/kg) or with 
HPMC ( 1 ml/100 gm. body weight) a t zero time. Other details are as in 
Table 2(ii). The results are expressed as the mean for the 6 animals with 
the standard error of the mean in brackets. Statistical significance was 
determined }jy Student*s t-Test -no significant differences were found 
between the control and tolbutamide groups.
Time after
(3h-2)-
Glucose
Blood Glucose Levels 
(mmol/1)
Quantity of (3h-2)-glucose 
in Plasma normalized to 1.0 
at Zero Time .
(mins) Control Tolbutamide Control Tolbutamide
0 20.63
(-2.09)
21.56
(-1.7D
1.000 1.000
1 19.64- 
(-2.20)
19.91
(*1.65)
0.331
(-0.033)
0.34-1
(*0.037)
3 19.91
(-1.76)
20.79
(*1.4-9)
Q.322
(ib.037)
0.328  
(—o.o4-i)
3 20.19
(-1.21)
20.96
(-1 •5Z0
0.319
(-0.039)
,0.328
(*0.033)
7 21.56
(±1.65)
20 AS 
(-1.76)
0.293
(io.027)
0.280
(*0.031)
9 21.34
(-2.26)
22.66
(-2.09)
0.258  
(io.030)
0.273
(*0.030)
30 19.47
(-1.05)
21.40-
(-2.26)
0.062
(±0.008)
0.060
(*0.006)
60 20.35
(*1.49)
21.67
(*2.15)
0.04-8
(*0.004-)
0.04-2
(*0.005)
90 21.18  
(-1.71)
'22.33
(*1.4-3)
0.031
(-0.004-)
0.027
(*o.oo4-)
Plasma insulin levels were below the sensitivity of the radio-immunoassay 
in both groups.
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Table 2(xiv)
.EFFECT OF,.ORAL.PHENFORMIN ON GLUCOSE AND (3h-2)-GLUCOSE LEVELS IN THE
BLOOD OF THE ALLOXAN-DIABETIC RAT,
Rats,alloxan-diabetic for 8 days (see Methods) ,were fasted for 2k hrs 
prior to the experiment and were then injected with 10 jiCi (-^-2)-glucose
i.v. and were orally dosed with either phenformin(0.2mmol/kg) or with 
HPMC (1 ml/100 gm.body weight) at zero time* Other details are as in 
Table 2(ii)* The results are expressed as the mean for 6 animals with the 
standard error of the mean in brackets. Statistical significance was 
determined by Student*s t-Test: * p<0.05 ; ** p<0.01 ; *** p<p.001
(NM : not measured)
Time after
(3h-2)-
Glucose
Blood Glucose Levels 
(mmol/1)
Quantity of (3h-2)-glucose 
in Plasma normalized to 1.0 
at Zero Time
(mins) Control Phenformin Control Phenformin
0 21.78  
(±1.71)
17.93
(-1 .^ 9)
1.00c 1.000
1 15.57
(±1.49)
17. bb 
(±2.15)
0.329
(-0.037)
0 .3 2 0
(io.oVi)
3 17.16
(-1.76)
18.59
(±1.32).
0.318
(-0.0^ 3)
0.325
(-0.039)
5 16.89
(±1.05)
18.81
(±1.65)
0.293
(-0 .0*f0 )
0.292
(-0.031)
7 16.06
(-1.38)
17.55
(±1,21)
Q.272
(-0.030)
0.269
(-0.030)
9 17.38 
(-1.32)
15.68
(±1.60)
0*2k9
(-0*022)
0.213
(-0.020)
30 17.99
(-1.93)
13.^2
(±1.16)
0.057
(^ 0.007)
0.028**
(±0.003)
60 16.^ 5
(±1.21)
11.22*
(-1.76)
0 .0V 1
(io.ooA-)
0,016***
(-0.002)
90 16.67
(io.99)
11.88*
(±1.5 )^
0.032
(-0.003)
O.007***
(±0.001)
Plasma insulin levels were below the sensitivity of the radio-immunoassay
in both groups.
Table 2(xv)
.EFFECT OF ORAL WY 23675 ON GLUCOSE AND (3H-2)-GLUCOSE LEVELS IN THE
BLOOD OF THE ALLOXAN-DIABETIC RAT.
Rats,alloxan-diabetic for 8 days (see Methods),were fasted for 2k hrs prior 
to the experiment and were then injected with 10 pCi (^H-2)-glucose i.v. 
and were orally dosed with either Wy 23675(0.2mmol/kg) or with HPMC (1 ml/ 
100 gra. body weight) at zero time# Other details are as in Table 2(ii).
The results are expressed as the mean for 6 animals with the standard error 
of the mean in brackets. Statistical significance was determined by 
Studentfs t-Test: * p(0.05 ; *** p(0.001 (NM : not measured)
Time after
(3h-2)-
Glucose
! Blood Glucose Levels 
(mmol/1)
Quantity of (^H-2)-glucose 
in Plasma normalized to 1.0 
at Zero Time
(mins) Control Wy 23675 Control Wy 23675
0 13.51
(-1.21)
16.72
(-1.65)
1.000 1.000
1 16.17 
(-1.71)
16.01
(-1.10)
0.318
(-0.037)
.0.338
(±0.039)
3 15.79 
(-1.60)
15.90
(-1.^9)
0.311
(-0.030)
0 ,322
(±0,0if2)
3 17.27
(-1.^9)
17.11
(-1.38)
0.301 
(-0.031)
0.291
(±0.03*0
7 16.3^
(-1.38)
16.50
(-1.65)
0,280
(±0.030)
0,650  
(±0.031)
9 16.-83
(-1.32)
16.06
(-1.76)
0.257
(±0.026)
0.218
(±0.023)
30 16.50
(-1.27)
12.05*
(-1.^9)
Q.063
(±0.007)
0.032**
(±0.003)
60 15.51
(-1^ 9)
9.35*
(-1.38)
0.050
(±0.005)
0.020***
(±0.002)
90 16.17
(-1.71)
10.12* 
(-1.21)
0.0^3
(±0.005)
0.007***
(io.001)
Plasma insulin levels were below the sensitivity of the radio-immunoassay
in both groups.
Table 2(xvi)
.COMPARISON OF THE USE OF (^H-2)-GLUCOSE AND (^H-3)-GLUCOSE TO MEASURE 
GLUCOSE UTILIZATION IN NORMAL#UNTREATED RATS *IN VIVO*.
Rats were injected ,with either 10 |aCi (^H«2)-glucose or 10 fiCi (^H-3)- 
glucose/200 gm body weight i*v«. Blood samples were taken at the time 
intervals shown and used for plasma insulin and glucose analysis 'and for 
measuring -'H-labelled glucose# Other details are as in Table 2(ii). The 
results are expressed &b the mean for 6 animals with the standard error of 
the mean in brackets* Statistical significance was determined by Student*s 
t-Test s * p<0,05 5 ** p<0*01 (Gl* « Glucose ; -NM = not measured)
Time after 
3H-Glucose
Change in Plasma 
Insulin relative to 
Zero Time CnUnits/ml)
Blood Glucose 
Levels
(mraol/l)
Quantity of ^H-Gl. 
Normalized to 1*0 at 
Zero Time
(mins) (^H^-Gl* pH-3)~Gl* pH-2)-Gl* (>H-3)-Gl, (3H-2)-Gl, (2h-3)-G1.
0 - -
(*>.28)
4.62
(±0.33)
1*000 1.000
1 NM NM 4.57
(±d.33) (io.39)
O.323
(io.033)
0.339 
(io.041)
3 NM NM V.51
(±0.22)
5.06
(±o.W
0.321
(io.030)
0.322
(±0.038)
5 NM NM W73
(-0.39)
4.95
(id.28)
0.297
(io.031)
0.307
(±0.039)
7 NM NM 4.29
(%28)
4.73
(±0.33)
0.268
(io.029)
q;292
(±0.032)
9 11
(±*0
6
(±3)
k.62
(±0,117)
«t.'62
(±0.33)
0.235
(±0.021)
0.278
(±0.030)
30 5
(±5)
7
(±*f) (±0?33)
4.8^
(io.39)
0.036
(±0.002)
0.0*6*
(±0.003)
60 12
<*fc)
7
(±3)
4.95
(—0*22)
4*73
(io.33)
0.018
(±0.002)
0.028**
(±0.002)
90 NM NM 4.57
(io.39)
4.35
(±0.22)
0.009
(±0.001)
0.016**
(±0.002)
At zero time9the plasma insulin levels were 38 (±7) and kO (*6) jiU/ml for
the (3h-2)-glucose and (^H-3)-glucose injected groupsRespectively*
* Table 2(xvii)
.EFFECT OF INTRAMUSCULAR INSULIN ON GLUC06B AND (?H-5)-GLUCOSE LEVELS IN
THE BLOCS) OF THE NORMAL RAT.
Rats were injected with 10 nCi (^H-3)-glucose i*v* and with either 0*1 mis 
of protamine zinc insulin (h jinits/rat ±.m*) or 0*1 mis saline i.m. 
(controls) at zero time* Other details are as in Table 2(ii)« The results 
are expressed as the mean * the standard error for 6 animals* Statistical 
significance was determined by Student*s t-Test:
** p(0.01 ; *** p(0«001 (NM = not measured)
Time after
(3h-3)-
Glucose
Blood Glucose Levels 
(mmol/l)
Quantity of (3h-3)-glucose 
in Plasma Normalized to 1*0 
at Zero Time
(mins) Control Insulin Control Insulin (
0 4.57  
(lb.28)
5 #01 ! 
(*3.33)
1.000 1.000
1 4.46
(lo.44)
4.73 ■ 
(-0,2$)
0-327
(±o,o4?)
0.313
(-0*039)
3 4.75
(10*28)
4.62
(io.33)
0.313
(I0.037)
0.306 
( -0 .okz)
5 4,62
(lo.22)
5.01 
(2b. 17)
0.291 - 
(I0.036)
0.288
(-0.038)
7 4.95
(I0.33)
4.84
Clo.17)
0.279
(I0.038)
0^.266
(-0.028)
9 4.84  
(lb,28)
4.73 ; 
;lo.22)
0.262
(I0.029)
O.23I
(-0.022)
30 4i57
(lo.17>
3.96 - 
:lo.22)
0.047
(I0.003)
0.028** 
(A ).002)
60 4.73 
(lb.28)
3.30*** Q.030
(lb.003)
O.OO7***
(io.001)
90 4.79
(-0,22)
3.31***
:io.j28)
Q.015
(lb.001)
0.002*** 
(4) .001)
Table 2(xviii)
.EFFECT OF ORAL WY 25675 ON GLUCOSE.INSULIN AND (^H-3)-GLUCOSE LEVELS IN
BLOOD OF THE NORMAL RAT.
Rats were injected with 10 pCi (-^ H-3)-glucose i.v. and were dosed orally 
with either Wy 23675(0#‘2 mmol/kg) or with HPMC (1 ml/100 gm body weight) at 
zero time. Other details are aa in Table 2(ii)« The results are expressed 
as the mean ± the standard error for 6 animals. Statistical significance 
was determined by Student1s t-Test:
* p<0.05 ; ** p^O.01 ; *** p^O.001 (NM = not measured)
Time after
(5H-3)-
Glucose
Change in Plasma 
Insulin relative to 
Zero Time (uUnits/ml]
Blood Glucose 
Levels 
(mmol/l)
Quantity of (3h-3)- 
Glucose Normalized to 
1.0 at Zero Time
(mins) Control Wy 23675 Control Wy 23675 Control Wy 23675
0 - - ^•35
(-0.33)
k.6Z
(±0.28)
1.000 1.000
1 NM . NM h.57
c-0 .28)
*[.57 ■ 
(±0.22)
0.308
(-0.0V D
0.322
(-0.039)
3 NM NM i .73
(±0.33)
>.73
(±0.1?)
0.305
(±0.036)
0.300
(±0.0^3)
5 NM NM k.zk
(±0.22)
4.79'
(±0.33)
0.289
(-0.035)
0.275
(±0.031)
7 1#! NM ^.51
(±0.17)
1.62
(±0.22)
0.269
(-0.031)
0.2A-8
(±0 .032)
9 7 1A- W.6Z k.29 0.252 0.229
(-3) (±5) (-0.33) (±0 .2 8) (-0.027) (±0.025)
3° 10 VI* <f.l8 3.63*
(±0.17)
Q.0^5 0.020***
(±*0 (-9) (±0.17) (-0.00A-) (±0.002)
60 6 63** ^.35 2.92** 0.031 O.OO7***
(±2) (±15) (±0.28) (iO.17) (±0.003) (±0.001)
90 NM NM *[.57
(±0.22)
2.59***
(-0.28)
0.017
(±0.002)
0.003***
(±0.001)
At zero time,the plasma insulin levels were 32 (*5) a^d 38 (*3) pU/ml f o r
the control and Wy 23675 groupsfrespectively*
Table 2(xix)
.EFFECT OF INTRAMUSCULAR INSULIN ON GLUCOSE AND C^H«5)GLUC(BE LEVELS IN
THE BLOOD OF THE ALLOXAN-DIABETIC RAT.
Rats,alloxan-diabetic for 8 days (see Methods) f were fasted for 24 hrs prior 
to the experiment and were then injected with 10 jiCi (*H-3)-glucose i.ir. 
and with either protamine zinc insulin (4 jinits/rat i.m.) or with 0 .9$ 
saline (0.1 ml/100 g® body weight) at zero time^ Other details are as in 
Table 2 (ii). The results are expressed as the mean * the standard-error 
for 6 animals^ Statistical significance was determined by Studentfs t-Test:: 
** p<0.01 j *** p<0.001 (NM = not measured)
Time after
(*H-3)-
Glucose
Blood Glucose Levels
(ramol/1)
Quantity of ( H-3)-glucose
in Plasma Normalized to 1.0 
at Zero Time
(mins) Control Insulin Control1 Insulin
0 19.36
(-2.09)
18.48
(±2.42)
1.000 1.000
1 20 .'19 
(±2.31)
19.31
(±2.o4)
.0**33? 
(±0 .036) ,
.0,313
(-0.034)
3 19.20
(±1,;82)
18.59
(±1.9-3)
cr±3l6
(±0.034)
0£502 
(-O.O38) ■
5 I9i«9
(-2W59)
19.03
(±1.76)
0 .50 2
(±0 .0 3 2)
0.27?
(-0.028)
7 20-^6
(±1.6 5)
17.71
(±1.98)
0^295
(±0.030)
0.233
(-O.026)
9 19ii'09
(±2.04)
16;89
(±1.71)
0.281
(±0 .025)
0.232
(-0*022)
30 19.’86
(±1.98)
10;23**
(±ii'7D
0,086 
(-0*006) ,
0,047***
(-O.OO5 )
60 19^9
(±1.8?)
,7.98***
(±1.54)
0,061
(&.007)
~0.A015***
(£0.001)
90 19.09
(±1.60)
37.92***
(±1.7 6)
0.043
(-0.003)
“0,008*** 
(io.001) :.
Table 2(xx)
.EFFECT OF ORAL WY 25675 ON GLUCOSE AND (^H-3)-GLUCOSE LEVELS IN THE
BLOOD OF THE ALLOXAN-DIABETIC RAT,
Rats,alloxan-diabetic for 8 days (see Methods),were fasted for 24 hours 
prior to the experiment and were then injected with 10 jiCi (3h-3)-glucose
i.v# and were dosed orally with either Wy 23675(0*2mmol/kg) or with HPMC 
(1 ml/100 gm body x^ eight) at zero time. Other details are as in Table 2(ii) 
The results are expressed as the mean - the standard error for 6 animals. 
Statistical significance was determined by Studentfs t-Test:
* p<0.05 ; ** p(0.01 ; *** p<0.001 (NM = not measured)
Time after
(3h-3)-
Glucose
Blood Glucose Levels 
(mmol/1)
Quantity of (^H-3)-glucose 
in Plasma Normalized to 1.0 
at Zero Time
(mins) Control Wy 23675 Control Wy 23675
0 17.66
(±2.31)
17.05
C-1.^9)
1.000 1.000
1 16.83
(±2.04)
17.99
(±1.8 2)
0.352
(-0.041)
0.327
(£0.035)
5 18.37.
(±2.48)
18,48
(±1.65)
0.342-
(-O.O36)
0.319
(£0.032)
5 19.09
(-1.93)
17,88 . 
(±1.38)
0.321
(i).032)
0.292
(£0.031)
7 18.1+8
(±1.82)
17.16
(±1.98)
0.309
(io.031)
0.278
(£0.028)
9 17.82
(-2.09)
16.6?
(±1.76)
0*293
(£0.030)
0,248
(^0.025)
30 17.49
(-1.87)
12.43*
(±1.16)
0/113
(-0.010)
0.054***
(£0.006)
60 18.48
(±2.09)
10.51*
(±1.54)
0.074
(-0.008)
0,033***
(£0.003)
90 18.04
(il.'76)
.9.63**
(±1.65)
0.050
(-0.004)
"0,012***
(£o.001)
Plasma insulin levels were below the sensitivity of the radio-immunoassay |
in both groups©
■Discussion#
The results described in this chapter have shown some effects of the 
hypoglycaemic agents-insulin,tolbutamide,phenformin and Wy 23675-on 
glucose utilization in vivo in normal,diazoxide-pretreated and alloxan- 
diabetic rats# The use of the three different models (ie: normal, 
diazoxide-pretreated and alloxan-diabetic rats) has enabled differences 
in the inodes of action of tolbutamide,phenformin and Wy 23675 to be 
high-lighted#
Diazoxide-pretreatment resulted in an inhibition of insulin release 
from the pancreatic J3-cells and therefore a fall in plasma insulin levels, 
which,in turn,resulted in a hyperglycaemia and an increase in the plasma 
glucose pool size# The injection of the same quantity of radiolabelled 
glucose into normal and diazoxide-treated rats resulted in a considerably 
greater dilution of radioactivity in the larger glucose pool of the 
diazoxide-treated rats than in the normal rats and,therefore.the quantity 
of radiolabelled glucose lost from the pool was very much less in the 
diazoxide-treated rats than in the normal rats,even though the rates of 
glucose utilization could have been the same in both situations# This 
emphasizes the necessity for the careful selection of controls when using 
comparative rates of radiolabelled glucose disposal to measure glucose 
utilization# For this reason,the effects of the hypoglycaemic agents were 
studied in diazoxide-pretreated rats,rather than investigating the effects 
of diaz oxide**tr eat ment in rats treated with the hypoglycaemic agents. 
Fhysiologically,diazoxide-pretreatment represented a situation of 
hyperglycaemia,in which insulin release was blocked.
Alloxan-treatment,on the other hand,resulted in a marked hyper- 
glycaemia through the destruction of the pancreatic B-cells,which caused 
a fall in plasma insulin to levels below the limits of detection by 
radioimmunoassay. Alloxan-diabetes caused an apparent decrease in tiie 
quantity of radiolabelled glucose lost from the plasma pool compared 
■frith normal controls. However,when the mean rate coefficient for glucose 
utilization was multiplied by the mean quantity of glucose in the pool
diabetic rats,was approximately 3»5~fold the value for the normal rats# 
Thus,alloxan-diabetes resulted in an increase in the rate of glucose 
utilization as compared'with.the fasted,control rats# Baker et al (7) 
have similarly reported increase in the rate of glucose utilization in 
fasted,alloxan-diabetic rats,which was accompanied by an increase in the 
rate of glucose oxidation to carbon dioxide as compared with normal,fastec 
rats# The high rate of glucose utilization in the fasted,alloxan-diabetic 
rat may be a reflection of the high circulating concentrations of glucose, 
in contrast to normal rats,where fasting results in a considerable 
reduction in blood glucose concentrations.
The rates of glucose utilization in control animals in the present 
experiments were similar to those reported by Heath and Corney (45) -
0.004 mmol glucose/min/100 gm rat body weight ; cf. 0.005 mmol/min/100 gm 
rat body weight in the present work.
Insulin,in these experiments,increased the rate of glucose utilizatio 
in both normal and alloxan-diabetic rats. Tolbutamide,by increasing 
plasma insulin levels in normal rats,stimulated glucose utilization 
indirectly. Thus,when insulin release was inhibited by diazoxide or in 
the alloxan-diabetic rat,tolbutamide had no effect on glucose utilization.
The results for tolbutamide contrast with those of phenformin,which
had no effects on either insulin release or glucose utilization in the
normal rat,while in the alloxan-diabetic rat it caused an increase in the
rates of glucose utilization. These findings for phenformin in the rat
are in contrast to those of Searle and Cavalieri (46) in human subjects.
14From studies using C-glucose,these authors concluded that glucose 
turnover is increased by phenformin,and that this effect is greater in 
non-diabetic than in diabetic subjects. They reason that the increased : 
removal of glucose in the non—diabetic is compensated by increased i
. . ■ ■ j
glueoneogenesis,and hypoglycaemia does not occur. In the diabetic, 
gluconeogenesis is already maximal and cannot be increased,resulting in I
i
a fall in blood glucose levels. However,the studies of Altschuld and *
gluconeogenesis from lactate and glycerol is inhibited by phenformin. 
Other workers have made similar findings in both the guinea-pig (48) and 
rat livers (49,50). The results reported in this chapter indicate,that 
at least part of the hypoglycaemia caused by phenformin in the alloxan- 
diabetic rat is due to an increase in glucose utilization.
The results for the novel hypoglycaemic agent ,Wy 23675,contrast with 
both those from the sulphonylurea,tolbutamide,and from the biguanide, 
phenformin. Unlike phenformin,Wy 23675 inoreased glucose utilization in 
the normal,fed rat. However,oral administration of Wy 23675 also increase 
plasma insulin levels and so,in this way resembled tolbutamide in its 
action. When Wy 23675 was administered intravenously it had no effect on 
plasma insulin levels,but still increased glucose utilization. Thus,the 
action of Wy 23675 differed from both phenformin and tolbutamide in the 
normal rat. Further confirmation of the insulin-independant action of 
Wy 23675 on glucose utilization was obtained in experiments in which 
diazoxide blocked insulin release. Under these conditions,Wy 23675 still 
stimulated glucose utilization..Wy 23675 also stimulated glucose 
utilization in the alloxan-diabetic rat,as did phenformin. Thus,a 
comparison of the effects of Wy 23675 on glucose utilization v/ith those 
of phenformin and tolbutamide,reveals novel aspects of Wy 23675 action.
In all cases,the stimulatory effects of these agents on glucose 
utilization paralleled their effectiveness in causing hypoglycaemia. It 
can be concluded,therefore,that this stimulation is part of the 
mechanism by xvhich these agents induce a fall in blood glucose levels*
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,Chapter 5# - Summary#
This section contains the results of experiments carried out with
investigate the effects of selected hypoglycaemic agents upon glucose 
utilization,lactate and pyruvate production,and glycogen synthesis# 
Results of incubations carried out with normal rat hemidiaphragms 
showed the following effects of these agents:-
1# Insulin stimulated glucose uptake and glycogen synthesis in a dose- 
related manner,but had no effect on lactate and pyruvate production#
2# Tolbutamide had no effect on glucose uptake,lactate and pyruvate 
production,or glycogen synthesis#
3# Phenformin had no effect on any of the parameters measured at 
therapeutic concentrations (2jiM),but did stimulate glucose uptake and
lactate production and lower glycogen levels at higher concentrations 
(200 fiM)# '
insulin was to bring the levels of glucose utilization and glycogen
3# Tolbutamide,as with normal rat hemidiaphragms,had no effect on
was a significant phenformin effect at ten-fold lower concentrations
rat hemidiaphragms (prepared from normal and alloxan-diabetic rats) to
4# Wy 23675 did stimulate glucose uptake and glycogen production at 
concentrations that would be reached with hypoglycaemic doses of the 
drug,but had no effect on lactate and pyruvate production#
Results from incubations carried out with hemidiaphragms from alloxa 
diabetic rats showed the following effects of these agents 
1# Hemidiaphragms from alloxan-diabetic rats had lower rates of glucose 
uptake and glycogen synthesis than those from normal rats,although 
the production of lactate and pyruvate v/as not significantly altered#
2#‘ Insulin significantly stimulated glucose uptake and glycogen synthesis 
but ahd no effect on lactate and pyruvate production# The effect of
synthesis to those of hemidiaphragms prepared from normal rats#
glucose uptake,lactate and pyruvate production,or glycogen synthesis#
4# Phenformin stimulated glucose utilization and lactate production and 
lowered glycogen levels,but had no effect on pyruvate production# There
with hemidiaphragms from alloxan-diabetic rats than from normal rats#
5*. Wy 23673,like insulin,elevated glucose uptake and glycogen synthesis 
by hemidiaphragms from alloxan-diabetic rats to levels normally seen with 
untreated rat hemidiaphragms# Wy 23675 had no effect on lactate or 
pyruvate production.
The results shown in this chapter support the in vivo findings on glucose 
utilization described in Chapter 2# Differences in the actions of 
Wy 23675 and the other drugs studied are further illustrated ; and their 
possible mechanisms of action are discussed#
Agents that lower blood glucose levels can do so by either stimulating 
glucose uptake and/or inhibiting glucose synthesis# Muscle is a major site 
of glucose utilization and probably the two most used animal models to 
study this are the rat hemidiaphragm and the isolated perfused rat hind- 
quarter preparation#
Insulin has been shown to accelerate both the utilization of glucose 
(1-10,2 7) and the synthesis of glycogen (1,7,8) by the isolated rat 
hemidiaphragm,but has no effect on lactate production (3?.&)* /# Studies in 
the isolated perfused rat hindquarter have shown similar effects of 
insulin (16-24)#
The studies with radiolabelled glucose in Chapter 2# have shown that 
tolbutamide has no effect on glucose utilization unless insulin is 
available and that phenformin has no effect on glucose utilization in the 
normal rat,but does stimulate it in alloxan-diabetic rats.
Feldman and Lebovitz (25) have presented evidence that tolbutamide 
may potentiate insulin effects on skeletal muscle metabolism# They used 
intact mouse diaphragm and showed that tolbutamide in vitro did not 
increase 2-deoxyglucose uptake nor did it augment insulin-mediated 
2-deoxyglucose uptake# However,when tolbutamide was administered in vivo 
up to twelve days before sacrifice a significant potentiation of the 
insulin effect on 2-deoxyglucose uptake was observed#
Biguanides have been reported to stimulate glucose uptake by hemi­
diaphragms from normal rats (3 ,12—15)»but the concentrations of drug used 
in these studies were well above those obtained in the blood following 
therapeutic doses# Frayn and Adnitt (7) have exposed rat hemidiaphragms 
to therapeutic concentrations of metformin (10 jig/ml) and failed to 
show any effect of the drug on glucose uptake,either in the absence or 
presence of insulin,although they showed a stimulation at higher non- 
therapeutic concentrations# In hemidiaphragms from alloxan-diabetic rats, 
they showed that metformin enhanced the insulin-stimulation of.glucose 
uptake# Work with isolated perfused hindquarter preparations from normal 
rats have shown a lack of any effect of biguanides in therapeutic
of insulin (21,22,26).
The work described in this chapter compares the effects of insulin, 
tolbutamide and phenformin with those of Wy. 23675 on glucose uptake, 
lactate and pyruvate production,and glycogen synthesis in both normal 
and alloxan-diabetic rat hemidiaphragms•
The sources of all drugs used were given in earlier chapters#
Enzymes used for lactate and pyruvate analyses were obtained from 
Sigma, Kingston-upon-Thames, Surrey •
Methods #
The preparation of isolated rat hemidiaphragms was based upon the 
method of Vallance-Owen and Hurlock (27)# Hemidiaphragms were prepared in 
the same way from both normal and alloxan-diabetic (blbod glucose levels 
greater than 16#3 mmol/litre after 48 hrs) rats#
110-140 gm male rats were fasted for 18 hrs prior to being killed by 
decapitation# The abdomen was opened and the diaphragm was carefully 
removed and placed in ice-cold glucose-free Krebs-bicarbonate buffer 
equilibrated with 93% 0^/3% (pH 7*4)# The diaphragm,while so immersed, 
was divided into two approximately equal halves,the thick posterior portio 
being discarded. For the incubations,one hemidiaphragm was used as a 
control and the other as a test# Each hemidiaphragm was gently blotted, 
weighed and placed in a small beaker containing 2 mis of the incubation 
medium#
Incubations were carried out at 37*0 for 90 minutes and shaken at 
90 Cscillations/minute# Each beaker was gassed throughout the incubation 
period with 93% 0£/5% C02# The incubation medium was Krebs-bicarbonate 
buffer,equilibrated with 95% 0^/5% 00^ (pH 7• 4),containing 16.5 mmol/litre 
glucose#
Drugs were added to the incubation medium prior to the addition of the 
hemidiaphragms# At the end of the incubations,the rat hemidiaphragms were 
removed from the medium and aliquots of the medium were thoroughly mixed 
with an equal volume of ice-cold 10% trichloroacetic acid (TCA) and 
centrifuged at 2000g. for 5 minutes.
Samples were assayed for glucose on the Autoanalyzer and for lactate 
and pyruvate,using enzymatic techniques (28)#
On removal from the medium,the rat hemidiaphragm was immediately 
homogenized in 10 mis of ice-cold 5% TCA and centrifuged at 2000g for 
10 minutes# 1 ml samples of the supernatant were treated as described by 
Pfleiderer (29) to hydrolyze the glycogen to glucose and the glucose 
concentration was then determined on the. Autoanalyzer#
a)# Glucose Uptake#Lactate and Pyruvate Production#and Glycogen Synthesis 
by Hemidiaphragms Prepared from Normal,Fasted Rats# !
Insulin caused a dose-related increase in glucose uptake by the rat 
hemidiaphragm in these experiments- Table 3(1)# There was no significant 
change in lactate or pyruvate production,but insulin did increase 
glycogen synthesis by the hemidiaphragm. In comparison,tolbutamide had 
no effect on any of the parameters measured in concentrations as high as 
20mM - Table 3(i)# Phenformin did cause an increase in glucose uptake by 
the rat hemidiaphragm,although this was only measurable at the 
concentration of 200juM - Table 3(i)* This increase in glucose uptake was 
accompanied by an increase in lactate production and a fall in glycogen 
synthesis. Wy 23675flike insulin,caused a dose-related increase in 
glucose uptake,which was accompanied by an increase in glycogen synthesis; 
with no apparent change in lactate or pyruvate production - Table 3(i)v '
b). Glucose Uptake#Lactate and Pyruvate Production,and Glyeogen Synthesis 
by Hemidiaphragms Prepared from Alloxan-Diabetic,Fasted Hats.
Hemidiaphragms from fasted,normal rats (mean blood glucose levels of 
3#20±0 .17 mmol/1.) were compared with hemidiaphragms from fasted,alloxan- 
diabetic rats (mean blood glucose levels of 17*21*3.65 mmol/l.). The rate 
of glucose uptake in the alloxan-diabetic rat hemidiaphragm was reduced by 
approximately 30% compared with that of the normal rat and glycogen 
synthesis was reduced by about 70% - Table 3(ii)* There was a slight 
reduction in lactate production in the alloxan-diabetic rat hemidiaphragm,; 
but this was not statistically significant.
Insulin stimulated glucose uptake by approximately 100& in the1/ 
alloxan-diabetic rat hemidiaphragm - Table 3(iii) ,increasing it' to a 
similar level to that recorded in the normal rat hemidiaphragms1 Similarly, 
insnUp stimulated glycogen synthesis by 180$ to bring it back to -the 
levels recorded in normal rat hemidiaphragm# There were no significant
observed in une normajL rau nemiaiapnragm,naa no eiieei; on any oi vu« s
• j
parameters measured in alloxan-diabetic r&t hemidiaphragms - Table 3(iii)* 
Phenformin,as seen in the normal rat hemidiaphragm,stimulated glucose 
uptake,deereased glycogen synthesis and stimulated lactate production - j 
Table 3(iii)* Wy 23675,also as seen in the normal rat hemidiaphragm, 
stimulated glucose uptake and glycogen formation,while having no effect 
on lactate or pyruvate production - Table 3(iii)*
♦Chapter 3*
♦THE EFFECT OF 'INSPLINtTOLBUTAMIDE,PHENFORMIN AND WY23675 ON GLUCOSE 
UPTAKE. LACTATE AMD PYRUVATE PRODUCT I ON .AND GLYCOGEN SYNTHESIS 3Y 
HEMIDIAPHRAGMS PREPARED FROM NORMS AND ALLOXAN-DIABETIC RATS.
Table No. Title
3(i) Glucose Uptake,Lactate and Pyruvate Production,and Glycogen
Synthesis by Hemidiaphragms J^epared from Normal,Fasted Rats# 
3(ii) Comparison of Glucose Uptake,Lactate and I^ruvate Production,
and Glycogen Synthesis by Hemidiaphragms Prepared from Fasted, 
Normal and Alloxan-Diabetic Rats.
3(iii) Glucose Uptake,Lactate and I^ruvate Production,and Glycogen 
Synthesis by Hemidiaphragms Prepared from Alloxan-Diabetic, 
Fasted Rats.
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.GLUCOSE UPTAKE. IACTAT 5 AND PYR U VA TE PRODUCT I ON, A IIP GLYCOGEN SYNTHESIS
BY HEMIDIAPHRAGMS PREPARED FROM ITQRMAL„FASTED RATS ,
Glucose
Uptake
(jimol
Lactate 
Production 
es/gm wet vie
Pyruvate 
Production 
ight/ hr)
Glycogen
Synthesis
1 * Control
Insulin 10 fiU/ml 
Difference relative 
to Control
Control
Insulin 100 /xU/ml 
Difference relative 
to Control
Control
Insulin 1000 juU/ml 
Difference relative 
to Control
9.8iil.02
10.5^ 1.89  
+ 0.7 3
10.2?±1.11
16.97*2.77
+6.70*
8.89*0.92
20.70*2.5*1
+11.81**
10#12*0.98 
8.29*0.91
-1.83
■8.79*1.89
11.34*1.12
+2.55
11.23*1.21
13.38^1.42
+2.15
0.97*0.11
0.77*0.09
-0.20
0.84*0.09
0.89*0.10
+0.05
1.06±0#11
1.12*0.13
+0 ,06
3.15*0.80
4.85*1.21
+1.70
2.92*0.33
6.21*1.07
+3.29*
3.31*0 .65  
6,96*1,28
+3.65**
2. Control
Tolbutamide 0•2mM 
Difference relative 
to Control
Control
Tolbutamide 2mM 
Difference relative 
to Control
Control
Tolbutamide 20mM 
Difference relative 
to Control
7.*i3*0.69
8.01*0.92
+0.58
9.95*1.12
10.66*0.97
+0.71
12.32*1.76
11.17*1.29
-1.15
6,01*0.74
5.87i0.66
-0.14
7.13*0.82
7.26*0.77
+0.13
9.74*1.09
8.66*1.12
-1.08
0.72*0 .08
0.64*0.08
-0 .08
0.86*0.09
0,74-0.09
-0.03
0 ,92*0 .10
0.89*0.09
-0.03
2.99-0.27
3.11*0.43
.+0,12
3.27*0.34
3.82*0.44
+0.55
4.22*0.46
3.97*0.41
-0.25
3. Control
Rienformin 2pH 
Difference relative 
to Control
Control
Rienformin 20jiM 
Difference relative 
to Control
Control
Rienf ormin 200juM 
Difference relative 
to Control
15.33*2.*17 
13.78*1.52
-1.55
11.75*1.11
12.03*1.3*1
+0 .28
8.36*0.9*1
11.27*1.01'
+2.91**
10.12*1.21
9.37*0.89
-0.75
8.93-0.92
7,84*0.82
-1.45
6.66*0.59
9.25*0.87
+2,59*
0.99*0.09
0.96*0.09
-0.03
0,94*0.07
1.06±0.09
+0.12
0.84*0,07
1.06*0.09
4 0 . 2 2
5.16*0.63
5.22*0.54
-0 .06
3.46*0.41
4.05*0.42
+0.59
3.24*0.34
1.92*0 .26
-1.32*
Glycogen levels sre expressed in terms of pmoles glucose equivalents/gm 
wet weight/hr#
Each figure is the mean ± the standard error of 6 observations. 
Statistically significant changes from the appropriate controls were 
determined by Studentfs t-Test:-
* p<0.05 ; ** p<0.01 ; *** p<0.00l
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BY HEM ID IA PER AGMS PREPARED FROM NORMAL, FASTED RATS.
Glucose 
Uptake , 
(jimo
Lactate 
Production 
les/gm wet we:
I^ruvate 
Production 
Lght/hr )
Glycogen
Synthesis
i-. Control
Wy 23675 20juM 
Difference relative 
to Control
Control
Wy 23675 200/uM 
Difference relative 
to Control
Control 
Wy 23675 2raM 
Difference relative 
•to Control
9.i2^1.01
10.67^0.98
♦1.25
10.35x0.99
lif.A-2-l.1i
+i.09*
8.76*0.86
i7.26il.3i
+8.5* **
10.,12±1.1i
9.22*0.89
-0.90
9.77*0.98
10.01i0.99
+0. 2 f^
, 9.1^ 1.02 , 
8.96*0.86
-0 .18
1.26*0.13
0.9i-0.09
-0.32
1.11*0.09
O.9i-0.O9
-0.17
0.89*0.07
0.92*0 .1 0
+0.03
b.k6-0.52
3.«io.39
-0.79
3.87*0.41
5 .0210.50
+1.15
4+13*0.39 
7 • 33-0.81
+3 .20**
Glycogen levels are expressed in terms of jnaoles glucose equivalents/gm 
wet weight/hr*
Each figure is the mean * the standard error of 6 observations. 
Statistically significant changes from the appropriate controls were 
determined by Student’s t-Tests-
* P<0.05 ? ** P<0.01 ; *** p<0.001
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♦COMPARISON OF GLUCOSE UPTAKE,LACTATE AND PYRUVATE PRODUCTION,AND 
GLYCOGEN SYNTHESIS BY HEMIDIAPHRAGMS PREPARED FROM FASTED,NORMAL 
AND ALLOXAN-DIABETIC RATS. j
I
As it was not possible in this comparison to use one hemidiaphragm
' i
from a rat for a control and the other for a test incubation,twelve
j
hemidiaphragms were prepared from six untreated rats and compared
' j
with twelve hemidiaphragms prepared from six alloxan-diabetic rats# 
Rats were made alloxan-diabetic by treatment with alloxan monohydrate 
(0.7 mmol/kg i.p.) two days prior to the 18-hr fast. Rats with blood 
glucose levels in excess of 16.5 mmol/1, were used.
Glucose
Uptake
(junol<
Lactate I ryruvate 
Production Production 
2s/gm wet weight/hr)
Glycogen
Synthesis
Normal
Alloxan-Diabetic
Difference
10.01*1.02
84*0.52
-5.17**
11.76*1.1** 
8.97*0.92 
-2.79
0.96*0.10 
0.84*0.07 
-0.12
^.89*0.57 
1,32-0,26 
-3.57***
Glycogen levels are expressed in terms of jimoles glucose equivalents/gm 
wet weight/hr.'
Each figure is the mean * the standard error of 12 observations. 
Statistically significant changes from the appropriate controls were 
determined by Student*s t-Test:-
* p<0.05 ; ** p^O.01 ; *** p<0.001
.GLUCQSS UPTAKE«IA CT AT E AND PYRUVATE PRODUCT I ON. AND GLYCOGEN SYNTHESIS
' BY KEHIDIDAPHRAGM5 PREPARED PROM ALLOXAN-DIABETIC,FASTED EATS,
Glucose i Lactate | I^ yruvate 
Uptake 1 Production] Production 
(/uaoles/gm wet weight/hr)
Glycogen
Synthesis
1# Control 
, Insulin ‘lOjuU/ml 
Difference relative 
to Control
Control
Insulin 10QjtiU/ml 
Difference relative 
to Control
Control
Insulin lOOQpiU/ml 
Difference relative 
to Control
5*87*0.64-
7*75*0.61
+1.88
4-.94-fcO.5l
9.59*1.27
+4-.4-5**
5 .62*0 ,62  
11.61 £1.4-9
+5.99**
8.74**0.96 
9. .4,2*1.12
+0 .68
8.17*0 .72
7.77*1.00
-0.4o
9.11*0 .96
8.43*0 .8 9
—0 .68
1.06*0.09
0.94-*0.11
-0 .1 2
0.96*0 .08
0.74-±1.00
-0.22
0.88*0.09
0.86*0 .08
-0 .02
1.4-6*0.22
2.07*0 .26
+0.61
2.11*0.31
^.62±0.57
+2.51**
1.76*0.37
Jf.g^O.SO
+3 .18***
2# Control
Tolbutamide 0*2mM 
Difference relative 
to Control
Control
Tolbutamide 2sM 
Difference relative 
to Control
Control
Tolbutamide 20mM 
Difference relative 
to Control
3.76*0.4-2
4-.25±0.51
+0.4-9
5.17-0,52
4-.88io.56
-0.29
4-.74-io.4-9 
3.95io .46
-0.81
7.4-7*0.86
9.21*1.21
+1.74
8.63*0.92
7.89*0 .88
-0.74
10.01*1.22
8.96-0.94-
-1.05
0,84**0.10
0.96*0 .09
+0 .1 2
0.97*0,11
1.01*0.09
+0.04
0.84-*0.08
0,87*0,09
+0.03
1.23*0.32
1.76£0.27
+0.53
2.72*0.5^
2.16*0 .3 6
-0 .56
1.<f7;0.27
1.66-0,31
+0 .1 9
3# Control 
Phenformin 
Difference relative 
to Control
Control
Phenformin 20pM 
Difference relative 
to Control
Control
Phenformin 200pH 
Difference relative 
to Control
4.18*0.44
5.07*0.65
+0.89
5.77*0.68
8.85*0 .87
+3.08*
3.91*0.52
6.75*0.72
+2.85**
7.79*0.82
7.54-*0.92
-0.4-5
8.44*0.96
10.36*1.14
+1.92
6.92*0.68
9.74-*0.96
+2.82*
0.91*0.08
0.87*0,07
-o.o4
0.94-*0.09
1.21*0.13
+O.27
0.77*0 .08
0.98*0.11
+0.21
1.62t0.29 
2.19*0.3^
+0 .5 7
2.47 0^ .3 6
1.56^0 .1^
-0 .91*
2.07*0 .3 7
0 .96*0 .1 2
-1.11*
Glycogen levels are expressed in terms of prioles glucose equivalents/gm 
wet weight/hr#
Each figure is the mean * the standard error of 6 observations# 
Statistically significant changes from the appropriate controls were 
determined by Student*s t-Test:-
* P<0.05 ? ** P<0.01 ; *** p<0.001
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♦ GLUCOSE) UPTAKE, LACTATE AND PYRUVATE PRODUCT I ON, AND GLYCOGEN SYNTHESIS
BY HEMIDIAPHRAGMS PREPARED FROM ALLOXAN-DL4.BETIC«FASTED RATS,
Glucose 1 Lactate I Pyruvate 
Uptake 1 Production 1 Production 
(jumoles/ga wet weight/hr)
Glycogen
Synthesis
*f. Control 5.21S0.78 10.17 ^ .3 2 1 .1*f-0 .12 2. 33±0.b2
Wy 23675 20pH 6.31=0.67 9.71*0.92 0.92i0 .10 2.73*0.36
Difference relative 
to Control *1.10 —0 .^ 6 -0 .22 +0 .<K>
Control ^#19-0#5^ 7 .99*0.91*- 0.98-0.08 2.56*0.37
Wy 23675 200joM 7.76^0 .82 8#ij4i0#91 0.96^0.09 3.92*0.33
Difference relative 
to Control +3.57**. +0 #%5 -0 .02 +1.36*
Control 3.37*0.50 5.96*0.72 0.76to.08 1.69*0.29
Wy 23675 2mM 7.2lto.8*f 5.03-0.62 0.61fto.07 3.19-0.30
Difference relative 
to Control +3.8*f** -0.93 -0 .12 +1.50**
Glycogen levels are expressed in terms of pmoles glucose equivalents/gm 
wet weigkt/hr*
Each figure is the mean ± tke standard error of 6 observations# 
Statistically significant ckanges from the appropriate controls were 
determined by Studentfs t-Test:-
* p<0 .05 ? ** p<0.01 ; *** p<0.001 • ■
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In chapter 2,it was shown that insulin,tolbutamide,phenformin and 
Wy 23675 were all able to stimulate glucose utilization in vivo. However, 
tolbutamide did so by stimulating the release of insulin and did not appear 
to have a direct effect on glucose utilization. Phenformin stimulated 
glucose utilization without causing the release of insulin but was only 
able to do this in the alloxan-diabetic rat v/here blood glucose levels 
were markedly elevated. Wy 23675,021 the other hand,was able to stimulate 
glucose utilization in both the normal and alloxan-diabetic rat, 1 
independant of any effect on insulin release. The results shown in this / 
chapter with rat hemidiaphragms support the above in vivo findings on j 
glucose utilization.
Insulin was shown to stimulate glucose uptake and glycogen synthesis 
into both the normal and alloxan-diabetic rat hemidiaphragm preparations. * 
No significant changes were observed with regard to lactate and pyruvate 
release. These results for insulin agree well with those of other workers 
(1-10,27). The release of alanine and CCL, were not measured in these 
studies. However,the increased uptake of glucose could not be solely 
accounted for by the measured increase in glycogen synthesis,so it seems 
likely that insulin also caused an increase in glucose oxidation and 
protein synthesis. Other workers have shown that insulin increases 
glucose oxidation(16,18,30) and stimulates the synthesis of protein from
amino acids (31-3*0 •
Tolbutamide had no effect on any of the parameters measured in either . 
the normal or alloxan-diabetic rat hemidiaphragms. These results are in 
agreement with the findings in chapter 2 where tolbutamide had no effect 
on glucose uptake in vivo unless it could stimulate insulin release. The 
possibility that tolbutamide administered in vivo might potentiate the 
action of insulin on the muscle in vitro (25) has not been investigated 
in this work.
o-i-i ^ j.jf  v > A U i m ^ A u u  jlaa u u i/u  xujxiuclx etna. u j .x o x a z i“ c iia o e x ; ic  ra x ;  
hemidiaphragms• This is in comparison with its effects in vivo where it 
only stimulated glucose utilisation in the alloxan-diabetic rat. However, 
the 200 pM concentration of phenformin necessary to see these effects in 
vitro with normal rat hemidiaphragm is considerably higher than the normal 
plasma level of phenformin seen in patients taking therapeutic doses of 
the drug (eg: 1-10joM (35)D• In the alloxan rat hemidiaphragm,phenformin 
had a significant effect on glucose uptake at the concentration of 20jiM 
- a ten-fold lower concentration than that at which a significant effect 
occurs on glucose uptake in the normal rat hemidiaphragm. Frayn and 
Adnitt (7) have also shown that hemidiaphragms are more sensitive to the 
action of phenformin when prepared from alloxan-diabetic rats as opposed 
to normal rats. Williams and coworkers (12) have also shown an increase' 
in glucose uptake into rat hemidiaphragms caused by phenformin they 
showed a similar increase in lactate production and a decrease in glycogen; - 
storage with, no. effect on glucose .oxidation. .
In muscle from a diabetic animal,the membrane transport of glucose > 
is reduced when compared with normal muscle and this defect is not: fully * 
overcome by the addition of insulin in vitro (36-39). Under these 
conditions,free intracellular glucose accumulates (37»^0,41) showing that - 
the phosphorylation of glucose by hexokinase is also impaired and may 
become the rate*limiting step in glucose utilization in muscle from a 
diabetic animal. Das (k2) has shown that the depression of hexokinase 
activity in diabetes is due to a decrease in $he total activity of this 
enzyme,as well as to its regulation by the intracellular concentration 
of glucose-6-phosphate (*f3). Frayn and Adnitt (7) have proposed that the 
abnormal free fatty acid metabolism associated with diabetes (¥*—46) may / 
be involved in the inhibition of hexokinase by virtue of increasing the 
concentration of glucose—6-pho^p.hate. {The elevation of intracellular' ‘ 
acetyl GoA concentration caused by fatty acid oxidation leads,via an j 
increase in citrate levels,to inhibition of phosphofructokinase and
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diabetic rats hemidiaphragms,where phosphorylation is rate-limiting,by 
causing an increase in the rate of utilization of glucose-6-phosphate in 
the presence of insulin (7)* They found that metformin,in the presence of 
insulin,increased the glycogen content of hemidiaphragms,which would 
result in an increased rate of removal of glucose-6-phosphate,and could 
thus account for the effect of metformin on glucose utilization (7). In 
contrast,Williams and coworkers (12) showed a decrease in the glycogen 
content of the rat hemidiaphragm in the presence of phenformin and 
similar effects have been demonstrated in the results reported in this , 
chapter# These findings combined with the measured increase in glucose 
uptake make the proposed mechanism of action of phenformin on glucose / 
utilization as put forward by Frayn and Adnitt (7) seem unlikely#
Other workers have failed to shov; any effects of biguanides on glucose 
uptake into muscle in either the presence or absence of insulin (21,22,26). 
Kemmer and coworkers (22) found a decreased rate of glycolytic flux 
together with an unaffected rate of glucose uptake in normal rats treated 
with metformin,despite a demonstrable hypoglycaemic effect of metformin 
in vivo. They and other workers (22,V7,48),in agreement with the findings 
of Frayn and Adnitt (7),who,however,demonstrated an increase in glucose 
uptake,showed an increase in glycogen synthesis to account for what 
happened to glucose under these conditions. Kemmer and coworkers (22) 
also showed an inhibition of lactate oxidation in the presence of added 
insulin. Inhibition of pyruvate oxidation by biguanides has been r.-t-: 
demonstrated by other researchers (*f9»50). Kemmer and coworkers (22) 
suggest,on the basis of these results,that biguanides inhibit muscle 
pyruvate dehydrogenase {the activity of pyruvate carboxylase is virtually 
zero in skeletal and heart muscle (51)J,and that this action could 
account for the development of lactic acidosis,which has been repeatedly 
associated with the use of biguanides (52-57). However,the extent to which
in pyruvate production,but this 
t-Test). However,an approximate
The apparent disagreements about the effects of the biguanides on 
muscle carbohydrate metabolism nay be due to the different experimental 
conditions and different concentrations of biguanide used. The results ' 
reported in this chapter appear to be in agreement with some workers and 
in disagreement with others.
The occurrence of an increase in glucose uptake together with a 
decrease in hemidiaphragm glycogen content and an increase in lactate 
production could best be explained by an increase in glycolysis together 
with a possible inhibition of lactate oxidation. There was a slight rise
was not statistically significant (Student
10:1 ratio of lactate and pyruvate was..
maintained when a significant increase in lactate production was/ measured'', 
indicating a possible similar decrease in pyruvate oxidation in agreement ' 
with the findings of other workers (22,*f9»5 0).
Wy 23675 stimulated glucose uptake and glycogen synthesis,while / 
having no effect on lactate or pyruvate production,in both normal and 
alloxan-diabetic rat hemidiaphragms. The concentrations at which these 
effects were observed were similar in both normal and alloxan-diabetic 
rat hemidiaphragms - 200jiM. (Plasma concentrations of Wy 23675 in the 1 
region, of l60fiM have been measured in monkeys following an oral 
hypoglycaemic dose of the drug (see Chapter 1)1. In hemidiaphragms 
from both normal and alloxan-diabetic rats the increase in glucose 
uptake was approximately 100% and the increase in glycogen content 
about 80%. The measured increasb in glucose uptake could not be solely 
accounted for by an increase in!glycogen synthesis and$as there was no 
increase in lactate or pyruvate production,the [results suggest an 
increase in glucose oxidation. However,no measurements were made of
j . ' ■ ,
oxygen consumption or of carbon j dioxide production by hemidiaphragmsi;' 
in these experiments. i
uptake and glycogen synthesis to those of insulinfbut differ from those 
of phenformin with regard to glycogen synthesis and lactate production. 
Insulin has been shown to activate pyruvate dehydrogenase in alloxan- 
diabetic heart muscle (60);as there was no increase in lactate production 
in the presence of Wy 23675»it is possible that this enzyme is also 
activated by Y/y 23675.
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This chapter contains the results of experiments carried out with 
isolated epididynal adipocytes (prepared from both normal and alloxan- 
diabetic rats) to investigate the effects of selected hypoglycaemic 
agents upon glucose incorporation intoadipocyte lipids.
Results of incubations carried out with adipocytes isolated from 
normal,fasted rat epididymal fat pads showed the following effects of 
these agents:-
1. Insulin stimulated glucose uptake intoadipocyte lipids in 4 dose- 
related manner to a maximum of approximately 260% of control values.
2. Tolbutamide had no effect on basal incorporation of glucose into 
adipocyte lipids at therapeutio dose levels (approx. 10mM),but did 
cause a slight stimulation (to 125% of control values) at higher 
concentrations. Further experiments showed that tolbutamide in high 
concentrations could potentiate a submaximal insulin-stiaulation of 
glucose incorporation,but had no effect on a maximal response to insulin.
3. Fhenformin stimulated glucose incorporation intoadipocyte lipids (to 
approximately 200% of control values),but only at concentrations well 
above those obtained in the blood with therapeutic doses (approximately 
1000 x greater concentrations). Fhenformin,at these high concentrations, 
was able to further stimulate a maximal response to insulin.
kt Wy 23675 stimulated glucose incorporation intoadipocyte lipids (to 
approximately 1*f0% of control values) at concentrations obtained in the 
blood with hypoglycaemic doses (ie: approximately lOOpH). VJy 23675 
stimulated further a maximal response to insulin,but only at 
concentrations approximately 100 x those obtained with hypoglycaemic
doses of the drug.
Results of incubations carried out with isolatedadipocytes prepared 
from alloxan-diabetic,fasted rats showed the following effects of these 
agents
1, The effect of alloxan-diabetes was to markedly reduce the basal rate
oi incorporation ox glucose xntoadxpocyce Hpxds (to approximately 30:* 
of the normal values).
2. Insulin stimulated the incorporation of glucose intoadipocyte lipids 
to a maximum of approximately 190% of alloxan-diabetic control values - 
this was still well below normal control values.
3» Tolbutamide had no significant effects on the rate of glucose 
incorporation intoadipocyte lipids,even at high concentrations that 
were stimulatory in normal fat cells.
4*. Phenformin had no effect on glucose incorporation into adipocyte lipids 
except for a stimulatory effect at a concentration approximately 1000 x 
greater than that normally observed \?ith therapeutic doses of the drug.
5* Wy 23675 stimulated glucose incorporation intoadipocyte lipids (to 
approximately 190% of alloxan-diabetic control values) at concentrations 
obtained in the blood with hypoglycaemic doses (ie: approximately 100jiH) 
— this level of stimulation was still well below normal control values.
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Intr oduc t ion .
The in vivo work described in Chapter 2 has shown that insulin, 
tolbutamide,phenformin and Wy 23675 have effects on glucose utilization. 
Two major sites of glucose utilization are fat and muscle;the work in 
this chapter looks at the incorporation of radiolabelled glucose into 
the lipids of isolated adipocytes*
Isolated epididymaiadipocyteshave been used extensively to study 
lipid metabolism in vitro* Similar results have been obtained with both 
fat'pads (7*8,14-) and isolatedadipoeytes (1 *4-,5,9*10)* The latter have 
been employed for the work described in this chapter for the advantages 
they possess over whole fat pads in terms of the numbers of incubations 
that can be carried out from the same cell pool and the reproducibility 
of results.
Insulin has been shown by many workers to stimulate the rate of 
conversion of glucose into fat in«rat epididymal adipose tissue (1,4-,5, 
8,16,17)# The mechanism of action is still not fully understood,although 
insulin has been shown to increase glucose transport (7 ,9,10,13),pyruvate 
dehydrogenase activity (18-29),acetyl CoA carboxylase activity (30,31), 
and possibly one or more steps in the process of fatty acid 
esterification (32,33)# Crofford and Renold (7) showed that the transport 
of glucose from the extracellular space to the intracellular space was 
the major rate-limiting step in glucose uptake under conditions of 
adequate diffusion;and that facilitation of glucose transport was the 
principle site of insulin action. However,insulin can stimulate fatty 
acid synthesis independant of its effects on glucose transport, Halperin 
(14-) demonstrated an increase in the conversion of pyruvate to fatty 
acids stimulated by insulin in adipose tissue from both normal and 
alloxan-diabetic rats.
Little work appears to have been done with regard to the effects of 
sulphonylureas on glucose utilization by rat adipose tissue,although
there is evidence to suggest that tolbutamide (4-0) and chlorpropamide (4-1) 
inhibit lipolysis.
The biguanides have been more extensively investigated with 
conflicting results. Some workers have reported that phenformin caused an 
increase in glucose uptake and utilization by rat adipose tissue (15,4-3- 
4-5),while others have shown that phenformin depressed glucose uptake and 
utilization (4-6,4-7)#
The work described in this chapter compares the effects of insulin, 
tolbutamide and phenformin with those of Wy 23675 on glucose incorporation 
into the lipids of isolated adipocytes prepared from both normal and 
alloxan-diabetic rats.
iiie sources ox &il drugs used were given in earlier chapters#
( H-3)-glucose was obtained from the Radiochemical Centre,Amersham,Bucks# 
The constituents of the toluene-based scmtillant were obtained from 
Koch-Light Laboratories,Colnbrook,Bucks#
Collagenase and Bovine serum albumin were obtained from Sigma,Kingston- 
upon-Thames^Surrey• 
jfethodis#-
The method used was based on that of Moody et al (1) and involved 
incubating rat epididymal fat pads with collagenase in order to isolate 
the adipocytes# Glucose incorporation into adipocyte lipids was measured 
by incubating adipocytes with (H-3)-glucose# Total lipids were extracted 
by adding a toluene-based scintillant (2) directly to the incubation 
vials and the radio-activity in the lipids was measured by liquid 
scintillation counting#
The Use of C^H-3)-glucose to Measure the Incorporation of Glucose into 
Adipose Tissue#
Moody et al (1) have recommended the use of (^H-3)-glucose to measure 
glucose incorporation into adipocyte lipids,based on previous knowledge 
concerning the fate of attached to different carbon atoms of glucose# 
(^H-3)-glucose can form three primary labelled products in adipose tissue 
(2) # These are:-
(i)» ^HOH from the isomerization of dihydroxyacetone-P with glyceraldehyde 
-3-P in the Embden-Meyerhof pathway#
H
H + OH *
♦H-Q-OH
;=o
Triosephosphate 0 
<rz — ------ * HHj-
h-9-opo3H2
isomerase OH
'HOH
h-c- opo5h2
[ T
(ii)# NADP^H from the oxidation of 6-phosphogluconic acid in the Pentose 
phosphate pathway.
00H
H-?-OH + Mg++
HO-C-H* + N A D P — * 
H-C-OH
h h J-oh
h-|-opo3h2
6-phospho- 
gluconic acid
H-C-OH
H-C-OH
H-C-OPO.H^
I 3 2
3-ketohexonic 
acid
t lated intermediate)
H-C-OH
■> 6=0 + NADP*H + H + CO,
H-t-OH 
H-C-OH
H-i-oPcy^
Ribulose-5-P
6=0 + NADH
h-£-opo_h2
 + H+ +
Dibydroxyacetone-P Glycerol-3-P
H H
**
E
•OH
•H
gpo3h2
+ ADP
Glycerol kinase
>  H + ATP
Glycerol-3-P Glycerol
x
Also, a significant amount of ^H appears din fatty acids through reduction 
via NADP^H - there is a very efficient utilization of NADPH for fatty acid 
reduction (2)* No appears in lactate,which indicates that NADP^H does
not exchange H+ with NADH (2).
Preparation of Isolated Adipocytes*
The preparation of isolated adipocytes was based on the methods of 
Gliemann (A-) and of Podbell (5)» 110-1*f0 gm male rats were killed by 
decapitation and the epididymal fat pads were rapidly removed and rinsed 
in Krebs-bicarbonate buffer* Each fat pad was ctft into four pieces and 
then placed in a plastic incubation vial containing 1 ml of Krebs- 
bicarbonate buffer containing 0.1 mg/ml glucose,35 mg/ml dialyzed bovine 
serum albumin - fraction V,and 2 mg/ml collagenase type II* Incubations 
were carried out at 3 7 in an atmosphere of 95% 0^/5% CO^, shaken at 
120 rpm for 1 hr*
At the end of the incubation period the incubations from several rats 
were pooled in a plastic dish and the fat cells liberated from tissue 
fragments by gently stirring with a rod* Any visible tissue fragments 
were removed with forceps* The free cells were then centrifuged in 
polythene tubes at ^00 g for 1 min* The adipocytes floated to the surface 
and the infranatant was discarded by aspiration* The adipocytes were then 
resuspended in Krebs-bicarbonate medium containing 10mg/6 glucose and 
10 mg/ml bovine serum albumin, fraction V* The adipocytes were centrifuged 
and resuspended a further three times,the final suspension being made up 
to give 3"5 rags lipid/ml.
■z
Incubations with (H-3)-glucose.
1 ml aliquots of the cell suspension were used for the incubations, 
which were carried out in plastic vials iin a water bath set at 37 and
•z
shaking at 120 rpm* 0*5 JttCi of ( H-3)-glucose was added to each incubation 
vial in a 20 jils volume* All drugs were also added in 20 |ils of Krebs- 
bicarbonate medium (at 50x the desired final concentration) to give a 
total incubation volume of 1#0*f mis*
The incubations were terminated by the addition of 15 mis of toluene- 
based scintillant (5g. Packard Premix or 5g* of 2.5 dipheyloxazol + 0.3g. 
1*^ 1—bis-2.2(4-methy 1-5-phenoloxazolyl)-benzene in 1 litre of toluene)* 
Lipids were extracted by adding the scintillator and allowing to stand 
overnight at before counting* The results were expressed as 
disintegrations per minute/5 og lipid (6)*
Results*
g)» Glucose Incorporation into Lipids of Isolated Adipocytes Prepared from
Normal,Fasted Rats*
Insulin caused a time [Fig* Mi)] and a dose-related (Table Mi)] 
increase in the incorporation of (^H-3)-glucose into the lipids of 
isolated adipocytes to a maximum of approximately 2S0% of control values* 
Concentrations of insulin as low as 5 jiUnits/ml caused measurable and 
statistically significant (Student*s t-Test) increases in glucose 
incorporation into lipids* In contrast,tolbutamide appeared to have no 
effect on glucose incorporation into lipids of adipocytes except at 
20mM concentration,where it caused a small (25%) increase ‘{Table Mi)]* 
Tolbutamide had no effect on the maximal stimulation of glucose 
incorporation into adipocyte lipids caused by insulin,but it did further 
enhance the submaximal insulin effect (Table Mi)-], when given in high 
concentrations (20mM)* Phenformin doubled the rate of glucose 
incorporation into adipocyte lipids,but this only occurred at 
concentrations f2-20mM ; Table Mi)J a thousand-fold or more greater 
than those obtained in the plasma with therapeutic administration of 
the drug (79-82)* Phenformin was also able to further stimulate both 
sub-maximal and maximal insulin effects on glucose incorporation into 
adipocyte lipids (Table Mi)] - however,these effects were again only 
seen at high concentrations* Wy 23675 stimulated glucose incorporation 
into adipocyte lipids at 0*2mM (Table Mi).],which'is a concentration 
obtained in monkeys with a hypoglycaemic dose of the drug* Wy 23675 also 
stimulated both submaximal and maximhl insulin effects on glucose 
incorporation into adipocyte lipids (Table Mi)] - however, higher 
concentrations than those that have been obtained in vivo were necessary 
for this effect to be apparent*
b)* Glucose Incorporation into Lipids of Isolated Adipocytes Prepared from
^Hoxan-Diabetic,Fasted Rats*
Alloxan-diabetes resulted in a marked decrease (to approximately 50%
of controls) in the rate of incorporation of glucose into the lipids of 
isolated adipocytes {Fig# Mil))* The mean blood glucose levels of the 
fasted,alloxan-diabetic rats was 20.76 mmo3/l# (- SEM of 7.2*f) compared j 
with the mean of 3*87 mmol/i# (* SEM of 0*29) -In normal rats. Insulin —  j
stimulated the incorporation of glucose into lipids to approximately the j
I
same extent (about 200$ of controls) in adipocytes from alloxan-diabetic J
rats tTable Mil)) as from normal rats {.Table Mi) ] • However,as the §
adipocytes from alloxan-diabetic rats had a measured glucose incorporation |
I
into lipid of only 30$ of the normal rats,insulin did not totally
compensate for the effect of alloxan-diabetes. Tolbutamide,in contrast j
[
to its effects in normal rat adipocytes,had no measurable effects on f
glucose incorporation into alloxan-diabetic rat adipocyte lipids at any j
of the concentrations used (Table Mii)l# Phenformin,as in the normal rat j
adipocytes,stimulated glucose incorporation into the lipids of alloxan- f 
diabetic rat adipocytes (Table Mii)l,but again required a higher j
concentration than that normally obtained with therapeutic use of the j
drug in order to have its effect (79*82)* Wy 23675t&£ in the normal rat 
adipocyte,stimulated the incorporation of glucose into the lipids of 
adipocytes from alloxan-diabetic rats (Table Mii)l. like insulin,the 
degree of stimulation was approximately 200% of the control values and 
thus not sufficient to compensate for the effect of alloxan-diabetes.
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.Chapter if.
.THE EFFECT OF IKSHLIN.TOLBUTAMIDE,PHENFORMIN AND WY 23675 ON GLUCOSE
INCORPORATION INTO THE LIPIDS OF ISOLATED ADIPOCYTES PREPARED FROM
NORMAL AND ALLOXAN-DIABETIC,FASTED RATS.
Figure No. Title
■2
if(i) Effect of Insulin with Time on ( H-3)-Glucose
Incorporation into Lipids of Isolated Adipocytes 
ITepared from Normal#Fasted Rats, 
if(ii) Comparison of (^H-3)-Glucose Uptake into Lipids of
Isolated Adipocytes Prepared from Normal and Alloxan-Diabetic 
Fasted Rats.
Table No. Title
if(i) Glucose Incorporation into Lipids of Isolated Adipocytes
Prepared from Normal,Fasted Rats. 
if(ii) Glucose Incorporation into Lipids of Isolated Adipocytes
Prepared from Alloxan-Diabetic,Fasted Rats.
.EFFECT OF INSULIN WITH TIME ON (^H-5)-GLUCOSE INC ORPQRATION INTO LIPIDS OF
IKOLA.TED ADIPOCYTES PREPARED FROM NORMAL,FASTED RATS.
Isolatedadipocytss-were prepared-^rom-the-epididymal fat pads of 18-hour 
fasted,normal rats and incubated as described in Methods. Incubations 
were carried out in the absence (controls-®) or presence of insulin 
200 fiTJnits/ml (a ) and were stopped at the time points shown by the 
addition of a toluene based scintillant. The H in the lipid extract was 
counted and the results expressed as dpm/5 nig* lipid. Each time point 
represents the mean £ the standard error of 6 observations.
in Lipid Extract
160^ 1°5 dpB^ 5
120
100
80 -
60 1501200 5 10 20 50 90
Time (mins)
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GLUCOSE INCORPORATION INTO LIPIDS OF ISOLATED ADIPOCYTES PREPARED FROM
NCRMAL*FASTED RATS.
Isolated- adipocytes were prepared from the epididymal fat pads of 18-hr 
fasted, normal rats and- incubated as" described in met hods V The '^if in the 
lipid extract was counted and the results expressed as dpm/5; mg -lipid* 
Each value represents the mean * the standard error- of 6 observations* 
Statistically significant ehangesr from the- appropriate controls were 
determined by Student* s t-Test:-
* p<0 .05 ; **•> p<O.Oi ; **^<0.001,';
1* Effect of Insulin on (^H-3)-glucose Uptake into Isolated Adipocytes, 
over 2 hrs Incubation*
Insulin Concentration 
(pU/ml)
in lipid Extract 
.(dpm/5 mg lipid)
% of 
Control
0 65172 ± 4522 100
77787 * 5toi 110
5 78493 * 3247 120*
10 97106 i 5^23 149**
50 i 144162 £ 6219 221***
100 165537 * 7to8 254***
200 184322 * 10127 283***
too 171758 * 9876 264***
Tolbutamide Concentration 3h in lipid Extract (dpm/5-mg lipid) at
(mM) the following times (wins)
30 60 fZo
.0 (control) 11794 * 876 25374 ±1127 52911 ± 2569
o & 11244 ± 723 27431 * 1239 56197 ± 3478
% of Control 95% 108% 9 8%
2 12762 ±419 19982 ± 2194 54657 ± 5431
% of Control 108% 79% 94%
20 14778 ± 523 31286 ± 1572 65567 ± 3261
■% of Control 125%* 123%* 113#
3* Effect of Tolbutamide on Sub-maximal and Maximal Insulin-Stimulated 
(%-3)-glucose Uptake into Isolatedadipocytes over 2 hrs Incubations*
Insulin Tolbutamide 3h in lipid Extract % of
Concentration Concentration (dpm/5 mg lipid) Control
(pUnits/ml) (mM)
0 0 76148 A  5231 100^
50 0 130773 ± 787^ 198
50 0*2 159149 * 12113 209
50 2 168287 ± 8324 221
50 20 190065 ± 9735 25CT
200 0 199508 ± 12367 262
200 0*2 188086 ± 7948 247
200 2 204838 ± 8631 269
200 20 208646 ± 6469 274 .
t o o 0 I 193416 ± 11237 254
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4. Effect of Phenformin on (^H-3)-glucose Uptake into Isolated Adipocytes
Phenformin
Concentration
(mM)
3h in Lipid Extract (dpn/5 mg lipid)at the following 
times (mins):-
30 60 /Zo
0 (control) 
0 .2
# of control 
2
# of control 
20
# of control
8976 t 659
10188 ± 712 
114#
16965 ± 894 
189%***
18311 - 1072 
204#***
18144 ± 984
20321 ± 941 
112#
35199 ± 2149 
19^***
36469 ± 2432 
201#***
39274 ±2417
42416 ± 9726 
108#
65588 ± 5124 
167#***
84046 t 5174 
214#***
5* Effect of Phenformin on Sub-maximal and Maximal Insulin-Stimulated 
(3h-3) -glucose Uptake into Isolated Adipocytes over 2 hrs Incubations.
Insulin Phenformin in lipid Extract # of
Concentration Concentration (dpm/5 nig lipid) Control
(ftUnits/ml) (EM)
0 0 61342 ± 3274 100
50 0 101214 ± 6273 165
50 0 .2 9753^ ± 5924 159
50 2 126978 ± 5421 207*
50 20 139246 ± 8262 227**
‘ 206 0 171144 ± 12977 279
200 0 .2 175438 ± 9742 286 ,
200 2 194454 ± 14127 317
200 20 ,223285 * 11722 364*
4oo 0 172984 * 10999 282
6# Effect of Wy 23675 on (^H-3)-glucose Uptake into Isolated Adipocytes
Wy 23675
Concentration
(mM)
3h in Lipid Extract (dpm/ 5 mg lipid) at the following 
times (minsIt- - --- .------ — ——
30 60 fZa
0 (control) 
0.2
# of control 
2
# of control 
20
# of control
11926 ± 897 
16935 * 924
142#**
31604 ± 1262 
265#***
34824 ± 2149 
292#***
23641 ±1021
32388 ± 1298 
137#***
64304 ± 2721 
272#***
72342 ± 3516
306#***
44237 ± 2229
66798 ± 2747 
151#***
116343 ± 6684 
263#***
126960 ± 5172 
287#***
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7# Effect of Wy 23675 on Sub-maximal and Maximal Insulin-Stimulated
(^H-3)-glucose Uptake into Isolated Adipocytes over 2 hrs Incubations.
Insulin Wy 23675 Sh in Lipid Extract Wo t
Concentration Concentration "(dpn/'5 mg lipid) Control
(flUnits/ml) (mM)
0 0 51376 2 3100 100
50 0 94532 ^ 6274 184
50 0 .2 110972 ± 5156 216
50 2 142311 ± 8970 277**
50 20 162348 * 9443 316***
200 0 HfifSSO ± 10721 282
200 0 .2 152587 * 7479 297
200 2 167486 ± 8867 326
200 20 202421 ± 10217 * *
*K>0 0 139229 ± 9766 5 271
Statistically significant changes from the appropriate controls were 
determined by Student*s t-Test:-
* p<0.05 ; ** p«>.01 ? *** p<0.001
# COMPARISON OF (^H-5)-GLUCOSE UPTAKE HTTP LIPIDS OF ISOLATED ADIPOCYTES
PREPARED PROM NORMAL AND ALLOXAN-DIABETIC,FASTED RATS,
Isolated adipocytes were prepared from the epididymal fat pads of 18 hr 
fasted rats# Control rats were previously untreatedfwhilst alloxan-diabetic 
rats were treated with alloxan (0#7mmo;iAg i*P#) two days previously and 
those with blood glucose levels in excess of 16#5 mmol/l# were used# 
Incubations were carried out as described in Methods with fat cells from 
either control (®) or alloxan-diabetic (•) rats# Each point on the figure 
represents the mean - the standard error of 6 observations#
E in Lipid Extract 
(IQ** dpm/5 mg lipid)
60 -
50 -
30-
20-
10-
120
Incubation Time (mins)
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♦Table
.GLUCOSE INCORPORATION IN T O  L IP ID S  OF ISO LATED  ADIPOCYTES PREPARED FROM 
A L L O X A N -D IA B E T IC «FAST ED R A T S .
Isolated adipocytes, were prepared from the epididymal fat pads of 
18-hr. fasted allosaji»d,iabet Ac rats. and. incubated as described in 
Methods# The in .the* lip'iC extract^ was. counted and expressed as 
dpnj/5 mg lipid# 3lh.ch feihe represents;, the; mean £ the standard 
error of 6 observations#5 Statistically* significant changes from 
the appropriate control were; determined- by Student *s t-Test 
* p<0#05 ; ** p<0.01 ; *** p<0.00i-
1# Effect of Insulin on (3h -3)-glucose Uptake into Isolated Adipocytes over 
2 hrs Incubation#
Insulin Concentration 
OnUnits/ml)
3h Un Lipid Extract 
(dpm/ 5  &g lipid)
# of 
Control
0 25263 * 2796 100#
2.5 24253 * 2318 96#
5 28800 ± 3134 114#
10 34863 - 3666 138#
50 Vi 431 - 3978 16A#**
100 **6231 * 1*868 183#**
200 1*9768 ± 1*627 197#**
4oo 1*5726 i 5012 181#**
2# Effect of Tolbutamide on (^H-3)-glucose Uptake into Isolated Adipocytes
Tolbutamide Concentration 
(mM)
in Lipid 
the followin
Extract (dpn/5 mg lipid) at 
r times (rains)
30 60 120
0 (control) 
0#2
# of Control
2
# of Control
20
# of Control
3921 £ 1*07
3291* * 398 
81*#
1*392 £ 464 
112#
427I* £ 447 
109#
7496 £ 812
5922 £ 726 
79#
7346 £ 818 
98#
8695 £ 902 
116#
15627 £ 2172
15002 £ 1786 
96#
16565 £ 1897 
106#
16408 £ 2062 
105#
3# Effect of Phenformin on (^H-3) -glucose Uptake into Isolated Adipocytes
Phenformin Concentration 
QllM)
*^ H in Lipid Extract (dpm/5 lipid) at 
the following times (rains) :~
. .30-.. - 60 120
0 (control) 
20
# of Control
200
# of Control
2000
# of Control
6766 £ 873
7510 £ 866 
111#
6225 £ 734 
92#
11029 * 1432
163#*
12178 £ 2001
13274 £ 1637 
109#
10595 £ 1299 
87#
21677 £ 2274 
178#*
23627 £ 3109
29061 £ 3407 
123#
22682 £ 2675 
96#
39930 £ 4321
169*
Each figure is the mean 1 the standard error of 6 observations.
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Effect of Wy 23675 on pH-3)-glucose Uptake into Isolated Adipocytes
Wy 25675 Concentration 
(pM)
in lipid Extract (dpnv/5 ag lipid) at 
the following times (mins)
30 60 120
0 (control) 
20
% of Control
200
% of Control
2000 
% of Control
3286 ± 388
3976 i 4-17 
121%
6112 i 721 
186%**
6539 - 687 
199%* *
6713 ± 792
8593 - 912
128%
13023 i 9?6 
194%* * *
15037 i 1621 
224%***
12327 * 2372
14546 - 1676 
118%
23298 ± 2572 
189%*
26626 ± 2922 
216%**
Each figure is the mean ± the standard error of 6 observations* 
Statistically signififcant changes from the appropriate controls were 
determined by Student*s t-Test:-
* p<0.05 ; ** p<0.01 ? *** p<0.001
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Discussion*
Insulin,tolbutamide!phenformin and Wy.23675 were all shown to 
stimulate glucose utilization in vivo (Chapter 2),although tolbutamide 
could only do so under conditions where it was able to stimulate insulin 
release* In the previous chapter,insulin,phenformin and Wy 23675 were 
shown to stimulate glucose uptake into rat hemi-diaphragms,while 
tolbutamide had no effect on this in vitro measurement. The effects of 
these agents on glucose utilization have been further investigated in 
the work described in this chapter with isolated adipocytes.
Insulin was shown to increase the uptake of glucose into the lipids 
of adipocytes prepared from both normal and alloxan-diabetic rats (Tables 
4(i) and 4(ii)J. This effect of insulin has been demonstrated by many 
other researchers (1,4,5,8,16,17*48-50).
The major rate-limiting step in glucose uptake under conditions of 
adequate diffusion is the transport of glucose from the extracellular 
space to the intracellular space and it has been proposed that the 
principle site of insulin action is the facilitation of glucose transport 
(7,52-55). However,the fundamental mechanism by which insulin enhances 
glucose transport is still unknown. Addition of insulin to adipose 
tissue results in a fall in the levels of cyclic adenosine monophosphate 
(cAMP) (10),but there is no good evidence that this is directly 
associated with glucose transport. Taylor and coworkers (10) have shown 
that when cAMP levels were lowered with antilipolytic agents (eg:insulin, 
nicotinate,clofibrate),the rates of glucose' transport were increased. 
Lipolytic agents (eg:glucagon,adrenocorticotrophic hormone,isoproterenol, 
theophylline) elevated cAMP levels and reduced the rate of glucose 
transport. It has been proposed that cAMP could induce inhibition of 
glucose transport into adipocytes by the phosphorylation of membrane 
proteins using ATP as the substrate (10,13,51)# However,other groups 
found that under certain conditions insulin had no effect (34-37) °r 
increased (38) cAMP levels in adipocytes,while inhibiting lipolysis.
5 '
In addition,lipolytic hormones have been shown to increase glucose
1 6 0
indicating that glucose transport can be increased in response to other 
stimuli even ivhen cAMP levels are elevated. Thus,the importance of the 
effects of these agents on cAMP levels with respect to their effects on 
glucose transportremains unclear.
More recently,Olefsky (56) has further investigated the'mechanisms 
by which insulin activates the glucose transport system in rat adipocytes. 
He used 2-deoxyglucose to measure glucose uptake as 2-deoxyglucose is 
transported and phosphorylated by the same process as D-glucose,but 
cannot be further metabolized (5 7)# 01efsky«s work (56) indicated that 
insulin increases the number of carriers available for glucose transport, 
rather than enhancing the intrinsic activity of already functioning 
carriers.
Insulin has been reported to increase fatty acid synthesis from 
glucose in rat epididymal adipose tissue by more than tv/ice the amount it 
can increase pyruvate output (58-61), This preferential incorporation of 
pyruvate carbon atoms into fatty acids compared with its release from fat 
pads in the presence of insulin led to the suggestion that insulin might 
specifically activate the conversion of pyruvate carbon atoms into fatty 
acids in addition to stimulating glucose transport. From Taylor and Jungas 
work (29),it appears that the activity of pyruvate dehydrogenase is one 
factor limiting the capacity of the pathway controlling the conversion ox 
glucose to fatty acid. It has been shown that insulin activates adipose 
tissue pyruvate dehydrogenase by means of the phosphorylation-dephosphor- 
ylation cycle (the unphosphorylated form being the active form of the 
enzyme) (18,20,22,29,62),previously shown to influence the activity of 
the enzyme complex from heart,liver,kidney and brain (63-65). Neither the 
pyruvate dehydrogenase kinase nor the pyruvate dehydrogenase phosphate 
phosphatase appear to be directly influenced by cAMP or cGMP (18,66-08), 
so it is unlikely that these nucleotides could directly mediate the ac-icm 
of insulin on oyruvate dehydrogenase. However,insulin has been shown to 
activate pyruvate dehydrogenase phosphate phosphatase (69,70) and it
fraction of pyruvate dehydrogenase present in the tissue in the active 
unphosphorylated form (70).
Insulin has also been shown to stimulate glycogen synthesis from
(55) and to stimulate the oxidation of glucose to carbon dioxide (4,5,8). 
Insulin stimulates glycogen synthetase I activity (55,71-73) without 
changing the total synthase activity(55). Insulin had no effect on 
phosphorylase a activity,although it did markedly oppose adrenaline- 
stimulation of phosphorylase a,as well as adrenaline-inhibition of 
glycogen synthase I (55)• Howvver,these aspects of the affect of insulin 
on glucose utilization by adipocytes are outside the context of the work 
reported in this chapter.
The sulphonylurea,tolbutamide,was shown to have no marked effects on 
basal rates of glucose incorporation into lipids jqfLa^P&sytejS: fSromeither 
normal or alloxan-diabetic rats,but it did potentiate a submaximal insulin 
effect,although a high concentration (20mM) of the drug had to be present 
for the effect to be recorded (Tables 4(i) and 4(ii)J. There is no 
published data illustrating this effect of sulphonylureas in adipocytes, 
although there is some evidence to suggest that tolbutamide,administered 
in vivo,potentiated the in vitrp insulin-stimulation of glucose uptake 
into skeletal muscle (74). However,in view of the high concentration of 
tolbutamide required for the observed effect on adipocytes,it is unlikely 
that this has any physiological significance.
The biguanide,phenformin,stimulated glucose incorporation into 
adipocyte lipids,but only at very high concentrations (2mM) (Tables 4(i) 
and 4(ii)J. Tranquada and Beigelman (15) have reported a stimulatory 
effect on glucose uptake into fat pads of phenformin at a concentration 
of 20|uM 'With no effect on lactate production. This contrasts with the 
findings of Pereira et al (47),who found that phenformin inhibited 
glucose oxidation to C02,inhibited lipogenesis and caused lactate 
accumulation. How ever, Pereira et al (47) used 0«5inM phenformin in their 
experiments,which is a concentration that has been shown to block
giucose independant” of its eff ects ^ n glucose~ transport' intoadipocy tes
greater than concentrations of phenformin normally obtained in the plasma 
with therapeutic doses of the drug (79-82). The findings reported in this 
chapter show no evidence of any inhibitory effects of phenformin on 
lipogenesis,but,in contrast to Pereira et al (47),show a stimulation at 
high concentrations. However,the concentrations at which these effects 
occurred were too high to have any therapeutic significance. The low 
doses of phenformin (20juM) at which Tran qua da and Beigelman (15) showed 
stimulatory effects on glucose uptake have hot affected glucose 
incorporation into lipid in the work reported in this chapter. Similarly, 
the findings of other workers (78) ,who,in contrast to Tranquada and 
Beigelman,showed inhibitory effects of biguanides on lipogenesis in 
concentrations similar to those seen in the plasma with therapeutic 
administration of the drug,have not been confirmed. Thus,with the 
conflicting results reported in the literature and the high concentrations 
of phenformin required for the results reported in this chapter,it is 
difficult to analyze biguanide action on lipogenesis and its importance 
in terms of effects on glucose utilization in vivo.
Wy 23675 stimulated the incorporation of glucose into adipocyte 
lipids in concentrations obtained in the blood with hypoglycaemic doses
of the drug (Tables 4(i) and 4(ii)];and the results reported in Chapter 3
demonstrated that Wy 23675 increased glucose utilization by rat 
hemidiaphragm. Taken together,these results illustrate an effect of 
Wy 23675 on glucose utilization by peripheral tissues in vitro.which 
has been shown in vivo using radiolabelled glucose (see Chapter 2).
Like insulin,Wy 23675 stimulated lipogenesis from glucose : however, 
further work is required in order to determine the mechanism of action
of Wy 23675. The results reported in Chapter 3 indicate that Wy 23675
could possibly activate pyruvate dehydrogenase. Insulin has been shown 
to activate this enzyme in adipose tissue (18,20,22,29,62) and,as this 
may be one of the rate-limiting factors in the conversion of glucose to 
fatty acid (29),this could be a significant site of action for both 
insulin and Wy 23675#
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Chapter ft ^  Summary.
The figures in this section show the results of experiments,which 
investigate the effects of selected hypoglycaemic agents on glucose 
production by the rat liver. Initially,perfused livers were used and the 
results correlated with similar experiments with isolated hepatocytes * 
which were used thereafter.
Results from perfusions with livers from 18-hr fasted rats showed the 
following effects of these agents:-
1. The rate of gluconeogenesis from alanine was markedly less than that 
from lactate plus pyruvate.
2. Glucagon trebled gluconeogenesis from both alanine and lactate plus 
pyruvate.
3. Insulin had no significant effect on gluconeogenesis from lactate plus 
pyruvate.
Both phenformin and Wy 23675 inhibited gluconeogenesis from lactate 
plus pyruvate.
Results from isolated liver cells prepared from fed rats showed the 
following effects of these agents:-
1. Glucagon more than doubled the basal rate of glucose production.
2. Insulin had no effect on basal rates of glucose production,but reduced 
glucagon-stimulation of it.
3. No effect was observed,on either basal or glucagon-stimulated glucose 
production,by tolbutamide,phenformin,or Wy 23675.
Results from isolated hepatocytes prepared from 18-hr fasted rats showed 
the following effects of these agents:-
1. The relative rates of gluconeogenesis from selected substrates were: 
xylitol>dihydroxyacetone>lactate plus pyruvate>alanine.
2. Glucaggn stimulated gluconeogenesis from alanine,lactate plus pyruvate 
and dihydroxyacetone,but not from xylitol.
3. Insulin had no effect on gluconeogenesis from lactate plus pyruvate, 
but did reduce glucagon-stimulation of it.
4, Tolbutamide had no effect on either gluconeogenesis from lactate plus
pyruvate or on glucagon-stimulation of it.
5* Phenformin reduced gluconeogenesis from both lactate plus pyruvate and 
dihydroxyacetonefbut did not affect gluconeogenesis from xylitol.
6. Wy 23673,like phenformin,reduced gluconeogenesis from lactate plus 
pyruvate and from dihydroxyacetone,but did not affect gluconeogenesis 
from xylitol.
Results from isolated hepatocytes prepared from 18-hr fas ted, alloxan- 
diabetic rats showed the following effects of these agents:- 
1. Alloxan-diabetes resulted in an increase in the rates of gluconeo­
genesis from lactate plus pyruvate,from dihydroxyacetone and from xylitol 
compared with control rates from normal rats,
2# Glucagon in vitro stimulated gluconeogenesis from lactate plus pyruvate,
but to a markedly lesser extent than in normal control rats,
3, Neither insulin not tolbutamide in vitro had any effect on gluconeo­
genesis from lavtate plus pyruvate.
*t. Insulin administered in vivo inhibited gluconeogenesis in isolated 
liver cells from lactate plus pyruvate,from dihydroxyacetone and from 
xylitol.
5, Tolbutamide administered in vivo had no effect on gluconeognnesis from 
lactate plus pyruvate.
6, Both phenformin and Wy 23675 ia vitro inhibited gluconeogenesis from 
lactate plus pyruvate and from dihydroxy acetone, but had no effect on 
gluconeogenesis from xylitol.
Introduction.
In Chapter 2,the effects of insulin,tolbutamide,phenfcu p ititn  
and ¥y 23675 upon glucose utilization in vivo were studied. The use of 
( H-2)-glucose in these experiments meant that the effects of these 
agents on glucose utilization were observed distinct from any effects 
that tfcey also may have had on glucose synthesis. The work reported in 
this chapter looks at the effects of these agents on glucose production 
hy the rat liver.
The rat liver has been used extensively in biochemical studies, 
particularly with regard to various aspects of glucose metabolism (23-35) 
The isolated perfused liver has been used in many of these studies, 
although there has been a considerable variation in the techniques used 
to perfuse the organ (1-5). The perfused liver provides a good technique 
for continuous monitoring of the products of liver metabolism. The main 
disadvantage is that the time for a single response can be very long in 
relation to the limited useful life of the preparation,so that very few 
results can be obtained per liver. This inevitably means that a great 
deal of repetition is necessary to establish a response.
Isolated hepatocytes have been used more recently in investigations 
into liver metabolism (6-22). Their chief advantage lies in the fact that, 
many results can be obtained from a single liver. Early doubts about 
their ability to retain their metabolic integrity have been largely 
allayed. Hems et al (2) have suggested that a stringent test of metabolic
v
integrity of hepatocytes is the ability to produce glucose from lactate 
since this process requires energy as well as the cooperation and 
integrity of both the mitochondrial and cytoplasmic compartments ; 
isolated hepatocytes have been shown to have this capability (18,20).
Results from work with isolated hepatocytes have been comparable to 
those from perfused livers. Ingebretson and Wagle (20) made a direct 
comparison on glucose formation by each of these preparations from 
lactate,alanine and pyruvate. They found that the results from the 
isolated hepatocytes were equivalent to those from the perfused liver ;
Garrison and Haynes (21) have produced similar results#
The effects of hormones on gluconeogenesis and glycogenolysis have 
also been looked at in isolated hepatocytes $ Garrison and Haynes (21) 
have shown that glucagon,adrenaline and cyclic AMP stimulate gluconeo­
genesis from lactate,alanine and pyruvate in fasted isolated hepatocytes# 
In the perfused liver,Exton et al (23) have shown similar effects# 
Glucagon,adrenaline and cyclic AMP have been shown to stimulate 
glycogenolysis in isolated hepatocytes (21,22),while insulin has been 
shown to inhibit this effect (22) ; similar results have been obtained 
in the perfused liver (33)• Glucagon has also been shown to increase 
cyclic AMP levels in isolated hepatocytes from both fed and fasted rats 
and this was followed by an increase in glycogenolysis or gluconeogenesis 
from lactate (21) ; similar results have been obtained in perfused livers
(33).
These findings suggest that the carbohydrate metabolism of isolated 
hepatocytes closely resembles that of the intact perfused liver# However, 
to justify the use of isolated hepatocytes in the work reported in this 
chapter,the initial work on glucose production by the rat liver has been 
completed in the perfused liver,so that a direct comparison can be made 
of the two techniques with the drugs being studied.
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Materials#
The sources of all drugs other than glucagon were given in earlier 
chapters# Glucagon,bovine serum albumin,eollagenase,hyaluronidase,EGTA, 
HEPES,lactate,pyruvate,alanine,dihydroxyacetone and xylitol were all
obtained from Sigma, Kings ton-up on-Thames , Surrey* --
Methods#
PE&FU5I0H5 #
The method used was based on that of Hems et al (2) and enabled the 
liver to be perfused in situ,although isolated from the rest of the 
animal#
1). Apparatus«
The perfusion apparatus was based on the designs of Hems et al (2) and 
was housed in a cabinet with a Perspex door and heated by thermostatically 
controlled bars with air circulated by a fan to maintain the temperature 
at 37*C.
2). Perfusion Medium#
The perfusion medium consisted of Krebs bicarbonate medium,dialysed 
bovine serum albumin Fraction V and washed goat red blood cells obtained 
fresh fnom the animal unit at Surrey University. The medium was prepared 
18 hrs prior to the liver perfusion,each perfusion requiring 60 mis of 
medium#
Bovine serum albumin - fatty acid poor - was added to the Krebs 
bicarbonate medium to give a J>% solution# The pH of the medium was then 
adjusted to 7«4 with NaOH,since albumin is acidic# The washed red cells 
were then added to the medium to give a final haematocrit value of 
approximately 35 “kk® pH was again checked to see that the value was
7>.
3)# Operative Procedure#
All the experiments with liver perfusions were carried out at Surrey 
University,using 110-1^0 gm# male rats bred in their animal unit#
The rat was anaesthetized with Nembutal (0*15 mis of a 6% solution per 
100 gm# body weight ±#^ >#3 and the abdomen was opened with a mid-line 
incision and transverse incisions to the left and right of the mid-line# 
The rat was then heparinized by injection of 0#1 mis of Pularin into the 
spleen# The intBstines were placed on damp tissue to the animal1 s left to 
expose the liver,portal vein,inferior vena cava and bile duct fsee Fig 
5(11)3.
A loose ligature was placed around the vena cava above the right renal 
vein# Next, the bile duct was cannulated with a length of Port ex tubing 
(for intravenous eannulation - 2FG Q/D 0.63 mm«). The portal vein was then 
cannulated with heparinized Portex tubing (5 FG 0/D 1#65 mm#) and tied off 
behind the point of eannulation#
The thorax was then opened by a transverse incision above and along the 
line of the diaphragm and by two longitudinal incisions towards the head 
from the ends of the transverse incision# The chest wall was flapped back 
towards the head and held in position there# The vagus and phrenic nerves 
and the oesophagus were cut in order to paralyse the the diaphragm and 
eliminate possible vasomotor effects of the vagus# The inferior vena cava 
was then cannulated with a length of heparinized Portex tubing (5 FG 0/D 
1.65 mm#) cut to a sharp point and pressed through the right atrium and 
down the vein towards the diaphragm,where it was tied in place# The loose 
ligature around the abdominal vena cava was then tied#
The liver was flushed out with 10 mis of the prepared perfusion medium 
through the cannula in the portal vein,before being attached to the 
perfusion apparatus as in Fig# 3.(3*). Care was taken to avoid letting air 
enter the portal vein during this procedure# The abdomen was covered by a 
damp tissue on a wire frame to prevent it from drying out during the 
experiment#
The perfusion pressure was 20—30 cm water obtained by adjusting the 
height of the reservoir at the base of the bulb oxygenator above the 
aniteal platform# The perfusion medium was kept oxygenated by a flow of 
95% 0^/5% C02 passing over it as it flowed through the bulb oxygenator#
The rate of flow of the medium through the liver was 15-25 ml/min, 
remaining constant during the experimental period,which did not exceed 
1^ -0 mins.
Several factors were observed during the course of an experiment as 
indicators of a successful liver perfusion. These were the maintenance of 
a uniform red colour of the perfused liver,the maintenance of oxygen 
uptake from the perfusate as indicated by a change in colour as it passed IfJ f l ?
through the liver, and the maintenance of a flow of bile from the cannula 1 
in the bile duct. Preparations that failed to satisfy these requirements 
were discarded. Each liver was weighed at the end of the experiment,so that 
the results could be expressed in terms of gms. wet liver weight. 
k)0 Perfusate Sampling and Addition of Substrates and Drugs,
Perfusate samples were taken from the reservoir below the animal 
platform at intervals throughout the experiment,which started after a 
period of 15 mins. during which time the liver was allowed to 1settle down*. 
Each sample was 0.5 mis in volume and was replaced by an equal volume of 
perfusate* The perfusate volume was measured at the end of the experiment, 
so that any losses could be measured (such losses did not normally 
represent more than 3% of the perfusate volume at the end of the 130 min# 
period).
Substrates or drugs were made up in 0,5 mis of Krebs bicarbonate medium 
and adjusted to a pH of 7.k and brought up to a temperature of 37*0 inside 
the cabinet before being added to the perfusate. All additions were placed 
into the reservoir below the animal platform,where a magnetic stirrer mixed 
them thoroughly with the perfusate. Substrates and drugs were added in the 
0.5 ml volume in a concentration of*120—times the final required concentrat­
ion,in order to compensate for the dilution in the 60 ml perfusate volume.
5), Treatment of Perfusate Samples.
The 0.5 ml perfusate samples were deproteinized with 1.5 mis of 7*5$ 
trichloroacetic acid (TCA) and centrifuged at 2000 g. for 10 mins. The 
supernatant was analyzed for glucose,using the ferricyanide method - 
Technicon Autoanalyser Method N-l6b.
Figure 5(i)
DIAGRAM OF APPARATUS FOR ISOLATED LIVER PERFUSION IN SITU
(Adapted from Hess et al (2))
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ISOLATED HEPATQGXTESV
The method used was based on that of Seglen(l9) a»d involved the 
sequential perfusion of the liver with,first,a Ca++-free buffer containing 
ethyleneglycol-bis-(|B-amino-ethylether)N,N,-tetra-acetic acid (EGTA) and, 
second#a Ca++-buffer containing the enzymes collagenase and hyaluronidase#
1)« Apparatus♦
The apparatus for perfusing the liver to isolate the hepatocytes had 
to be adapted from the apparatus described for liver perfusions (see Fig 
5 (iX?,so that the liver was perfused in isolation from the body in order 
to collect the perfusion medium that leaked from the liver surface as the 
enzymes caused disruption of the liver structure# Two reservoirs also had 
to be incorporated into the apparatus for the two different perfusion 
media used to isolate the hepatocytes The design of the apparatus can be 
seen in Fig# 5(iii)#
2). Perfusion and Incubation Media Employed#
(i)# The first perfusion medium was a 0.5 mM EGTA,Ca++-free buffer made 
up as follows
8.00 g NaCl } 0.35 g KC1 5 0.16 g KHgPO^ { 0.16 g M g S O ^ ^ O  } 2.38 g
HEPES buffer ; 0#19 g EGTA ; 51 mis 0.15 N NaOH and distilled water to
make up to 1000 mis#
(ii)# The second perfusion medium was a 10 mis stock enzyme solution +
10 mis 50 mM Ca++-buffer + 90 mis Ca++-free buffer,made up as follows:-
a)#Enzyme stock solution:
220 mgs collagenase Type II j 50 mgs hyaluronidase Type V ; 30 mis 
Ca++-free buffer and filtered through a 0#22 p Millipore filter#
b)#50 mM Ca++-buffer:
0ok9 g NaCl ; O.OMf g KC1 ; 0#013 g MgCl2#6H20 ; 0.735 g CaCl^.
2H20 ; 0.238 g HEPES j 3.6 mis 0.15 N NaOH ; distilled water to
make up to 100 mis#
c)#Ca++-free buffer:
8.18 g NaCl ? 0.35 g KC1 ; 0.16 g KH^O^? 0.16 g M g S O ^ ^ O  ;
2#38 g HEPES ; k5 ttiTf; 0.15 N NaOH 5 distilled water to make up
t o  1000 mis# 1 7 8
operative iroceciure.
The rats used were 110-140 gm# Charles River CD male rats.' They were 
anaesthetized with Nembutal (0*15 mis of 6% solution per 100 gm body 
weight) administered by the intraperitoneal route# The liver,portal vein 
and bile duct were exposed as described in the Methods for the in situ 
liver perfusion# The rats were then heparinized# Ligatures were placed 
around the gastrohepatic and gastroduodenal ligaments,two around the 
latter to include the pancreatico-duodenal vessels,and the ligaments were 
divided# In addition,other connections of the liver were dividedjthese 
preliminaries permitted the liver to be removed with the minimum of delay 
when eannulation was completed.
The bile duct was then cannulated and cut beyond the point of the 
eannulation# The portal vein was cannulated and three ligatures were tied 
as shown in Fig 5 (ii)# Immediately after this eannulation,the first 
perfusion was started through the portal vein# The portal vein was cut 
between the two ligatures holding the cannula in place and the third 
ligature# The inferior vena cava was cut between the heart and the 
diaphragm by cuttding through the diaphragm to leave only a small collar 
of it attached to the vein# The liver could then be removed and placed in 
the perfusing apparatus# It was found unnecessary in perfusions (for the 
purpose of isolating liver cells) to cannulate the inferior vena vava#
4)* Isolation of the Hepatocytes#
The first perfusion medium consisted of 150 mis of 0#5 mM EGTA,Ca++- 
free buffer# The liver was perfused with this medium immediately after 
eannulation of the hepatic portal vein at 37*0 at the rate of 30 mls/min# 
The first 50 mis of medium were discarded via a 3-way tap (No#1 on Fig# 
5(iii)Jto t;he drains, having been perfused through the liver# The perfusion 
was then switched to the recirculating system,so that the medium was 
returned to its reservoir prior to being pumped back to the liver via the 
oxygenator# After 10 mins of this initial perfusion,the four 3-way taps 
in the system were switched so that the medium in reservoir 2 was 
perfused through the liver# The first 10 mis of the second perfusion was
contaminate the enzyme-containing medium# Following this,the perfusion was 
switched to a recirculating system,which was continued until the appearance 
of the liver indicated that the structure had been disrupted (touching the 
liver surface with a spatula would cause the cells below to move,the whole 
liver consistency became soft and,by the end of the second perfusion,the 
medium was leaking from the surface of the liver lobes - this usually 
occurred within 10 mins)#
The liver was then carefully lifted out of the perfusion apparatus and 
placed in a Petri dish containing Krebs-bicarbonate solution# The liver 
membrane was broken and the cells dispersed by gentle agitation with a 
glass rod# The resulting suspension was filtered through a 30 fx pore size 
filter to remove any debris and large clumps of cells# The filtered 
suspension was centrifuged at: 50g# for 2 mins# and the supernatant poured 
away# The cell plug was resuspended in Krebs-bicarbonate medium and then 
recentrifuged at 50g# for 2 mins# The wet weight of the hepatocytes was 
measured after the final centrifugation and removal of the supernatant, 
and the cells were then resuspended at a concentration of 100-150mg/ml in 
Krebs-bicarbonate medium (this is equivalent to 8-10x10^ cells/ml - (41)# 
5J* Viability of the Cell Preparation#
The viability of the hepatocyte preparation was measured as the % of 
cells which resisted trypan blue uptake(19,21)# A 0»5% solution of trypan 
blue in Krebs -bicarbonate medium was filtered through a 0«22 p. Millipore 
filter and one drop mixed with one drop of cell suspension# The proportion 
of stained to unstained cells was measured under a light microscope# Cell 
viability,as measured by this method,was normally about 90% in the 
preparations used in this study# This figure is similar to the findings of 
Seglen (19)«
6)# Incubations with the Cell Suspension#
All incubations were carried out in 25 ml conical beakers in a water 
bath at 37*C with the shaker set at 120 rpm. Each incubation beaker 
contained a total volume of 0#7 mis of which 0#5 mis was the cell
suspension. In the remaining 0.2 mis was a 3.5-times the desired final 
concentration of the additive (ie: substrates/drugs). All the additives 
were dissolved in the Krebs-bicarbonate medium, except glucagon which was 
made up in 0*01 M NaOH - in this latter case,the controls also had 0.2 mis 
of 0*01 M NaOH added instead of 0.2 mis of Krebs-bicarbonate medium.
Incubations were stopped by the addition of 0.7 mis of ice-cold 10%
TCA solution and were immediately centrifuged at 2000 g. for 10 mins. 
Samples of the supernatant were used for glucose analysis by the 
Autoanalyzer and the results were expressed as fimoles glucose formed/gm, 
wet liver cell weight.
Figure 5(iii)«
.^ DIAGRAM OF APPARATUS FOB PERFUSION OF LIVER WITH MEDIA FOB ISOLATING
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Results.
a). Gluconeogenesis -by Isolated Perfused Rat livers.
The experimental results described in this section illustrate the 
effects of insulinfphenformin and Wy 23675 on gluconeogenesis by perfused 
livers prepared from fasted rats.
Gluconeogenesis from lactate (10 mM) plus pyruvate (1 mM) and from 
alanine (10 mM) is illustrated in Figures 3(iv) and 3(v) Respectively.
The rate of formation of glucose after the addition of lactate plus 
pyruvate to the perfusate was approximately 62 pmoles/gm. wet liver weight 
/hrfwhile in the control perfusions with no exogenous lactate plus 
pyruvate it was approximately 17 jimoles/gm. wet liver weight/hr. The 
addition of alanine resulted in rates of glucose formation of 
approximately 2k pmoles/gm. wet liver weight/hr. - this was not markedly 
greater than the control levels.
Glucagon stimulated gluconeogenesis from both lactate plus pyruvate 
(Figure 5(vi) /} and alanine (Figure 5(vii)»] ; in both cases the 
magnitude of stimulation was approximately 3-fold. Insulin had no effect 
on the rate of gluconeogenesis from lactate plus pyruvate in these 
experiments (Figure 5(viii).J. However,both phenformin (Figure 5(ix).3 
and Wy 23675 (Figure 5(x).3 inhibited gluconeogenesis from lactate plus 
pyruvate to approximately one-third of the control values.
b). Glycogenolysis by Isolated Hepatocytes Prepared from Normal.Fed
Rats .
The results described in this section illustrate the effects of 
glucagon,insulin,tolbutamide,phenformin and Wy 23673 on glucose 
production by isolated hepatocytes prepared from normal,fed rats and are 
summarized in Table 5(i). No exogenous gluconeogenic substrate was added 
to any of these incubations. t - 
'The basal rate of glucose production from these preparations was 
approximately 63 jimoles/gm. Wet liver cell weight/hr (Figure 5(xi) .3 • 
Glucagon|at all concentrations used (50nM-5|*M),significantly stimulated 
the producticn of glucose • ^hb’ highest concentration used (3pM)
stimulated glucose production by approximately 2-fold. Insulin,in 
concentrations from k pUnits/ml to *f00 ;iUnits/mlfhad no effect on basal 
glucose production,but did decrease the stimulation of glucose production 
caused by 500 nM glucagon,although not back to control levels. Tolbutamide, 
in concentrations from 0.2mM to 20mM,had no effect on either basal or 
glucagon-stimulated glucose production. Phenformin and Wy 23675,in the 
same concentrations as tolbutamide,also had no effect on either basal 
or glucagon-stimulated glucose production.
c). Gluconeogenesis by Isolated Hepatocytes Prepared from Normal.Fasted
Rats.
The results described in this section illustrate the effects of 
glucagon,insulin,tolbutamide,phenformin and Wy 23675 on gluconeogenesis 
by isolated hepatocytes prepared from normal,fasted rats and are 
summarized in Table 5(ii)«
Basal rates of gluconeogenesis from lactate plus pyruvate,alanine, 
dihydroxyacetone and xylitol were established (65,31 *93»1^1 pmoles glucose 
formed/gm. wet liver cell weight/hr*,respectively). These rates were 
comparable to those obtained in experiments using perfused livers (ie: 
gluconeogenesis from lactate plus pyruvate in the perfused liver was 
62 pmoles glucose/gm. wet liver cell weight/hr compared with 65 pmoles 
glucose/gm. wet liver cell weight/hr in isolated liver cells ; similarly, 
gluconeogenesis from alanine in the perfused liver was 2k pinoles glucose/ 
gm. wet liver weight/hr. compared with 31 jumoles/gm. wet liver cell 
weight/hr. in isolated liver cells).
Glucagon (5uM) stimulated gluconeogenesis from lactate plus pyruvate 
and from alanine by approximately 2«5-fold,while it stimulated by 
approximately 1.7-fold from dihydroxyacetone and had no effect on 
gluconeogenesis from xylitol. Insulin had no effect on the rate of 
gluconeogenesis from lactate plus pyruvate — this was similar to the 
finding in perfused livers - but it did inhibit a submaximal glucagon- 
stimulation of gluconeogenesis from lactate plus pyruvate in a dose- 
related manner.
Tolbutamide bad no effects on either the basal rate of gluconeogenesis 
from lactate plus pyruvate or on submaximal glucagon-stimulated 
gluconeogenesis from lactate plus pyruvate* In contrastfphenformin 
inhibited gluconeogenesis from lactate plus pyruvate and from dihydroxy­
acetone, while having no effect on gluconeogenesis from xylitol. Similarly, 
Wy 23675 inhibited gluconeogenesis from lactate plus pyruvate and from 
dihydroxyacetone,but had no effect on gluconeogenesis from xylitol.
However,it should be noted that the concentrations of phenformin required 
to inhibit rat liver gluconeogenesis (2mM) are approximately 100-fold 
higher than those normally achieved in the plasma of patients on 
therapeutic doses of phenformin (52-5^) • When gluconeogenesis from lactate 
plus pyruvate and from dihydroxyacetone was submaximally-stimulated by 
glucagon,phenformin had inhibitory effects in concentrations as low as 
2fiM. Wy 23675 also inhibited gluconeogenesis from lactate plus pyruvate 
and from dihydroxyacetone in lower doses when it was submaximally-stimulatec 
by glucagon than under basal conditions.
d). Comparison of Gluconeogenesis by Isolated Hepatocytes Prepared from 
Normal.Fasted and AHoxan^Piabetic.Fasted Rats#
Comparisons were made of the rates of gluconeogenesis from lactate 
plus pyruvate and from dihydroxyacetone and from xylitol in hepatocytes 
prepared from normal,fasted and alloxan-diabetic,fasted rats CTable 5(iii)3‘ 
In all instances,the rate of gluconeogenesis was greater in hepatocytes 
prepared from alloxan-diabetic rats than from normal rats. The increase 
was approximately 1.5-times with regard to gluconeogenesis from both 
lactate plus pyruvate and from dihydroxyacetone and approximately 1.3— 
times with regard to gluconeogenesis from xylitol.
e)» Gluooneogenesis by Isolated Hepatocytes Prepared from Fasted.Alloxan- 
Diabetic Rats.
The results described in this section illustrate the effects of 
glucagon,insulin,tolbutamide,phenformin and Wy 23675 on gluconeogenesis 
by isolated hepatocytes prepared from fasted,alloxan-diabetic rats.
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plus pyruvate {table 5(iv)3* Insulin appeared to Inhibit gluconeogenesis [
from lactate plus pyruvate in e dose-related manner {Table 3(iv)3,but 
these results were not statistically significant (Students t-Test), \
„ .. " - .. j
However ,when alloxan-diabetic rats were treated with insulin in vivo for j
3 days prior to the preparation of the isolated hepatocytes the rate of J
gluconeogenesis from lactate plus pyruvate was inhibited by approximately ■
30% as compared with the controls CTable 5(v)3* In similar experiments, j
insulin treatment in vivo was shown to inhibit gluconeogenesis from f
dihydroxyacetone by approximately 30% and from xylitol by approximately I
kO% fTable 5(v)3# j
ITolbutamide had no effect on gluconeogenesis from lactate plus pyruvate j
Ieither in vitro CTable 5(iv)3 or when administered in vivo for three days j
prior to the preparation of isolated hepatocytes {Table 5(v)3* la contrast* j
phenformin inhibited gluconeogenesis from both lactate plus pyruvate and I
from dihydroxyacetone*but had no effect on gluconeogenesis from xylitol J
1
in vitro CTable 5(iv)J* The concentration of phenformin required for an j
j
inhibitory effect on gluconeogenesis in hepatocytes prepared from 
alloxan-diabetic rats was 100-fold less than that required for inhibitory 
effects in hepatocytes prepared from normal rats Ceg: Compare Table 5(ii) 
with Table 5(iv)J# Wy 23675*like phenformin,inhibited gluconeogenesis from 
lactate plus pyruvate and from dihydroxyacetone,but had no effect on 
gluconeogenesis from xylitol B?able 5(iv)3#
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.THE ACTIONS OF SELECTED AGENTS ON GLUCOSE PRODUCTION BY THE RAT LIVER,
TitleFigure No, 
5(i)
5 (iii) 
5 (iv) 
5(v)
5 (vi)
5 (vii)
5 (viii)
5( ix)
5 (x)
5 (xi)
Table No,
5(0
5(ii)
5(iii)
Diagram of Apparatus for Isolated Liver Perfusion’in Situ’# 
Diagram of Operative Preparation for Liver Perfusion ’in Situ’* 
Diagram of Apparatus for Perfusion of Liver with Media for 
Isolating Liver Cells*
Effect of Lactate plus lyruvate on Gluconeogenesis by Perfused 
Livers from Fasted Rats.
Effect of Alanine on Gluconeogenesis by Perfused Livers from 
Fasted Rats* -
Effect of Glucagon on Lactate plus Pyruvate-Stimulated 
Gluconeogenesis by Perfused Livers from Fasted Rats*
Effect of Glucagon on Alanine-Stimulated Gluconeogenesis by 
Perfused Livers from Fasted Rats*
Effect of Insulin on Lactate plus iy*ruvate-Stimulated 
Gluconeogenesis by Perfused Livers from Fasted Rats*
Effect of Phenformin on Lactate plus Pyruvate-Stimulated 
Gluconeogenesis by Perfused Livers from Fasted Rats*
Effect of Wy 23675 on Lactate plus lyruvate-Stimulated 
Gluconeogenesis by Perfused Livers from Fasted Rats*
Glucose Production by Isolated Hepatocytes Prepared from a 
Normal,Fed Rat.
^ Title -
Glycogenolysis by Isolated Hepatocytes Prepared from Normal,
Fed Rats*
Gluconeogenesis by Isolated Hepatocytes Prepared from Normal, 
Fasted Rats*
Comparison of Rates of Gluconeogenesis by Isolated Hepatocytes 
Prepared from Fasted,Normal and Alloxan—Diabetic Rats*
Miv)
5(v)
Gluconeogenesis by Isolated Hepatocytes Prepared from Fasted, 
Alloxan-Diabetic Rats#
Effect of1In Vivo*Administration of Drugs on Gluconeogenesis 
by Isolated Hepatocytes Prepared from Fasted,Alloxan-Diabetic 
Rats#
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Figure 5(iv).
.EFFECT OF LACTATE 10mM + PYRUVATE 1 aM ON GLUCONEOGENESIS BY PERFUSED
LIVERS FROM FASTED RATS»
Livers from 18 hr fasted rats were perfused in situ for 55 mins with 
a recirculating medium,containing no substrate,as described in Methods. 
Perfusions were continued for a further 70 mins in the absence 
(controls) or presence of 10 mM lactate plus 1 mM pyruvate. 0.5 ml 
samples of the perfusion medium were taken from the reservoir for 
glucose analysis at 10 minute intervals,beginning 15 mins after the 
start of the perfusion. Each 0.5 ml sample was replaced with 0.5 mis 
of the red blood cell/Krebs medium. The results are expressed in 
umoles of glucose formed/gm wet liver weight. 3 control perfusions 
(■) were compared with k to which lactate/pyruvate had been added (A ) .  
Each point on the figure represents the mean “ the standard error of 
the mean for these perfusions.
Glucose Formed
(|imoles/gm. wet liver weight)
100
80..
60_
ko~
Krebs bicarh 
group;lactat< 
to test grou;
- - - - - - ,- - - - ,- - - - 1- - - - 1- - - - 1- - - - 1- - - - 1- - - - 1- - - - 1- - - - 1- - - - r- - - - »
0 15 25 35 **5 55 65 75 85 95 105 115 125
Time (mins)
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♦EFFECT OF ALANINE 10aM ON GLUCONEOGENESIS BY PERFUSED LIVERS FROM
FASTED RATS,
Livers from 18 hr fasted rats were perfused in situ for 55 mins with a 
~recirculating medium containing no substratefas described in Methods# 
Perfusions were continued for a ftirther 70 mins in the absence (controls) 
or presence of 10 mM alanine# Other details are as described in Figure 
5(1*“)# 5 control perfusions (s) were compared with 4 to which alanine
had been added (A)* Each point on the figure represents the mean i the 
standard error of the mean for these perfusions#
Glucose Formed
(jimoles/gm. wet liver weight)
100
80-
Krebs bicarbonate added to control 
group;alanine added to test group
Time (mins)
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.EFFECT OF GLUCAGON ON LACTATE + PYRUVATE~STIMULATED GLUCONEOGENESIS
BT PERFUSED LIVERS FROM FASTED RATS.
Livers from 48 hr fasted rats were perfused in situ (as described in 
Methods) for 55 min with a recirculating medium containing 10 mM lactate 
plus 1 mM pyruvate before the addition of glucagon (in a final concent­
ration of 5Q nM in the perfusion medium). Other details are as
described in Figure 5(iv),» This figure shows the mean — the standard 
error of the mean of k such perfusions.
Glucose Formed
(|imoles/gm. wet liver weight)
10mM lactate + 1mM pyruvate added 
at zero time.
200
Glucagon 50nM 
added
100-
Extrapolation of the 
gluconeogenesis from 
before glucagon addition
25 35 ^5 55 65 75 85 95 105 115 1250
Time (mins)
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*EFFECT OF GLUCAGON ON ALANINE^TIMULATED GLUCONEOGENESIS BI PERFUSED
LIVERS FROM FASTED RATS*
Livers from l8 hr fasted rats were perfused in situ (as described in 
Methods) for 55 mins with a recirculating medium containing 10 mM 
alanine before the addition of glucagon (in a final concentration of 
50 nK in the perfusion medium)* Other details are as described
in Figure 5(iv)« This figure shows the mean - the standard error of 
the mean of 4- such perfusions*
Glucose Formed
(junoles/gm. wet liver weight)
300-
10mM alanine added 
at zero time
200
100- Glucagon 50nM 
added
Extrapolation of gluconeogenesis 
from before glucagon addition
15 25 35 ^5 55 65 75 85 95 105 115 1250
Time (mins)
♦EFFECT OF INSULIN ON LACTATE + PYRUVATE-STIMULATED GLUCONEOGENESIS BI
PERFUSED LIVERS FROM FASTED RATS.
Livers from 18 hr fasted rats were perfused in situ (as described in 
Methods) for 55 mins with a recirculating perfusion medium containing 
10 mM lactate plus 1 mM pyruvate before the addition of insulin (final 
concentration of kO uUnits/ml in the perfusion medium) Other details 
are as described in Figure *>(*•▼)• \Tkis figure shows the mean - the 
standard error of the mean of k such perfusions*
Glucose Formed
(pmoles/gm. wet liver weight)
1-4-0 t
10 mM lactate + 1 mM pyruvate 
added at zero time
120
100'
80,
60-
40"
20-
Insulin kOpXf/wl 
added
t  1----1----1----»---- 1----r
15 25 35 ^5 55 65 75
Time (mins)
"1---- 1---- 1---- 1----"?
85 95 105 115 125
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.EFFECT OF PHENFORMIN ON LACTATE + PYRUVATE-STIMULATED GLUCONEOGENESIS
BY PERFUSED LIVERS FROM FASTED RATS.
Livers from 18 hr fasted rats were perfused in_sittL (as described in 
Methods) for 55 Pins with a recirculating medium containing 10 mM lactate 
plus 1 mM pyruvate before the addition of phenformin (final concentration 
of 2 mM in the perfusion medium). Other details are as described in 
Figure 5 (iv)  ^This figure shows the mean - the standard error of the 
mean of h such perfusions.
Glucose Formed
(|imoles/gm. wet liver weight)
1*f0
10mM lactate + 1mM pyruvate 
added at zero time
120-
100-
80-
60-
ko~
20'
Extrapolation of gluconeogenesis 
from before phenformin s 
addition ' *
/
/
/
/
Phenformin 2mM
added
— r------1-- 1-----r
15 25 55 ^5
T
55
-i r
65 75
-1— — r— — i---- 1 ...1
85 95 105 115 125
Time (mins)
♦ EFFECT OF WY 25675 ON LACTATE + PYRUVATE-STIMULATED GLUCONEOGENESIS BI
PERFUSED LIVERS FROM FASTED RATS,
Livers from 18 hr fasted rats were perfused in situ (as described in 
Methods) for 55 mins with & recirculating medium containing 10 mM lactate 
plus 1 mM pyruvate before the addition of Wy 23675 (final concentration 
'Of 2 mM in the perfusion medium)* Other details were as described in 
Figure 5 (iy))« This figure shows the mean - the standard error of the 
mean of k such perfusions#
Glucose Formed
(pmoles/gm# wet liver weight)
10mM lactate + 1mM pyruvate 
added at zero time
120-
100-
80-
60r
ko~
20-
Extrapolation of gluconeogenesis 
from before Wy 23§75 addition
/
/
/
/
— r— i---r
15 25 35
TT 1 n  1 T
**5 55 65 75 85
Time (mins)
T T~t— 1---r~— r
95 105 115 125 135 1^5
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.GLUCOSE PRODUCTION BT ISOLATED HEPATOCYTES PREPARED FROM A NORMAL.
FED RAT.
Isolated hepatocytes were prepared from fed rats and incubated as 
described in Methods♦ Incubations werestopped at the time points 
shown and jthe gluc^eCdntent of the melium was measured and expressed 
in fimoles/gm wet liver cell weight. No additions were made to these 
incubations. Each time point represents the mean * the standard error 
of 6 observations.
Glucose Formed
(|imoles/gm. wet liver cell weight)
2010
Time (mins)
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.GLYCOGENOLYSIS BI ISOLATED HEPATOCYTES PREPARED FROM NORMAL,FED RATS,
Isolated hepatocytes were prepared from fed rats and incubated as described 
in Methods# Incubations were stopped at the ti^e points indicated and the 
glucose content of the medium was measured and expressed in jamoles/gm# wet 
- Oliver cell weight# ilo additions1 Were'toade to theSe; incubations# Each time 
point represents the mean * the standard error of 6 observations#
Glucose Production (pnoles/gm. wet liver cell weight) j 
for the Following Incubation Times (mins) s- ‘ |
20 <(0 r.' 60 I
Control 30 (±5) k9 i±k) 59 (±4) |
Glucagon 50nM 39 (-7) 63 (±6 ) 77' (±8 )
Glucagon 500m 56 (±7)« 93 (±3)*** 111 (±6)***
Glucagon' 6k (±>0*** 109 (±5)*** 136 (±3)*** J
Control 39 (±8) k9 (±5) 60 (±6 ) |
Insulin fyiTJ/ml 35 (±10) 53 (±8) 58 (±12)
Insulin JfOpTJ/ml 33 (±7) 58 (±k) 67 (±6.)
Insulin *fOOfiU/ml 31 (±6 ) k8 (±9) 62 (±10)
Control 22 (±5) k8 (±6) •*5 (±5)
Glucagon 500nM k6 (±«t)** 95 (±k)*** , 120. (±5)***
Glucagon
Insulin
500nM + 
^OfiU/ml
30 (±7) 65 (±6 ) 75 (±10)*
Control 27 (±6 ) 52 (±3) 61 (±7,)
Tolbutamide 0#2mM 33 <±40 k6 (±6 ) 5k (±6)
Tolbutamide 2mM 29 (±6) k? (±2) 56 (Zk)
Tolbutamide 20mM 22 .(4ft)). 51 (±7) ? 58 (±3)
Control 38 (*0 k5 (±5) 58 (±6)
Glucagon 500nM 55 (±8) 102 (±7)*** 129 (±10)***
Glucagon 500nM + 
Tolbutamide 20mM
61 <46)**' 87 (±9.)** . 107 (±13)**
t
Statistically significant changes from the appropriate controls were 
determined by Student*s t-Test:-
* p<0.05 ; ** p<0.01 ; *** p<0.001
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♦ xta.uj.c
♦GLYCOGENOLYSIS BY ISOLATED HEPAgQCYTBS PREPARED FROM NORMAL.FED RATS.
i
Glucose Production (pmoles/gm# wet liver cell weight) j 
for the Following Incubation Times {mins) j
" 20 ' V- 40
»
60 j
Control 19 (16) 39 (*4) 53 1-7> |
Phenformin 0*2mM 23 (±3 ) 37 (-7) 61 (±5 ) )
Phenformin 2mM 1? (±4) 41 (±5) 52 (±10) |
Phenformin 20mM 21 (±3 ) 46'(±8) r 59 (±6)
Control 27 (*6) 47 (±3) 67 (±5) !
Glucagon 500nM 72 (±11)** 113 (±17)** - 152 (±12)***
Glucagon 500nM + 
Phenformin 20mM
61 (±8)** 98 (±12)** . 151 (±13)***
Control 44 (±9) 65 (±8) 74 (±9)
Wy 23675 0.2mM 32 (±7) 57! (±11) 63 (±8)
Wy 23675 2mM 43 (±10) 61 (±7) . 69 (14)
Wy 23675 20mM 30 (±6) 39 (±16) 49 (I11)
Control 31 <*6) 51 (±4) 66 (17)
Glucagon 500nl*I 63 <-5)**- • 101 (±7)***, < 1^1 (±11)***
Glucagon 300°^ 4 c 
Wy 23675 20eM
64 (±6)** , 92 (±4)***. , 133 (±8)***
Statistically significant changes from the appropriate controls were 
determined by Student*s t-Test:«-
* p<0.05 J ** p<0.01 5 *** p<0.001
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♦Table
♦GLUCONEOGENESIS BY ISOLATED HEPATOCYTES PREPARED FROM NORMAL * FASTED RATS,
Isolated hepatocytes prepared from 18-hr* fasted rats and incubated as 
described in Methods were used* Incubations were stopped at the time 
points shown and the glucose content of the medium was measured and 
expressed in /umoles/gm. wet liver cell weight* Each value represents the 
mean ± the standard error of 6 observations*
Statistically significant changes from the appropriate controls were 
determined by Student»s t-Test:-
* F<0.05 ; ** p<0.01 ? ••• p<0*001 ‘ ~
Glucose Production (pmoles/gm* wet liver cell weight) 
for the Follo\*ing Incubation Times (mins):-
20 <40 60
Control 7 C±2) 11 (±3) 15 (±2)
Lactate 10 mM + 14 (±6) 26 (-5)* 65 (£7)***
Pyruvate 1 mM
Control 6 (±3) 11 (-3) 17 (£2)
Alanine 10 mM 9 (-3) 22 (i2)* 31 (±*0*
Control 5 (±2) 9 (±2) 12 (±3)
Dihydroxyacetone 10mM 28 (i<4)*»* 63 (i6)*»* 93 (£7)***
Control 6 (±2) 10 (±2) 14 (£1)
Xylitol 10 mM 3k (±6)** 93 (±11)**« 141 (±12)***
Control 8 (*1) 11 (±2) 16 (±2)
Glucagon 30nM 9 (-2) 15 (±1) 22 (±4)
Glucagon 5faM 7 (±U 17 C-3) 26 (£3)*
Lactate 10 mM + 11 (£2) 27 (.-3) 58 (£6)
pyruvate 1 mM (I/P)
I/P + Glucagon 50nM 1^4- (±2) <4<4 (±6)* 108 (±12)**
I/P + Glucagon 23 (*k)* 55 (-6)** 123 (£11)***
Alanine 10 mM 8 (i2) 19 (-k) 26 (-3)
Alanine 10 mM + 20 (tk)* <46 (±8)* 66 (±7 )***
Glucagon
Dihydroxyacetone 29 (*3) 70 (*8) 110 (*12)
10 mM (D)
D + Glucagon 50nM k2 (±3)* 106 (±10)* 159 (±13)*
D + Glucagon <46 (±5 )* 113 (£9)** 183 (*16)*»
Xylitol 10 mM (X) <40 (±3) 110 (±9) 162 (*16)
X + Glucagon 50nM 39 W 97 (±10) 151 (*13)
X + Glucagon 5»M <46 (±5) 103 (in) 175 <-17)
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♦GLUCONEOGENESIS BY ISOLATED HEPATOCYTES PREPARED FROM NORMAL.FASTED RATS,
Glucose Production (pmoles/gm. wet liver cell weight) 
for the Following Incubation Times (mins):-
20 40 60
Lactate 10 mM + I^ rruvate 1 mM 20 (±4) 33 (44) 59 (45)
(I/P)
I/P + Insulin kQ jiUnits/ml 18 (42) 36 (±3) 57 (47)
I/P + Insulin 400 ^Units/ml 22 (±3 ) 28 (±5 ) 59 (44)
Lactate 10 mM + I^ rruvate 1 mM 39 (46) 75 (49) .141 (416)
+ Glucagon 50nM (I/P/G)
I/P/G + Insulin b pUnits/ml 41 (±4) 68 (±7) 130 ( 4 n )
I/P/G + Insulin kO piUnits/ml 31 (-3) 61 (i?) 110 (49)
I/P/G + Insulin 400 jiUnits/ml 27 (±3) 53 (-5) 96 (4n)*
Lactate 10 mM + Ityruvate 1 mM 18 (±3) 44 (46.) 71 (45)
(I/P)
I/P + Tolbutamide 0 .2 mM 20 (±4) 51 (±5) 65 (45)
I/P + Tolbutamide 2 mM 17 (±2) 47 (45) 69 (44)
I/P + Tolbutamide 20 mM 22 (±3) 39 (44) 62 (47)
Lactate 10 mM + Ityruvate 1 mM 13 (±4) 51 (48) 111 (iio)
+ Glucagon 50nM (I/P/G)
I/P/G + Tolbutamide 0*2 mM 16 (±4) 42 (±4) 96 (4n)
I/P/G + Tolbutamide 2 mM 19 (±6) 45 (44) 122 (415)
I/P/G + Tolbutamide 20 mM 11 (42) 41 (46) 103 (412)
Lactate 10 mM + pyruvate 1 mM 18 (±3 ) 38 (±5) 60 (45)
(I/P)
I/P + Phenformin 0.2 mM 17 (±2) 41 (44) 56 (46)
I/P + Phenformin 2 mM 14 (±2) 30 (43) 44 (45)*
I/P + Phenformin 20 mM 8 (±2)‘ 17 (44)** 23 (44)***
Dihydroxyacetone 10 mM (D) 27 (43) 67 (44) 103 (49)
D + Phenformin 0.2 mM 32 (-4) 72 (47) 111 (±10)
D + Phenformin 2 mM 21 (-3) 47 (45)* 75 (49)
D + Phenformin 20 mM 17 (44) 39 (47)** 61 (411)*
Statistically significant changes from the appropriate controls were 
determined by Student*s t-Test:-
* p<0.05 ? ** p<0.01 5 *** P<0.001
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♦GLUCONEOGENESIS BY IS OLA.TED HEPATOCYTES PREPARED FROM NQRMAL.FASTED RATS .
Glucose Production (pmoles/gm. wet liver cell weight) 
for the Following Incubation Time (mins);-
20 IfO 60
Xylitol 10 mM (X)
X + Phenformin 0*2 mM 
X + Phenformin 2 mM 
X + Phenformin 20 mM
47 (±5) 
43 (±6) 
57 (±6) 
38 (±7)
103 (±11) 
96 (in) 
112 (±13) 
99 (±12)
159 (412) 
147 (£17) 
161 (ii9) 
153 (£15)
Lactate 10 mM + pyruvate 1 mM 
(I/P)
I/P + Wy 23675 0.2 mM 
I/P + Wy 23675 2 mM 
I/P + Wy 23675 20 mM
23 (£2)
25 (*2)
19 (42)
10 (42)***
44 (-5)
in (£4)
32 (45)
24 (42)**
73 (£8)
64 (£7 )
57 (46)
33 (44)**
Dihydroxyacetone 10 mM (D) 
D + Wy 23675 0.2 mM 
D + Wy 23675 2 mM 
D + Wy 23675 20 mM
30 (±2)
28 (±4)
21 (*3)* 
17 (£3)**
71 (47)
72 (£4)
50 (46)* 
34 (£5 )**
112 (411)
104 (£9)
76 (48)* 
57 (£6)**
Xylitol 10 mM (X)
X + Wy 23675 0.2 mM 
X + Wy 23675 2 mM 
X + Wv 23675 20 mM
VI (46) 
39 (44) 
44 (45) 
33 (4*f)
108 (410) 
107 (49) 
98 (410) 
96 (46)
167 (4i8) 
154 (412) 
147 (£13) 
144 (411)
Lactate 10 mM + ]yruvate 1mM 
+ Glucagon 50nM (I/P/G)
I/P/G + Phenformin 2 pM
I/P/G + Phenformin 20 pM
I/P/G + Phenformin 0j2 mM
I/P/G * Phenformin 2 mM
3-1 (£3)
17 (£3)**
8 (±2)*** 
10 (£2)*** 
8 (£1)* * *
70 (£5 )
37 (£5 )*** 
22 ( £3) * * *  
25 (42)***
18 (43)***
103 (£9)
50 (46)*** 
30 (43)*** 
33 (43)*** 
24 (42)***
Dihydroxyacetone 10 mM + 
Glucagon 50nM (D/G)
D/G + Phenformin 2 pM
D/G + Phenformin 20 pM
D/G + Phenformin 0.2 mM
D/G + Phenformin 2 mM
59 (^0
29 (£**.)***
22 (±3 ) * * *  
18 (±2 ) * * *  
20 ( ±3 ) * * *
111 (412)
62 (£6)**
Zf 1 ( ±5 ) * * *
39
35 ( ± 3 ) * * *
163 (£15)
86 (£9)** 
64 (46)*** 
55 ( £6 ) * * *  
52 (47)***
Statistical significance was determined by Student*s T-test 
* P<0 .05  ? * *  P<0.01  ; * * *  p<0 .001
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.GLUC0NE0GENE5IS BY ISOLATED HEPATOCYTES PREPARED FROM NORMAL,FASTED RATS,
Glucose Production (|moles/gm. wet liver cell weight) 
for the Following Incubation Time (mins)
20 4-0 60
Lactate 10 mM + Pyruvate 1mM
+ Glucagon 50nM (I/P/G) 36 (±3) 82 (±9) 116 (±12)
I/P/G + Wy 23675 2 pM 15 (fe)*** 39 51 (±6)***
I/P/G + Wy 23675 20 |iM 9 (i2)*** 22 (±2 )*** 29 (±if)***
I/P/G + Wy 23675 0.2 mM 8 (±1)*** 19 (±3)*** 23 (±2)***
I/P/G + Wy 23675 2 mM 6 (±1)*** 16 C—3 )* * * 1V  (±2)***
Dihydroxyacetone 10 mM +
Glucagon 50nM OVG) ^  ( 3^) 100 (-11) 1^7 (-15)
D/G + Wy 23675 2 jllM 23 (£3)* * * 60 (±7)* 82 (±9)**
D/G + Wy 23675 20 jiM 16 (^ 2)*** 37 (if)*** 52 (±7 )***
D/G + Wy 23675 0.2 mM 13 (±2)*** 32 (if)*** Zjif (±5 )***
D/G + Wy 23675 2 mM 10 (±2)*** 29 (-3)* * * Vi (if)***
Statistical significance was determined by Student*s T-test
* p<0.05 ; ** p<0.01 ? *** p(0.001
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*Table 5(iii)«
* COMPARISON OF RATES OF GLUCONEOGENESIS BY ISOLATED HEPATOCYTES PREPARED
FROM FASTED,NORMAL AND ALLOXAN-DIABKTIC RATS,
Test rats were treatedwith Alloxan (O*7nimol/kg i*p*) and those with 
blood glucose levels in excess of l6*5mmol/l* two days later were 
used (control rats recieved no treatment)* Isolated hepatocytes were 
prepared from 18—hr* fasted rats and incubated as described in Methods* 
Each value represents the mean (* the standard error) of 6 observations*
Statistical significance was determined by Student’s t-Testj- 
* P<0.05 ? ** p<0.01 5 **« p<0.001
Glucose Production (jimoles/gm. wet liver cell weight) 
for the Following Incubation Times (rains):-
20 bo 60
Lactate 10 mM + pyruvate 1 mM 
Normal Rats 
Alloxan-diabetic Rats
14 (£6) 
2? (£4)
26 (£5 )
61 (£7)**
65 (£7 ) 
96 (£9)*
Dihydroxyacetone 10 mM 
Normal Rats 
Alloxan-diabetic Rats
28 (£4) 
39 (£5)
63 (£6)
8b (£8)
93 (£7 )
141 (£12)**
Xylitol 10 mM 
Normal Rats 
Alloxan-diabetic Rats
34 (£6) 
44 (-5 )
93 (£11) 
124 (£10)
141 (£12) 
186 (£i4)*
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je GLUCONEOGENES IS BY ISOLATED HEPATOCYTES PREPARED FROM FAS TED. ALLOXAN-
DIABETIC RATS.
Rats were treated with alloxan (0,7mmol/hg i#P#) and those with blood 
glucose levels in excess of l6#5mmol/l* two days later. Isolated 
hepatocytes were prepared from 18 hr, fasted rats and incubated as 
described in Methods,
Each value represents the mean (* the standard error) of 6 observations, '
Glucose Production (pmoles/gm, wet liver cell weight) 
for the Following Incubation Times (mins):-
20 40 60
Lactate 10 mM + I^ruvate 1 mM 
(I/P)
I/P + Glucagon «50nM 
I/P + Glucagon 5
25 (-3)
29 (-3)
30 (±4)
66 (±7)
54 (±6) 
89 (±9)
104 (±10)
97 (*9) 
136 (±10)*
Lactate 10 mM + lyruvate 1 mM 
(I/P)
I/P + Insulin k /aU/ml 
I/P + Insulin kO pU/ml 
I/P + Insulin *f00 pU/ml
22 (if)
23 (±3) 
19 (.-3) 
18 (±2)
60 (-7 )
65 (±6) 
53 (±6) 
50 (±5)
83 (±10)
92 (±11) 
77 (±8) 
65 (±7)
lactate 10 mM + I^ rruvate 1 mM 
(I/P)
I/P + Tolbutamide 0,2 mM 
I/P + Tolbutamide 2 mM 
I/P + Tolbutamide 20 mM
36 (if)
41 (-3) 
38 (±6) 
4o (if )
78 (±9)
84 (±11) 
76 (±8)
82 (±9)
122 (±15)
131 (±13) 
114 (±15) 
119 (±12)
Lactate 10 mM + I^xuvate 1 mM 
(I/P)
I/P + Rienformin 2 pM 
I/P + Phenformin 20 pM 
I/P + Phenformin 0/2 mM
35 (±4)
33 (±5)
20 (*4)* 
14 (±3)**
74 (±8)
69 (-7)
39 (±6)** 
33 (-5)**
111 (±13)
98 (±10) 
63 (±9)* 
48 (±8)**
Dihydroxyacetone 10 mM (D) 
D + Rienformin 2 pM 
D + Phenformin 20 pM 
D + Rienformin 0,2 mM
51 (-7)
46 (±6)
27 (-5)* 
21 (±4)**
109 (±11)
91 (±11)
69 (±8)* 
51 (-7)**
162 (±18) 
144 (±15)
94 (±12)* 
73 (±9)**
Xylitol 10 mM (X)
X + Rienformin 2 pM 
X + Rienformin 20 pM 
X + Rienformin 0,2 mM
64 (±8) 
59 (±7) 
54 (±5) 
49 (±6)
131 (-11)
130 (±13) 
125 (±13) 
107 (±11)
203 (±22) 
197 (±20) 
192 (±18) 
163 (±15)
Statistical significance was determined by Student*s t-Testj- ___ 
* p<0,05 ? ** p<0.01 ? *** P<0.001 204
♦Table 5(iv).-cont«
.GLUC ONE 0GENE5 IS BY IS OLA. TED HEPATOCYTES PREPARED FROM FASTED. ALL QXAN-
y
DIABETIC RATS,
Glucose Production (jomoles/gm. wet liver cell weight) 
for the Following Incubation Times (mins):-
20 ko 60
Lactate 10 mM + pyruvate 1 mM 
(I/P)
I/P + Wy 23675 2 pM 
I/P + Wy 23675 20 pH 
I/P + Wy 23675 0 .2 mM
31 (±4)
21 (±3)
15 (-3)* 
13 (±3)**
64 (±7)
bb (-5)*
31 (if)** 
25 ( -3)***
97 (±11)
69 (±9) 
50 (±6)** 
in (£6)**
Dihydroxyacetone 10 mM (D) 
D + Wy 23675 2 pM 
D + Wy 23675 20 nM .
D.+ Wy 23675 0 .2 mM
50 (±6)
37 (±4)
31 (£4)* 
26 (if)**
103 (£11) 
80 (±9)
60 (£7 )**
57 (£?)**
155 (±17) 
124- (£i4) 
97 (±11)* 
79 (±9)**
Xylitol 10 mM (X)
X + Wy 23675 2 pM 
X + Wy 23675 20 11M 
X + Wy 23675 0.2 mM
61 (±7) 
65 (±6) 
59 (±7) 
52 (-5)
130 (£l4) 
138 (±12) 
126 (£13) 
109 (±11)
191 (±20) 
202 (±21) 
186 (£19) 
155 (±17)
Statistical significance was determined by Student*s t-Test:-
* p<0.05 ; ** P<0.01 ; *** p<0.001
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» x a p j .e
* EFFECT OF* IN VIVO1ADMINISTRAIIOH OF DRUGS ON GLUCONEOGENESIS BY IS OLA.TED
HEPATOCYTES PREPARED FROM FAS TED. ALLOXAN-DIABETIC RATS,
Rats were treated with alloxan (O.7mmol/kg i#p#) and those with blood 
glucose levels in excess of l6#5mmol/l# two days later were used* Control 
rats recieved no further treatment* Test rats recieved either units of 
n n«niA r> per day by intraiouscular injection or 0#2mmol/kg p#o# of tolbutamide 
twice a day for three days prior to an experiment# Blood glucose' levels 
were measured immediately prior to the preparation of the isolated 
hepatocytes and for the insulin-treated rats were 3*36-6#60mmol/l* and 
for the tolbutamide-treated rats were 11#01—13•76mmol/l#fwhile controls 
were l8#75-25#62mmol/l# Isolated hepatocytes were prepared from 18-hr# 
fasted rats and incubated as described in Methods#
Each value represents the mean (* the standard error) of 6 observations#
Glucose Production (pmoles/gm# wet liver cell weight) 
for the Following Incubation Times (mins)
20 40 60
Lactate 10 mM + I^ruvate 1 mM 
Control
Insulin-Treated (in vivo)
30 (±*0 
11 ( - 5 ) *
83 (S i o') 
35 (± 8 )* *
108 c ± n )  
52 (± 1 2 )**
Dihydroxyacetone 10 mM 
Control
Insulin-Treated (in vivo)
50 (±8 ) 
26 (± 6 )*
131 (±16)
63 (± 1 1 )* * '
172 (£19) 
86 (± 2 1 )*
Xylitol 10 mM 
Control
Insulin-Treated (in vivo)
55 (.-7) 
32 (±9 )
122 (±16) 
69 (S i8)
I 81f (±20)
109 (± 15) *
Lactate 10 mM + lyruvate 1 mM 
Control
Tolbutamide-Treated (in vivo)
28 (S O  
25 ( - 5 )
63 (-7) 
52 (±6 )
99 (±10 ) 
78 (± 9 )
Statistical significance was determined by Student*s t-Test: 
* p<b#05 ; ** p<0.01 ; •**_p<0.001
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Insulin,tolbutamide,phenformin and Wy 23673 have all been shown to 
possess hypoglycaemic properties. The effects of these agents on glucose 
utilization have been investigated and the results described in Chapters 
2,3 and 4. However,these agents have also been shown to lower blood 
glucose levels in 24-hr. fasted normal rats (sefe Table 1,Chapter 1) - a 
situation where gluconeogenesis is enhanced. The work in this chapter 
has investigated the effects of these agents on glucose production by 
the rat liver.
Comparison of Perfused Livers with Isolated Hepatocytes.
Most of the work reported in this chapter is with isolated' rat 
hepatocytes. However,in order to justify their use,some of the results 
obtained with isolated hepatocytes have been compared with results 
from similar experiments with perfused livers CPable 5 (vi) J# Rates of 
gluconeogenesis from lactate plus pyruvate and from alanine were similar 
with either perfused livers or with isolated hepatocytes from starved 
rats. The rates of gluconeogenesis from these substrates compare closely 
with those reported by other workers for both perfused livers (2,23,24) 
and for isolated hepatocytes (21,46).
Insulin had no effect on gluconeogenesis from lactate plus pyruvate 
with either the perfused liver or isolated hepatocytes. There is some 
controversy as to whether insulin has a direct inhibitory effect on 
basal gluconeogenesis or glycogenolysis in the liver (43,45) or not 
(36,37),or whether it acts in vivo by inhibiting the actions of glucagon 
and catecholamines* There seems to be general agreement that insulin 
acts in the isolated perfused liver ±n vitro to inhibit the glucagon- 
and adrenaline-stimulation of gluconeogenesis (33,34,38).
Isolated hepatocytes5 appeared'to be less sensitive to the effects of 
glucagon,phenformin and Wy 23673 on gluconeogenesis than did perfused 
livers (Table 5(vi)J. The percentage stimulation of gluconeogenesis 
by glucagon is similar to that reported by other workers for both the 
perfused liver (23,35) and the isolated hepatocyte (21,47-50)*
♦Table 5(vi)»
♦ COMPARISON OF RATES OF GLUCONEOGENESIS BY PERFUSED LIVERS AND BY 
ISOLATED HEPATOCYTES FROM 18-HR. FASTED RATS ♦
Substrate and , 
Drugs IJsed
Glucose Production (pmoles/gm, wet liver weight/hr) by:-
Perfused Rat Livers Isolated Rat Hepatocytes
Glucose
Production
% Change
from
Control
Figure
No*
Glucose
Production
% Change
from
Control
No.
Control
Lactate 10mM + 
Pyruvate 1mM
(I/P)
17 (-2)
63 (£*) +271#
5(iv) 15 (£2) 
65 (£7) +33355
5(ii)
Control 
Alanine 10mM
17 (*2) 
2b (±k) +41#
5(v) 17 (£2 ) 
31 (±W +82#
5(ii)
I/P
I/P + Glucagon 
50nM
6b
196 (£18) +206#
5(v) 58 (£6) 
108 (£12) +86%
5(ii)
I/P
I/P + Insulin 
*K)uU/ml
58
58 (±3) 0#
5(viii) 59 (£5 ) 
57 (£7) -3%
5(ii)
I/P 
I/P +
Rienformin
2mM
57
20 (i8) -65#
5(ix) 60 (£5 ) 
bb (£5 ) -27%
5(ii)
I/P
I/P + %  23675 
2mM
6b
21 (£7) -67#
5(x) 73 (£8) 
57 (£6) -22%
5(ii)
Each value represents the mean £ the standard error of 4 observations 
for the perfusions and of 6 observations for the isolated hepatocytes♦
greater extent in the perfused liver compared to the isolated hepatocyte; 
similar effects were observed with Wy 23675. The reason for the 
differences in the responses to glucagon,phenformin and Wy 23675 in 
perfused livers and isolated hepatocytes could be due to a proportion of 
the cells and their hormone receptors being damaged during the enzyme 
isolation of the hepatocytes. However,in all the comparisons the drugs 
had the same effects on gluconeogenesis in both the perfused liver and the 
isolated hepatocyte,albeit of a different magnitude. For this reason,and 
for experimental convenience,further work involved using isolated 
hepatocytes.
The Effects of Insulin.Tolbutamide.Phenformin and Wy 25675 on 
Glycogenolysis.
Hepatic glucose production involves glycogenolysis as well as 
gluconeogenesis ; thus,the effects of insulin,tolbutamide,phenformin 
and Wy 23675 on glycogenolysis have been investigated. The basal rate 
of glucose production from isolated hepatocytes prepared from normal, 
fed rats was similar to that reported by others with isolated 
hepatocytes (21,22,42) or perfused livers (43).
Glucagon stimulated glycogenolysis in a dose-related manner to more
—6than twice the basal rate of glucose production at 10 M {Table 5(i)0# 
Insulin,however,had no effect on the basal rate of glucose production, 
but inhibited the stimulation by glucagon ©able 5(i).3. Other workers 
have shown similar effects of glucagon (21,22,42,44) and insulin (22).
The regulation of glycogen metabolism by glucagon and insulin has 
been the subject of extensive investigation. Both hormones have been 
shown to affect the levels of cyclic adenosine-3,5-monophosphate (cAMP) 
in liver cells (21-,43,55-59)# In muscle,it has been shown that the 
binding of these hormones to specific membrane sites is accompanied by 
stimulation of a plasma membrane adenylate cyclase system (61—63). The 
cAMP produced activates in turn a protein kinase (64,65),which regulates
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metabolism : glycogen phosphorylase and glycogen synthase (66). In the 
liver,glucagon has been shown to have a glycogenolytic effect (21,22,3 1,43, 
55,59,60,71 -74) and this is mimicked by cAMP and its dibutyryl derivative 
(55) and potentiated by theophylline (55)• It has also been shown that,in 
the perfused liver (60) and isolated hepatocytes (21,43,67),glycogenolysis 
is accompanied by an increase in cAMP levels It has been suggested that, 
in the liver,cAMP produced after glucagon administration is responsible 
for both the activation of glycogen phosphorylase (68) and the inactivation 
of glycogen synthase (68,69). Insulin has been shown to oppose both 
glucagon-stimulated glycogenolysis (31,41-43,71*74,75) and the glucagon- 
elevation of cAMP levels (43,57*56). Insulin also opposes the glucagon 
effects on glycogen synthase (69,70,76,77,79-84) and glycogen phosphorylase
However,the role of cAMP as an intermediary in the actions of glucagon 
and insulin in the liver is still unclear (5 8). The activation of liver 
glycogenolysis and gluconeogenesis by ©(-adrenergic agonists (5 9,85,86),by 
vasopressin (87,88) and by angiotensin (89) appears to be independant of 
a change in cAMP concentration,although such activation appears to occur 
at the same enzyme sites as for glucagon. It has been shown that 
increasing K+ concentration causes inactivation of glycogen phosphorylase 
and activation of glycogen synthase (90) and that the absence of Ca++ 
affects the action of several agonists of both gluconeogenesis (91,92) 
and phosphorylase activation (93)# Van deWerve,Hue and Hers (57) have 
proposed a role of Ca++ in the effects of glucagon and insulin on 
phosphorylase in the liver. Changes have been observed in Ca 
concentration (57, 94-96),Ca++ binding to membranes (97,98) and in 
mitochondrial Ca++ transport (99) following treatment by these hormones ? 
and Ca++ has been shown to activate phosphorylase kinase (57 , 100) .  Thus, 
the relationship between these hormones,cAMP and Ca and thei£ effects 
on glycogen metabolism in the liver still has to be -fully elucidated.
Neither tolbutamide,phenformin nor Wy 23675 bad any effect on basal 
or glucagon-stimulated glycogenolysis (Table 5(i).].
(22,31,57,76,78,82).
Steps of Gluconeogenesis.
Gluconeogenesis was investigated in isolated hepatocytes prepared from 
fasted,normal rats and from fasted,alloxan-diabetic rats. The rates of 
gluconeogenesis from different substrates with these animals (Table 5(ii).3 
gave similar values to those reported by others (20,21,24,46,116,117).
The rate of glucose production declined in the order:- [Table 5(ii).l 
xylitol > dihydroxyacetone > lactate plus pyruvate > alanine
Figure 5(xii) illustrates the points at which these substrates enter 
the gluconeogenic pathway and the proposed rate-limiting steps in the 
pathway (numbered 1,2 and 3 on the figure - for review,see 159). Thus, 
these substrates cai^ 'be used to study the effects of the drugs at the 
various rate-limiting steps of gluconeogenesis.
The Effects of Glucagon and Insulin on Gluconeogenesis.
Glucagon was shown to stimulate gluconeogenesis from lactate plus 
pyruvate and from alanine to a greater extent than it did from 
dihydroxyacetone,while it did not affect gluconeogenesis from xylitol 
(Table 5(ii)0• This indicates that glucagon stimulates gluconeogenesis 
at the rate-limiting steps marked 2 and 3»not at step 1 (Fig. 5(xii)*3«
Insulin had no effect on gluconeogenesis from lactate plus pyruvate, 
but inhibited the submaximal glucagon-stimulation of gluconeogenesis 
from lactate plus pyruvate ©able 5(ii)*}* However,this latter effect 
only became statistically significant at high,non-physiological conce 
concentrations of insulin.
Glucagon stimulation of gluconeogenesis in the liver is well-documentec 
(pee Table 5(vii) and 27,51,60,111,113,124,127,134,135,158,160,161,163,
164,171,175,203,204,207,215,249,25(3,but there is still no agreement 
about its site of action. Different gluconeogenic substrates have been 
used in attempts to isolate the rate-limiting step(s) at which glucagon 
acts (see Table 5(vii).3. As can be seen,different workers have found 
considerable variation in the degree of stimulation of gluconeogenesis
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♦ DIAGRAM TO ILLUSTRATE THE POINTS OF ENTRANCE OF SUBSTRATES INTO THE
GLUCONEOGENIC PATHWAY•
GLUCOSE 
4v
Glucokinase (1) Glueose-6-phosphatase
GLUC OS E-6-PHCSPHAT E 
A
XYLITOL
\
FRUCT OS E-6-PHQS PHATAS E --------
Phosp^ofruct okinas e (2) Fructose bisphosphatase
D-XYLULQSE
D-XYLULQSE-5-P
/
FRUCTOSE BIS PHOSPHATE 
dv
/
/
V
DIHYDROXYACETONE DIHYDROXYACETONE PHOSPHATE 
*
LACTATE
\
4,
PHOS PHOENOLPYRUVATE
Lactate
I^ruvate
dehydrog­
enase
^  PYRUVATE
kinase
PEP
car b oxykinas e
QXALOACETATE
CITRATEKREBS
CYCLE
(NB: Effects of metabolic compart mentation of the reactions in the
pathway have been omitted for clarity)#
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«EFFECT OF GLUCAGON ON GLUCONEOGENE5IS FROM SELECTED SUBSTRATES BY FASTED
RAT LIVERS,
%  Increase in Gluconeogenesis by Glucagon
Alanine Lactate and/or 
Pyruvate
Dihydroxyacetone Fructose Xylitol
k5% (21) 75% (4) 31% (21) 32% (21) 18% (46)
00 s 6o% (21) 21% (25) 20% (23) 15% (91)
37% (71) 227% (23) 58% (46) 21% (25) 22% (112)
42% (91) 145% (25) 100% (49) 59% (46)
50% (128) 222% (29) 50% (74) 20% (91)
19% (217) 134% (35) 37% (112)
50% (253) 40% (44) 
33% (46) 
24% (48) 
57% (71)
50% (116) 
34% (230)
56% (91) 
51% (101) 
78% (112) 
71% (121) 
44% (138) 
89% (141) 
30% (214) 
21% (217)
-
x=kO% x =81% x=48% x=33% X=18%
(NBs Figures in parenthesis Indicate references)
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is general agreement that such a stimulation does occur. Their findings 
have pointed to effects of glucagon on rate-limiting steps 2 and 3 in 
Figure 5(xii).
The effects of glucagon on the enzymes in these rate-limiting steps 
have been extensively investigated. It has been shown that glucagon 
stimulates pyruvate carboxylase (4,51,121,128,253) and phosphoenolpyruvate 
carboxykinase (25,5 1) and inhibits pyruvate kinase (46,48,49,51,114,135- 
138,175-177,183,202-204,215,216,220,221,258,259),while having no effect on 
pyruvate dehydrogenase (217) at step 3* At step 2,glucagon stimulates 
fructose bis phosphatase (51,1*12,114,120,121 ,134,220,227,228,258,259) and 
inhibits phosphofructokinase (51,112,114-116,120,121,134,216,218,219,220,
227,228,230,258,259,272,273)• All of these effects of glucagon would tend 
to restrict glycolysis and to increase gluconeogenesis.
Despite considerable research,the primary site of glucagon action 
remains unknown. It was thought that glucagon acted only on the conversion 
of pyruvate to phosphoenolpyruvate (25,60,158,159),but more recent 
studies (49,91,111,112,124,134,160,171) have shown that gluconeogenesis 
from dihydroxyacetone,fructose,xylitol and glycerol,which enter the 
gluconeogenic pathway above phosphoenolpyruvate,is also stimulated. There 
is the possibility that glucagon stimulates gluconeogenesis from these 
substrates by converting lactate formed by glycolysis to glucose.
However,quinolinate has been used to inhibit phosphoenolpyruvate 
carboxykinase and glucagon still stimulated glucose production from 
dihydroxyacetone (111,112^indicating that the effect did not depend 
on the resynthesis of phosphoenolpyruvate from pyruvate. It has also 
been shown that inhibitors of steps from lactate to dihydroxyacetone 
phosphate have no effect on gluconeogenesis from dihydroxyacetone 
Cie: using p-phenylpyruvate to inhibit pyruvate carboxylase;
*(- cyanocinnamate to inhibit pyruvate transport ; hydrazine and tryptophan 
to inhibit phosphoenolpyruvate carboxykinase ; n-butylmalonate to inhibit 
iaalate transport ; and amino-oxyacetate to inhibit transamination («t9)
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13*f,175) and it has been proposed that this could account for most of the 
increase seen in gluconeogenesis from dihydroxyacetone and the cross-over 
between pyruvate and phosphoenolpyruvate (4-9),indicating pyruvate kinase 
as a site of glucagon action. In support of this concept#is the finding 
that glucagon loses its ability to stimulate gluconeogenesis from 
dihydroxyacetone during periods of prolonged starvation (49),when pyruvate 
kinase activity is already low (172-37*0# It has been reported that S0% 
of phosphoenolpyruvate formed from pyruvate is reconverted to pyruvate 
via pyruvate kinase in the liver from fed rats,whilst only 30% is recycled 
in liver from starved rats (183)• Thus,an effect of glucagon that 
diminished recycling of phosphoenolpyruvate to pyruvate could be very 
important in gluconeogenesis from physiological substrates. Not 
surprisingly,pyruvate kinase has been proposed as a primary site of 
glucagon action (133*175)# However,van Berkel et al (226) have shown that 
glucagon regulation of pyruvate kinase is relatively insensitive to 
changes in the extracellular environment (such as the concentrations of 
lactate,glucose,extracellular Ca++,Na+ or K+),whereas these factors do 
influence the effects of glucagon on gluconeogenesis. They,therefore, 
concluded that glucagon action on pyruvate kinase is not the only site 
of its regulation of gluconeogenesis.
Liver pyruvate kinase can be phosphorylated and simultaneously 
inactivated by a cAMP-dependant protein kinase ( 1 8 1 , 2 2 9 , 2 7 5 )  : glucagon 
has also been shown to phosphorylate and inactivate pyruvate kinase as 
well as to cause a decrease in the apparent flux through pyruvate 
kinase ( 2 1 3 , 2 7 5 , 2 7 6 ) .  It,therefore,appears likely that the glucagon 
effects on pyruvate kinase are mediated by cAMP.
Recent studies with isotopes have suggested that glucagon affects 
gluconeogenesis at the phosphofructokinase/ fructose bis phosphatase cycle 
(134,227) as well as the phosphoenolpyruvate cycles,involving pyruvate 
carboxylase,phosphoenolpyruvate carboxykinase and pyruvate kinase (175* 
205). It has,thus,been suggested that the primary site of glucagon
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bisphoaphatase cycle (49,112,134,228) and that the regulation of the 
phosphoenolpyruvate cycle is a result of changes in fructose bisphosphate 
levels,an allosteric activator of pyruvate kinase (178-180).
It has also been proposed that glucagon could affect gluconeogenesis 
by stimulating the transport of pyruvate into mitochondria (101,108,147, 
287)* Pyruvate enters the mitochondria on a specific carrier (130,133, 
278- 285) , a net flux of pyruvate occurring with a H+ (285) ,  Mitochondria 
isolated from livers of rats pretreated with glucagon exhibited enhanced 
rates of pyruvate metabolism ( 108)  : this effect is also observed with 
hepatocytes incubated with glucagon or dibutyryl cAMP (286). Glucagon 
has been shown to cause enhanced rates of pyruvate transport (133,147,287), 
the effect being mediated by an increase in matrix pH,which in turn 
stimulates pyruvate transport ( 287) •
Glucagon activation of gluconeogen#^tr has also been attributed to its 
lipolytic action (121,129,154-157,161,207,208). Glucagon has been shown 
to elevate matrix acetyl CoA (142-145) ,wbich is the end product of fatty 
acid oxidation and is an obligatory activator of pyruvate carboxylase 
(142-145,162) • Tissue concentration of long-chain acyl CoA has been 
suggested as a factor which could affect the major pathways of glucose 
metabolism (188). The concentration of long chain acyl CoA in the liver 
has been shown to coincide with different states of intermediary 
glucose metabolism,being increased in diabetes and after prolonged 
starvation and decreased after restoration of insulin or glucose 
refeeding (188,192,193). The liver concentration of long chain acyl CoA 
has been shown to be increased by increasing circulating oleic acid 
(129,188) ; the latter depends upon the circulating concentrations of 
glucagon and in w u lln  ( 188) .  It has been shown that several long chain 
acyl CoA derivatives inhibit the translocation of adenine nucleotides 
through the inner mitochondrial membrane (194),thus affecting the 
ATP/ADP ratio,which affects gluconeogenesis (195,196),pyruvate conversion 
to acetyl CoA (196,197) and citric acid cycle activity (198). An
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presence of oleic acid and glucagon (71,161,163). Also,like oleic acid, 
glucagon increases the redox state <51,127,128,145,146) and an increase 
in the matrix ATP/ADP ratio can activate pyruvate carboxylase (145,146). 
However,most workers (51,139-141,158,164,206,274) now agree that glucagon 
does not stimulate gluconeogenesis by merely increasing fatty acid supply. 
It has been shown that glycodiazine,an inhibitor of lipolysis (209),does 
not prevent the glucagon stimulation of gluconeogenesis (141). Also, 
studies on the Effects of glucagon and oleate on the metabolic 
compartmentation in the liver (51),have revealed marked differehces in 
their effects on cellular concentrations of glutamate,2-oxoglutarate and 
phosphoenolpyruvate ; and oleate in the presence of lactate stimulates 
citrate formation,while glucagon does not (51).
It seems unlikely that any one of the above effects of glucagon can 
explain its stimulation of gluconeogenesis ; probably,glucagon achieves 
its effect by a concerted mechanism involving some or all of the above 
actions.
There appears to be a general agreement that cAMP acts as a mediator 
of the glucagon-stimulation of gluconeogenesis (23,25,44,277)# It has been 
shown that glucagon elevates cAMP levels in the hepatocyte (21,33,43,60,
71.101.114.184.273) and stimulates adenyl cyclase (168,185)• Also cAMP 
and its analogs have been shown to mimick many of the effects of glucagon 
(21,23,25,^, 60,101,110,112,114-116,12^, 134, 135,138,158,175,176,203, 204,
216.218.219.229.273).
TtirhI 1 n has been shown to have no effect on basal rates of 
gluconeogenesis (36,37,49,165),but it does inhibit glucagon-stimulated 
gluconeogenesis (31,33,34,38,43,49,58,71,128,165,243) and cAMP-stimulated 
gluconeogenesis (165,167).
Insulin appears to act by opposing the actions of glucagon. For 
example,insulin reverses the glucagon inhibition of pyruvate kinase (138), 
but has negligible effects on pyruvate kinase in the absence of glucagon 
(138). Insulin may also prevent the glucagon-stimulation of pyruvate
redox state (127*^28). Insulin is an antilipolytic agent and can inhibit 
glucagon-stimulation of lipolysis(288-291)• By opposing these actions of 
glucagon,many of which are thought to contribute to the glucagon- 
stimulation of gluconeogenesis,insulin is able to exert a •moderating1 
influence on the glucagon effect#
The actions of glucagon are thought to be mediated by cAMP : insulin 
lowers cAMP levels (33*43,158,166). Insulin has been shown to inhibit 
adenyl cyclase (168,247,248) and to stimulate cAMP-phosphodiesterase (169, 
211,212,245,246,252). Hwever,insulin has been shown to inhibit cAMP- 
stimulated gluconeogenesis (165,167) and it has been suggested that it 
might act by inhibiting cAMP at the level of protein kinase (244).
The Effects of Tolbutamide and Phenformin on Gluconeogenesis#
In this work,tolbutamide had no effect on either basal rates of 
gluconeogenesis or on glucagon-stimulated gluconeogenesis C^able 5 (ii)#l# 
As mentioned in the introduction to this thesis,various effects of 
sulphonylureas have been reported on glucose metabolism in the liver, 
including some inhibition of gluconeogenesis*in diabetic subjects (292). 
However,most of the hepatic effects of the Sulphonylureas are thought to 
require the presence of insulin (293)*
Phenformin was shown to inhibit gluconeogenesis from lactate plus 
pyruvate and from dihydroxyacetone,but had no effect on gluconeogenesis 
from xylitol EPable 5(ii).}. However,these inhibitory effects were only 
seen with high concentrations of phenformin. When gluconeogenesis was 
stimulated by glucagon,the concentration of phenformin required to produce 
an inhibitory effect was considerably lowered (table 5(ii)0«
Inhibition by phenformin of gluconeogenesis in the liver is well- 
documented (32,39*^01 *^04,105,231*234,257*261,262,265$ for further 
references,see also the Introduction to this thesis). Much of this work 
is with concentrations of phenformin that (i). are not attained during 
therapeutic use of the drug and (ii). inhibit mitochondrial respiration.
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of phenformin that can be achieved with therapeutic administration (101, 
105,29^) and which are too low to be associated with inhibition of
mitochondrial respiration# It has also been shown that phenformin can
inhibit gluconeogenesis when it is stimulated by glucagon (101) or by 
diabetes (257*265) at lower concentrations than those necessary to 
inhibit basal rates of gluconeogenesis# These findings are in agreement 
with the results reported in this chapter#
Phenformin is without effect on many of the enzymes of gluconeogenesis 
(unless given at high concentrations) - for example,it does not affect 
fructose bisphosphatase (262),phosphofructokinase (263) or the conversion 
of 3-phosphoglycerate to glyceraldehyde-3-phosphate at concentrations up 
to 8mM (261)# However,at *f7mM phenformin did inhibit 3-pbosphoglycerate 
kinase by 50%'(26k)9 At concentrations up to 0#8mM,it had no effect on 
pyruvate carboxylase (105) and up to 50mM had no effect on enolase (26*f)#
Thus,the effects of phenformin on gluconeogenesis do not appear to be
due to a direct effect on the enzymes of gluconeogenesis#
For reasons discussed in detail in the Introduction to this thesis, 
the effect of phenformin on gluconeogenesis does not seem to be related 
directly to the energy requirements of gluconeogenesis# The membrane- 
biguanide interaction mechanisms proposed by Schafer (267,268) and the 
enhancement of Ca++-uptake into mitochondria by biguanides proposed by 
Davidoff (269) appear to offer the most likely possibilities for the 
subcellular site of biguanide action# The evidence for these theories 
is discussed in the Introduction to this thesis#
The Effect of Wy 23675 on Gluconeogenesis #
Wy 23675 exhibited similar effects to phenformin on gluconeogenesis 
in hepatocytes prepared from normal starved rats in the results reported 
in this chapter (Table 5(ii)#3# Wy 23675 inhibited gluconeogenesis from 
lactate plus pyruvate and from dihydroxyacetone,but had no effects on 
gluconeogenesis from xylitol# When gluconeogenesis was stimulated by
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for inhibitory effects on basal rates of gluconeogenesis*
The possibility for an effect of Wy 23675 on pyruvate dehydrogenase 
was mentioned in Chapters 3 and k of this thesis. This raises the 
question of whether such an activation of pyruvate dehydrogenase in the 
liver cell could affect gluconeogenesis as observed in the results 
reported in this chapter* Theoretically,an activation of pyruvate 
dehydrogenase could divert the supply of lactate and pyruvate from 
gluconeogenesis through pyruvate carboxylase to the formation of acetyl 
CoA# Could this also account for the observed inhibition of gluconeogenesis 
from dihydroxyacetone? This seems unlikely as dihydroxyacetone enters 
the gluconeogenic pathway at the level of the triose phosphates# Also,
Wy 23675 is most potent at inhibiting gluconeogenesis when it is 
stimulated by glucagon and therefore under circumstances where very little 
glycolysis occurs# Thus,Wy 23675 unlikely to be inhibiting gluconeo­
genesis from dihydroxyacetone by preventing any pyruvate formed by 
glycolysis from re-entering the gluconeogenic pathway by diverting it 
through pyruvate dehydrogenase#
There is also other evidence which argues against activation of 
pyruvate dehydrogenase being involved in inhibition of gluconeogenesis. 
Dichloroacetate is a potent activator of pyruvate dehydrogenase (295*296) 
and,under certain circumstances,it can inhibit gluconeogenesis (297*298)# 
However,this inhibition is only seen in the presence of a low-bicarbonate 
medium and not in Krebs-Henseleit ; therefore,these effects on 
gluconeogenesis are probably not important in vivo (299)* Wy 23675 
inhibits gluconeogenesis in a Krebs-bicarbonate medium,so it is unlikely 
to be acting through the same mechanism as dichloroacetate# Also,even 
under circumstances where dichloroacetate did inhibit gluconeogenesis 
it only did so from pyruvate,lactate and alanine,and not from glycerol, 
which enters the gluconeogenic pathway at the level of the triose 
phosphates (300). This is a further difference between the observed 
effects of activation of pyruvate dehydrogenase and those seen in the
One of the arguments presented in the introduction in this thesis 
against the likelihood of phenformin affecting gluconeogenesis by 
inhibiting mitochondrial respiration was that it inhibited the rate of 
glucoheogenesis from lactate plus pyruvate and dihydroxyacetone to the 
same extent and had no effect on gluconeogenesis from xylitol,despite 
the fact that more high energy phosphate is required for glucose synthesis 
from lactate than from dihydroxyacetone and,also,that some high energy 
phosphate is required for glucose synthesis from xylitol* The same 
argument can be applied to the results with Wy 23675,so it is unlikely 
that it is inhibiting gluconeogenesis by affecting the energy supply*
It has been suggested that glucagon stimulates gluconeogenesis by 
inhibiting pyruvate kinase (135*175) and also that changes in pyruvate 
kinase activity are brought about by changes in fructose bisphosphate 
levels through effects of glucagon on the phosphofructokinase/fructose 
bisphosphatase cycle (4-9,112,13^,228). It is possible that Wy 23675 is 
also acting at these levels to inhibit gluconeogenesis by inhibiting 
fructose bisphosphatase and/or stimulating phosphofructokinase,leading 
to an increase in fructose bisphosphate and an activation of pyruvate 
kinase* Such an effect could explain why Wy 23675 affects gluconeogenesis 
from both lactate plus pyruvate and from dihydroxyacetone and not from 
xylitol;and also why lower concentrations of Wy 23675 are required for 
inhibitory effects when gluconeogenesis is stimulated by glucagon*
The Effects of Insulin*Tolbutamide*Phenformin and Wy 23675 on 
Gluconeogenesis in Alloxan-Diabetic Rats*
Alloxan-diabetic rats were shown to have significantly higher 
rates of gluconeogenesis from lactate plus pyruvate,from dihydroxyacetone 
and from xylitol than normal rats [Table 5(iii)»3# This effect has been 
established by many other researchers (158,256,301-305). Glucagon was 
able to further stimulate gluconeogenesis from lactate plus pyruvate 
{Table 5(iv)*],but this effect was only seen with concentrations of
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gluconeogenesis in the normal,fasted rats and,even then,the degree of 
stimulation was relatively small : this is a reflection of the near- j
maximal rates of gluconeogenesis that were occurring in these diabetic j
rats. t
The lack of insulin has been shown to result in an elevated cAMP level j
6
in the liver (43,184-,251) and an elevated rate of gluconeogenesis ; insulin]
I
therapy reverses these effects (256,305,306). In the results reported in j
this chapter,insulin had no acute effect on gluconeogenesis from lactate I
and pyruvate in hepatooytes prepared from alloxan-diabetic rats ©able 
5 (iv).] ,but did inhibit gluconeogenesis when it was administered in vivo 
for several days prior to the preparation of the hepatocytes [Table 5 (v).D.
Tolbutamide had no effect on gluconeogenesis in hepatocytes prepared 
from alloxan-diabetic rats either when it was administered in vitro or 
in vivo [Tables 5(iv) and 5(v).3. Phenformin inhibited gluconeogenesis 
in hepatocytes from alloxan-diabetic rats in concentrations 100-fold 
lower than those required Cor inhibition of basal rates in hepatocytes 
from normal rats {Table 5(iv).J. Other researchers have shown similar 
effects (257,265)#
Wy 23675 had similar effects to phenformin ©able 5(iv) .1,requiring 
a lower concentration of the drug to inhibit gluconeogenesis in 
hepatocytes prepared from alloxan-diabetic rats than in those prepared 
from normal rats. These effects correspond to those seen in normal 
hepatocytes when gluconeogenesis is stimulated by glucagon.
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This chapter contains measurements of hepatic metabolite levels in 
untreatedfalloxan-diabetic rats compared to alloxan-diabetic rats after 
seven days administration of phenformin or Uy 23675 in vivo. Following 
alloxan-treafcment,the body weights of the rats in the control group fell, 
while those in the phenformin-treated group remained cons.t&nt and those 
in the Wy 23675-treated group increased* Phenformin treatment resulted 
in a fall in blood glucose levels compared with the controls and a 
doubling of the blood lactate/pyruvate ratio#while Wy 23675 treatment 
resulted in a greater fall in blood glucose than phenformin without any
change in the lactate/pyruvate ratio. .......
The pattern of hepatic metabolite levels following phenformin 
treatment showed a negative cross-over between 3-phosphoglycerate and 
dihydroxyacetone phosphate. Measurement of appropriate metabolite ratios 
showed a more reduced state in the cytosol and mitochondria following 
phenformin treatment and these redox changes are discussed,
Wy 23675 treatment showed a negative cross-over in hepatic metabolite 
levels between malate and phosphoenolpyruvate,indicating a possible 
effect of this drug on the enzyme phosphoenolpyruvate carboxykinase 
(PEPCK). However,there was no increase in lactate levels,and this is 
discussed in comparison with a known inhibitor of PEPCK, 
3-mercaptopicolinate,which causes marked increases in lactate levels,
A further experiment described in this chapter failed to show any 
direct effect of Wy 23675 in vitro on PEPCK,while 3-mercaptopicolinate 
inhibited by 87% at 1mM, The possibility that differences in the 
experimental conditions,which were employed to measure PEPCK and those 
used in the experiments to measure hepatic metabolite levels,could 
explain the lack of any effect of Wy 23675 on the enzyme is discussed 
together with possible alternative modes of action of Wy 23675 on 
glueoneogenesis.
In chapter 5fphenformin and Wy 23675 were both shown to inhibit 
gluconeogenesis from lactate plus pyruvate and from dihydroxyacetone, 
but to have no effects on gluconeogenesis from xylitol. These results 
indicated effects of these compounds (either direct or indirect) on the 
rate-limiting steps in gluconeogenesis involving the enzymes pyruvate 
carboxylase,phosphoenolpyruvate carboxykinase and pyruvate kinase 
(controlling the conversion of pyruvate to phosphoenolpyruvate) and by 
fructose bisphosphate and phosphofructokinase (controlling the conversion 
of fructose bisphosphate to fructose-6-phosphate).
In this chapter,the effects of phenformin and Wy 23675 have been 
investigated on selected metabolite levels in the livers of alloxan- 
diabfetic rats,following seven days treatment with the drugs jLn vivo. This 
approach has been used extensively to determine the sites of action of 
many hormones and drugs on glucose metabolism in the liver (1—24).
The results of this experiment indicated a possible effect of Wy 23675 
on the enzyme phosphoenolpyruvate carboxykinase (PEPCK). This possibility 
has been further investigated by measuring the effect of Wy 23675 jua 
vitro on rat liver cytosolic PEPCK activity.
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Materials
The sources of all drugs used were given in earlier chapters. All 
enzymes,chemicals and reagents were obtained from Sigma,Kingston-upon- 
Thames,Surrey, with the exception of hydrazine hydrate,which was obtained 
from Koch-Light,Colnbrook,Buckinghamshire.
1. Methods For Measurements of Hepatic Metabolite Levels.
Treatment of Animals.
The rats used were male Charles River CD strain (l80-220gms) , 
maintained as described in Chapter 1. They were made alloxan-diabetic by 
treatment with' alloxan monohydrate (0*mmol/kg i.p.),following a 24-hr 
fast. Blood samples were collected from the tail vein 48 hours after 
alloxan-treatment and rats with fed blood glucose levels in excess of 
20 mmol/l. were randomized into 3 groups of 6 rats for the purposes of 
this study. Each group was then orally dosed twice daily (at 0800 and 
2000 hrs) with either CMC (Group 1),phenformin (0.2mmol/kg) (Group 2), or 
Wy 23675 (0.2mmol/kg) (Group 3) for 7 days. Rats were bled immediately 
prior to drug treatment and after 4 days of treatment ; the blood samples 
were analyzed for glucose (see Chapter 1),lactate and pyruvate (Sigma Kit 
No*s 826-UV and 726-UV,respectively).
On day 8,the rats were orally dosed in the morning and killed 1 hr. 
afterwards by cervical dislocation. The livers were removed and freeze- 
clamped within 15 seconds,by pressing them between plates of aluminium 
tongs,which had been previously placed in liquid nitrogen. The frozen 
livers were then individually powdered in a Teflon percussion mortar 
cooled in dry ice.
Preparation of Acid Extracts.
An acid extract was made from each powdered liver. Aliquots of the 
powdered livers were placed in pre-weighed centrifuge tubes stored in 
powdered dry ice. The tubes were weighed after addition of the powered 
liver to determine the weight of the aliquot added. 3»5—volumes of 
8# (v/v) HClO/j. made up in k0% (v/v) ethanol was added to the powdere^ ■
using a Teflon pestle. The homogenate was decanted into glass centrifuge 
tubes and was centrifuged at 25f000g. for 10 minutes at -10#C. The 
supernatant was decanted into graduated centrifuge tubes and stored in 
dry ice,while any precipitate remaining in the homogenizing tubes was 
transferred to the pellet in the appropriate centrifuge tube by washing 
with 2.5-volumes of 6% (v/v) HCIO^. This was then mixed to a smooth paste 
with a teflon rod and centrifuged at 25,000g« for 10 minutes at -10#C. The 
two supernatants thus obtained from each liver homogenate were combined 
and the volume recorded* The pH was then adjusted to 5.5 - 6.0 by slow 
addition of 3M containing 0.5M triethanolamine base,mixing
continuously,and the total volume recorded. After recentrifugation to 
remove the precipitated KC10^,the final supernatants were stored at -20*C* 
The number of grams of powdered liver was calculated per 100 mis of acid 
extract and recorded for each liver (the average was 171 gms/1000 mis). 
Measurement of Metabolites.
The following metabolites were measured for each liver extract:- 
Glucose (Glc) ; Glucose-6-phosphate (G6P) ; Fructose-6-phosphate (F6P) ; 
Fructose bisphosphate (FBP) ? Dihydroxyacetone-phosphate (DHAP) ; 
Glyceraldehyde-3-phospbate (GLAP) ; 3-Fhosphoglycerate (3FG) » 
2-Phosphoglycerate (2PG) ; Phosphoenolpyruvate (PEP) ; Pyruvate (Ppr) ; 
Lactate (Lac) ? Oxaloacetate (QAA) ; Citrate (Git) ; Isocitrate (Isocit) ;
2-Qxoglutarate (20G) ; Glutamate (Glut) ; Malate (Mai) ; Acetyl CoA (AcCoA)
3-Hydroxybutyrate (30H-B) ; Acetoacetate (AcAc) ? Adenosine triphosphate 
(ATP) ; Adenosine diphosphate (ADP) ; Adenosine monophosphate (AMP).
All the metabolites were measured by the methods published by Bergmeyer 
(38),except for lactate and pyruvate (Sigma kits 826-TJV and 726-UV) and 
glucose (Autoanalyser - see Chapter 1). The metabolites were measured in 
Sarstedt plastic disposable cuvettes,using a Cecil CE 292 ultraviolet 
spectrophotometer. The concentrations were determined by measuring the 
change in optical density of reduced pyridine nucleotides at 3 ^  nM in the 
enzyme tests. The results were expressed in jimoles/gm. of wet liver weight.
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2. Methods For Measurement of Phosphoenolpyruvate Carboxykinase Activity#
The methods described here have been developed at Glaxo Research (Ware) 
Ltd.,Priory Street,Ware,Hertfordshire from previously published assays,
1, Preparation of the Enzyme (39),
A crude PEPCK preparation was produced as follows (the procedure was 
carried out at *f#c) •-
^8-hour fasted,normal female rats (weight range l80-220gms) were killed 
by cervical dislocation and their livers removed and rinsed in ice-cold 
saline (0.9^NaCl). Following mincing,a 1:3 (w/v) homogenate was prepared 
in 0,25M sucrose containing 10mM triethanolamine chloride (pH 8,1),using 
an •Ultraturex' homogeniser.
The homogenate was then aliquoted into Eppendorf centrifuge tubes and 
centrifuged in an Eppendorf 3200 bench centrifuge at approximately 1^000g 
for 10 minutes. The resultant supernatant comprised the cytosolic fraction 
of the homogenate. This was decanted and stored on iee until used (for up 
to k hours),
2, Pre-incubation of Cytosolic Preparation with Test Compounds.
The compounds under investigation were pre-incubated with the cytosol 
preparation in the presence of FeC^ for 10 minutes at 0#C. The final 
incubation volume was 1 ml^made up as follows:—
0 .2 mis cytosol preparation
0.3 mis 1*nnM-HEPES/NaOH,pH8.Vcontaining 2.7nM dithiothreitol (giving 
final concentrations of A-.2mM and 0,8mM,respectively).
0#1 mis 1mM FeC^ (giving final concentration of 0,1mM).
0 ,4  mis 2,5mM test compound or control (giving 1mM final eoncentratior 
At the end of the 10 minute period,0,2 mis of this pre-incubation mixture 
was transferred into tubes containing the other constituents for the 
PEPCK assay (see PEPCK assay,Part A).
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PEPCK activity was monitored in the physiological direction of 
phosphoenolpyruvate (PEP) synthesis from oxaloacetate (OAA). The assay 
comprised two parts : PEP generated by the activity of PEPCK was removed 
from a deproteinized assay mixture and measured using a linked, 
speetrophotometrie assay. This involved the conversion of PEP to pyruvate 
and lactate with a coneommitant reduction in optical density due to NADH 
oxidation:-
CO
OAA — —  2----- >PEP REACTION STOPPED.
S'. Mg++ \
ITP « ++ I DP
(GTP) (GDP)
PEP -PK------  ^Pyruvate--------------- ^-Lactate
ADP s ATP NADH NAD
(ITP = Inosine-5*-triphosphate ; GTP = Guanosine-5* -triphosphate)
(PK = Pyruvate kinase ; LDH = Lactate dehydrogenase)
Since 1 mole of PEP causes the oxidation of 1 mole of NADH,the assay 
effectively measured PEP concentration.
(i). PEPCK Assay,Part A: PEP Generation.
The final 1 ml reaction mixture,pH 8.1,was made up as follows:-
0 .2 mis pre-incubation mixture
0.1 mis 80mM OAA (adjusted to pH 7*0)(Final concentration: 8mM OAA)
0.7 mis 1*f3mM Tris-HGl,pH 8.1,containing 23*7mM MgCl^ and 8.6mM NA4ITP 
(Final concentrations: 100mM Tris-HCl,l8mM MgCl2 ,6mM Na^ITP)
After a 5 minute temperature equilibration period at 37*C,the reaction was
initiated by the addition of the 0 .2 mis of pre-incubation mixture. The
reaction was terminated by the addition of 0.1 mis of a 50nig KBHj^ /l ml
1mM NaOH after 10 minutes at 37*C. (The KBH^NaOH solution reduced
unreacted OAA to malate,thereby preventing spontaneous decarboxylation to
pyruvate). After 5 minutes on ice,excess KBH^ was removed by acidification
with 0.2 mis 20% (w/v) HCIO^ followed by vortex mixing. Following
neutralization with 0 .16 mis 0.3M triethanolamine—HCl,pH 7*^/2M KOH (Jinal
pH = 13-1*0, the samples were centrifuged in an Eppendorf 3200 for 2 mins.
determinations.
(ii). PEPCK Assay,Part B: PEP Determination.(41)
This assay was run at room temperature at pH 7.6. The final 1 ml 
reaction volume was made up as follows
0.1 mis deproteinized sampie from Part A
0.1 mis (40units/ml) pyruvate kinase (Final concentration: 4units/mj
0.8 mis 87.3mM Tris-ClfpH 7.6,containing 5.25mM MgSOK,41.25mM KC1, 
0,15mM NADH,2.13mM Na-ADP and 6 .#units LDH 
(Final concentrations: 70mM Tris-Cl,4.2mM MgSOi^ 3^3xnM KC1,
0.12mM NADH,1.7mM Na2ADP,5.5 units/ml LDH)
The initial optical density was measured at 340 nM before the pyruvate
kinase was added to the reaction mixture (this permitted residual pyruvate
to be reduced to lactate and thus prevented it from interfering with the
estimation of PEP concentration). The pyruvate kinase was then added to the
assay mixture and 23 minutes later a second optical density was measured*
the optical density change was then calculated.
4. Calculations.
PEPCK activity is expressed as punoles PEP produced per minute per ml of
cytosol and is calculated from the equation:-
&0D x V1 x 36.3 
( x V2 x t
where AOD = the change in optical density at 340nM
V1 = Volume of assay Part B mixture (ie:1 ml)
36.5 = Multiplication factor to allow for dilutions.
£ = millimolar extinction coefficient of NADH (ie:6.22)
V2 = Volume of assay Part A taken for PEP determination(O.lml) 
t = Reaction time of Part A of the assay (ie: 10 minutes)
Therefore jimoles PEP produced/min/ml cytosol = &0D x 5.868
5. Experimental Controls.
Blanks were run containing 0.2 mis sucrose buffer instead of 0.2 mis 
cytosol. Controls were run containing 0.4 mis water and a positive control 
was run with 0.4 mis 3—mercaptopicolinate to give 1 mM final concentratiot 
C-mercaptopicolinate is a known inhibitor of PEPCK ?13,14,22,42)J.
1. Measurement of Hepatic Metabolite Levels#
a). Rat Body Weights#Blood Glucose.Lactate and ftyruvate Levels#
The body weights of the rats in the control group fell by a mean of 
9*7# by the end of seven days dosing with CMC,while those for the 
phenformin-treated group had virtually no change and those for the 
Wy 23675-treated group increased by a mean of 8.6$ Cable 6 (i)J.
It was shown that after four days drug treatment the blood glucose
levels of the control group rose by a mean of 37.6^,while that of the
phenformin-treated group fell by a mean of 21#5% and that of the
Wy 23675-treated group fell by a. mean of 33.7/S Cable 6(ii)3. During the 
same period,it was shown that the lactate and pyruvate levels remained 
unaltered in both the control and the Wy 23673-treated groups,while the 
phenformin-treated group showed a marked elevation in lactate levels (the 
mean rising by 220$),but no change in pyruvate levels# Thus,the phenformin 
-treated group showed an increase in the lactate/pyruvate ratio Cable 
6(iii)3 .
b)» Liver Metabolite Levels#
The liver metabolite levels are summarized in Table 6(iv) and Figure 
6 (i). In the phenformin-treated group,there were significant reductions 
in the levels of glucose,fructose bisphosphate,dihydroxyacetone phosphate, 
citrate,acetoacetate and adenosine triphosphate# There were also 
significant increases in the levels of 3-phosphoglycerate,phosphoenol­
pyruvate, lactate,glutamate,acetyl CoA,3-hydroxybutyrate and adenosine 
diphosphate. The ratios of lactate/pyruvate,glutamate/2-oxoglutarate, 
and 3-hydroxybutyrate/acetoacetate were markedly elevated,while the
ratio of ATP/ADP was reduced.
In the Wy 23675-treated group,there were significant reductions in
the levels of glueose,glueose-6-phosphate,fructose-6-phosphate,fructose
bisphosphate,dihydroxyacetone phosphate and phosphoenolpyruvate. There
were also significant increases in the levels of citrate and malate.
There were no changes in the ratios of lactate/pyruvate,glutamate/
2. Measurement of Phosphoenolpyruvate Carboxykinase Activity#
3-mercaptopicolinate,a known inhibitor of phosphoenolpyruvate 
carboxykinase (13,14,22,42),inhibited the enzyme by 87/6 at 1mM 
coneentration,while Wy 23673 had no significant effect at either 0#1mM 
or 1mM# The details of these results are shown in Table 6(v)#
♦Chapter 6,
♦THE EFFECTS OF PHENFORMIN AND WY 25675 ON HEPATIC METABOLITE LEVELS,
Figure No, Title
6(i) Cross-over Plots of Metabolite Levels in Liver After Seven
Days Drug Treatment*
Table No, Title
6(i) Rat Body Weights and Weight of Powdered Liver in the Extract,
6(ii) Blood Glucose Levels Before and After Four Days of Drug
Treatment,
6(iii) Blood Lactate and i^ruvate Levels Before and After Four Days
of Drug Treatment,
6(iv) Summary of Metabolite Levels in Liver After Seven Days Drug
Treatment,
6(v) The Effect of Wy 23675 on the Eazyme Phosphoenolpyruvate
Carboxykinase,
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.RAT BODY WEIGHTS AND WEIGHT OF POWDERED LIVER IN ACID EXTRACT.
For practical details,see text.
Statistical significance was determined by Student*s t-Test:- 
* p<0 .0 5 ? ** p<0.01 ? *** p<0.001
Group Rat Body Weights (gms) Weight of Poxtfdered Liver 
in Acid Extract
(gms/1 0 0 0 mis)
Treatment Prior to 
Drug
Treatment
At
Sacrifice
Difference
1. 217 164 -53 176.5
CMC 203 176 -27 173.5
Control 210 153 -57 166.7 - -
217 229 +12 171.4
195 196 + 1 173.3
210 212 + 2 189.9
Mean 208.7 188.3 -20.3
± SEM * 3.3 ±11.9 ±1 2 .2
2. 199 21 4 +15 164.5
Phenformin 20 5 236 +31 164.2
(0*2imnol/kg 20 6 200 - 6 170.7
twice 186 176 -1 0 169.5
daily)• 211 204 - 7 170.9
208 194 -14 169.9
Mean 202.5 204.0 + 1.5
± SEM ± 3.7 i 8 .2 - 7.2
3. 184 224 +40 169.5
Wy 23673 219 231 +12 151 .8
>('0 e2mmol/kg 199 184 -15 171.9
twice 200 207 + 7 173.8
daily)• 191 232 +41 170.4
211 229 +18 172.7
Mean 
± SEM
200.7 
- 5.2
217 .8  
i 7.7-
+17.2* 
i 8.7
.Table 6(ii).
.BLOOD GLUCOSE LEVELS BEFORE AND AFTER FOUR DAYS OF DRUG TREATMENT.
For practical details,see text.
Statistical significance was determined by Student's t-Tests-
* p<0.05 ; ** p<0.01 ; *** p<0.001
Group
Treatment
Blood Glucose Levels (mmol/l.)
1.
Prior to Drug 
Treatment
2.
After 4- Days Drug 
Treatment
Difference 
(2 - 1)
1. 29.04- 3 9 .60 +1 0 .56
CMC 37.13 61 .38 +2A.25
Control 24-. 92 42 .08 +1 7 .16
28 .3 8 2 4 .92 - 3.4-6
23.74- 2 4 .09 - 1 .6 3
29.04- 47 .69 +18 .63
Mean 29.04- 39.96 +10.92
i SEM ±1.77 ±5.78 ± 4-.62
2 . 31.19 1 3 .8 0 -17.39
Phenformin 38.4-3 2 2 .9 4 -15.51
;0«2mmol/kg 30 .86 2 8 .5 5 - 2.31
twice 23.25 1 7 .16 - 8 .0 9
daily)• 29.70 33.73 + 4-.03
32.51 31.35 - 1 .16
Mean 31.33 2A.59* ~ .6,74-*
± SEM ■ -1.75 -3 .2 6 ±3.46
3. 33.33 15.31 -18 .02
Wy 23673 2 8 .38 23 .08 - 3.30
;0 «2imol/kg‘ f 2 3 .58 21 .12 - 4-. 4-6
twice 3^.32 27.72 - 6 ,6 0
daily). 35.97 15.51 -20.4-6
4-1.75 27.39 -14-.36
Mean 33.22 2 2.0Z** -11.20**
± SEM ±2.33 ±2.30 ±3.01
♦ -D-bUU-U J_tH.UTAT.fc AINU YYK U V AT iU LtiM&L& Ui^'UKF AINU AJtfTEH if’OUK DAYS OF DKUG
treatmentT '
For practical details,see text.
Statistical significance was determined by Student*s t-Test:-
* p<0 .05 ; ** p<0.01 ; *** p<0.001
Group
Treatment
Blood 5actate Levels Blood Fyruvate Levels La c t a t e/Pvr u vat e
1.
Before 
Drugs,
2.
After 
4 Days 
Drugs,
Diff.
(2-1)
1.
Before 
Drugs.
2.
After 
4 Days 
Drugs,
Diff.
(2-1)
1 .
Before 
Drugs,
2.
After 
4 Days 
Drugs.
Diff,
(2-1)
1.
CMC
Control
1.02 
1 .43 
0 .8 7  
0.96 
1.02 
1.17
1.17
1.66 
1.09 
0.88 
1.14 
1.21
+0.15 
+0.23 
+0.22 
-0 .0 8  
+0.12 
+0 .04
0.11
0.19
0 .0 8
0.10
0.10
0.09
0.12
0.14
0.09
0.09
0.12
0.13
+0.01
-0.05
+0.01
-0.01
+0,02
+0.04
9.27
7.53
10.88
9 .6 0
10.20
13 .0 0
9.75
11.86
12.11
9.78
9.50
9.31
+0 ,48 
+4.33 
+1.23 
+0 .1 8  
-0 .7 0  
-3.69
Mean 
± SEM
1 .08
±0 .0 8
1.19
±0.11
+0.11
±0.05
0.11
±0.02
0.12
±0,01
+0.01
±0.01
1 0 .0 8
±0.74
10.39
±0.51
+0 .3 1
±1 .0 7
2.
Phenformin
(0,2mmol/kg
twice
daily).
1.12
1 .2 8
0.89
0.73
0.84
1 .0 6
5 .1 3
4 .0 6
2 .2 3
3.57
2.03
1.96
+4,01
+2.78
+1.34
+2.84
+1.-19
+0,90
0.13
0.11
0 .0 8
0 .0 8
0.07
0 .1 2
0.14
0.17
0.11
0.14
0 .1 2
0.09
+0.01
+0 .0 6
+0 .0 3
+0 ,0 6
+0 .0 3
-0 .0 3
8 .6 9  
1 1.64 
11 .13  
9 .1 3  
12 .0 0  
8 .8 3
36.64 
2 3 .8 8  
20.27 
25.50 
16-. 92; 
2 1 v 7 8 ;
*•2 7.95 
1*12.24 
h 9.14
+16 .37
h 4,92 
+12.95
Mean
± SEM
.0.99
±0 .0 8
3.1*2-
-0.53
+2 .1 8
±0 .5 0
4.0 .1 0
-0.01
+0.13
-0.01
^0.04
-0 .01
10.24
±0 .6 5
« » * * * 24.17
i a . 7 7
*■13.93
* 3 .2 2
3 .
Wy 23675 
(0,2ramol/kg 
twice 
daily)v
0.94
0 .7 6
1.14
1.24
1.19
1.36
0 .9 6  
1 .0 2  
1.09
1.$4 
1.14 
1.27
+0 .0 2
+0 .2 6
-0.05
+0 .1 0
-0.05
-0.09
0 .1 3
0 .0 7
0.14
0.11
0 .1 2
0.14
0 .1 0
0.11
0.09
0.14
0.13
0.11
+0 .0 3
+0.04
-0 .0 5
+0 .0 3
+0.01
-0 ,0 3
7.23
10 .8 6
8.14
11.27
9.92
9.71
9 .6 0
9 .2 7
12.11
9.57
8.77
11.55
+2.37 
-1.59 
+3.97. 
-1.79 
-1.15 
+1.84
Mean
ism
1.11
i0 .09
1.14
io.06
+0.03
±0 ,05.
0 .12
io.01
0 ,11  
to. 01
-0.01
io.02
9.52
±0.64
10.15
io.55
+0 .6 2
io.99
• i
1
i
f
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*SflMMARY OF METABOLITE LEVELS IN LIVER AFTER SEVEN DAYS DRUG ’TREATMENT.
For practical detailstsee text*
Statistical significance was determined by Student,s t-Test
♦ p<0 .0 5 ; ** p<0.01 ; **♦ p<0.001
Metabolite levels are expressed in jimoles/gm« wet liver weight - Mean ± SEM 
(n=6 for each group)*
Abbreviations are as listed in the methods section under Measurement of 
Metabolites.
Metabolite
Measured
Control
Values
Phenformin.
Values
% of 
Control
VJy 23675 
Values
% of - 
Control
Glc. 30*09 
... -±2.*49.
21.05
±1.23
70** 16.25 
_-0*59
Cj/j.# * *
g 6 p 0 ,0 6 8
±0 .0 0 6
0.065
±0 .006
96 0.048
±0.005
71*
F6P 0.023
±0.004
0.030  
±0 .006 .
130 0.013
±0 .0 0 2
57***
FBP 0 .020
±0.003
0 .008
±0.002
40** 0.007
±0.003
35*
GLAP ---—  To<d Low To Measure ----
'
DHAP 0 .062
±0 .002
0.037 
±0.004. .
60*** 0.035
±0.007
57**
3PG 0.313
±0.013
0.417
±0.031
132* 0.255
±0.033
81
2PG 0.023
±0 .002
0.033
10 .006
144 0.015
±0.003
£>5
PEP 0 .262
±0.011
0.787
±0.042:
300*** 0.130
±0.013
50***
Lac 1 .460 
±0.174
2.533
±0.254
174** 1 .702
±0.174
117
fyr 0.163
±0 .026
0.153
±0.031
93 0 .158
±0,015
96
OAA 0.023
±0.003
0.018
±0.001
78 0.035
±0 .0 0 6
152 -
Cit 0.248
±0.016
0 .1 9 0
± 0 . 0 0 3
77** 0 .3 1 2
±0 .022
126*
Lsocit 0 .213
±0.049
0 .132
±0.040
62 0 .1 8 8
±0.014
88
20G 0.037
±0.008
0 .022
±0.005
60 0.042
±0 .0 0 6
114
Glut 0.990
±0.017
1 .220
±0.046
123*** 0.958
±0.047
97
Mai 0 .282
±0.046
0.412
±0.088 ’
146 0.428
±0 .0 3 4
152*
AcCoA, 0 .110
±0.011
0 .168
±0 .018
153* 0 .0 9 0
±0.011
82
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,Table 6(iv) - cont.
Metabolite
Measured
[Control
[Values
1'henformin
Values
fj of 
Control
'-T 236^5 
Values
3 of 
Control
30H-B 5.258
±0.322
6.758
±0 .238
129** 4.917
±0.313
94
Ac.Ac. 3.157
±0.139
2.767
±0.081
86* 2.963
±0.178
95
ATP 1.335
±0.^43
1.133
±0.052
85* 1.265
±0 .120
95
ADP 1.115
±0 .029
1.230
±0.052
110* 1.053
±0 .050
94
AMP 0.273
±0.015
0.343
±0 .010
126 0.255
±0.025
93
Total
Adenine
Nucleotides
2.723
±0 .0 8 8
2.707
±0 .068
99 2.573
±0.113
95
I/P 9.478 
±1.021
18.415
±1.984
194** 10.810
±0.502
114
Glut/2-OG 32.31
±5.51
72.22
±16.33
224* 2 6 ,80
±5.°2
83
30H-B/AcAg» 1.^75
±0.054
2.443
±0.056
146*** 1 .6 58 
±r'.0'^ 3
99
ATP/ANP 1.197
±0.024
0.923
±0.037
77*** 1 .200
±0.041
101
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.CROSS-OVER PLOTS OF MESTABOLITE LEVEIS IN LIVER AFTER SEVEN DAYS DRUG
IQ
©
3
d
>
HO
u+>
o
o
o•rf•p©.o
a
<Mo
300
PHENFORMIN
200
100
Lac: Jfyr QAAj ; Mai: PEP* 2BG JPO DHA.P FBP F&P G6P . Gltr 
For practical details,see text.
Wy 25675
200
* **
Lac Pyr OAA Mai PEP 2PG 3HJ DHAP FBP F6P G6P Glc
Statistical significance was determined by Student*s t—Test:-
* P <0 .05  ; * *  p < 0 .0 1  • * ♦ *  p < 0 .001
For practical details,see text.
Statistical significance was determined by Student*s t-Test:-
* P<0.05 ; •• >'<0.01 ; *** p<0.001
Treatment Initial
O.D.
Final
O.D.
O.D.
Change
1
Minus
Blank Change
PEPCK
Activity
Mean
*SEM
% of 
Control
Blank
(no cytosol, 
no drug)
0.83
O .87
0.81
0.81
0,04
0 .06
Mean
0.05 - - -
Controls 0.89 0.33 0.51 0.46 2.70
(no drug) 0.89 0.39 0 .5 0 0.45 2.64
0.90 0.39 0.51 0.46 2.70
O .87 0.37 0 .5 0 0.45 2.64 2.70
0.87 0.35 0.32 0.47 2.76 *0.02
O .87 0 .36 0.51 0.46 2.70
0.88 0.35 0.53 0.48 2.82
0.95 0.43 0.50 0.45 2.64
3-mercapto- 0.91 0.81 0.10 O .05 0.29 * * *
picolinate 0.87 0 .78 0.09 0.04 0.23 0
(1mM) 0.89 0 .78 0.11 0.06 0.35 *0 04
1 J fQ
(Positive 0.89 0 .76 0.13 0 .08 0.47
Control) 0.91 0.79 0.12 0 .07 0.41
Wy 23675 0.83 0.31 0 .52 0.47 2.76
2 .76(1mM) 0.95 0.42 0.51 .0,46 2.70 102#
0.88 0.35 0.53 0.48 2.82 *0.03
0.90 0 .38 0 .52 0.47 2.76
Wy 23675 
(0.1mM)
0.88
0.90
0.91
0.91
0.35
0.37
0.39
0.39
0 .52
0.53
0 .52
0.52
0.4?
0.48
0.47
0.47
2.76 
2.82
2 .76
2 .76
2 .78
*0.02
103#
(PEPCK activity is expressed in jimoles PEP produced/min./ml of cytosol)
Phenformin and Wy 23675 were shown to inhibit gluconeogenesis in the 
results reported in Chapter 5# In this chapter,the effects of these drugs 
have been measured on liver metabolite levels in alloxan-diabetic rats.
Alloxan-treatment resulted in a fall in body weight and a rise in 
blood glucose levelsfboth phenformin and Wy 23675-treatments lowered 
blood glucose levels in the diabetic rats* In the Wy 23675-treated group 
there was an increase in average body weight. The fall in blood glucose 
in the phenf ormin-treated group was accompanied by a rise in blood 
lactate levelsfsuggesting a possible inhibition of gluconeogenesis. 
Alternatively,the change in blood lactate concentration may reflect a 
balance between hepatic utilization and production in peripheral tissues, 
both of which may be affected by phenformin. Neither blood ketone bodies 
nor fatty acids were measured,so it is not possible to determine whether 
or not phenformin-treatment resulted in a diversion of lactate into the 
formation of these metabolites. However,total liver ketone bodies were 
increased only marginally (+13^) in phenf ormin-treated rats* On the other 
hand,elevations in ketone bodies have been reported to be associated with 
phenformin administration (24-29)# Recently,Alberti et al (24) have 
shown that phenformin caused marked elevations in blood ketone bodies 
in normal and streptozotocin-diabetic rats and also that phenformin 
caused a dose-related inhibition of gluconeogenesis and stimulation of 
ketogenesis from lactate in isolated perfused rat livers ; they suggested 
that there was an intrahepatic diversion of lactate from gluconeogenesis 
to ketogenesis. Such an effect could explain the rather moderate rise 
in lactate levels compared with the large fall in blood glucose levels
shown in this work.
Wy 23675 caused a greater fall in blood glucose levels than phenformin, 
but had no apnarent effect on blood lactate levels. This suggests that 
its effect in stimulating peripheral glucose utilization might be of 
more importance to its hypoglycaemic action than its effect of 
inhibiting gluconeogenesis. However,as with phenformin,no measurements
part of the hypoglycaemic action of Wy 23675 was due to inhibition of 
gluconeogenesis and that the lactate,that might have accumulated,was 
diverted to ketone body or fatty acid formation# However,total ketone 
body concentration in the liver was not affected by Wy 23675#
The general pattern of hepatic metabolites following seven days 
treatment of alloxan-diabetic rats with phenformin was similar to that 
reported in perfused liver by others (8,24,30).
The ATP/ADP ratio and the levels of ATP were reduced compared with 
the control group# This finding of a decrease in hepatic ATP levels with 
biguanides has been reported by many workers (31-34),who have implicated 
this effect in the inhibition of gluconeogenesis by these compounds. 
However, under certain circumstances,a reduction in the ATP/ADP ratio has 
been shown without an accompanying decrease in gluconeogenesis (30) and 
gluconeogenesis has been inhibited by biguanides without affecting the 
ATP/ADP ratio (30). Alberti et al (24) have also shown significant changes 
in gluconeogenic metabolite levels in livers exposed to phenformin 
without significant changes in the ATP/ADP ratio#
The results reported in this chapter also show significant increases 
in the ratios of lactate/pyruvate and 3-hydroxybutyrate/acetoacetate, 
which indicate a more reduced state in the cytoplasm and the mitochondria 
with phenformin-treatment#
Phenformin caused a negative cross-over in the levfels of the 
gluconeogenic metabolites between 3-pkosphoglycerate and dihydroxyacetone 
phosphate* Marked elevations in phosphoenolpyruvate and 3-phosphoglycerate 
levels and reductions in dihydroxyacetone phosphate have been similarly 
reported by others (8,24,30)# These same workers have also shown that 
phenformin-treatment causes a reduction in the levels of citrate and
2-oxoglutarate : citrate was significantly lowered in the results 
reported in this chapter though decreases in 2—oxoglutarate levels did 
not reach statistical significance# Acetyl CoA levels were shown to be 
elevated,a finding that other workers have also reported (29*30)#
has led to the suggestion (29,35) of special inhibitory effects of 
phenformin on phosphoglycerate kinase or on glyceraldehyde-3-phosphate 
dehydrogenase# However,there is no evidence to suggests specific 
inhibition of an enzyme and Toews et al (29) have shown that the cross­
over at this point is accompanied by too small a decrease in ATP 
concentration to account for inhibition of phosphoglycerate kinase#
A cross-over at this point can also indicate a disturbance in the redox 
state resulting in a lower cytoplasmic NADH level for the glyceraldehyde- 
3-phosphate dehydrogenase reaction,perhaps through inhibition of the 
malate shuttle system# However,the lactate/pyruvate ratio was elevated 
with phenformin treatment,indicating a higher level of NADH in the 
cytoplasm - so this explanation is not likely to account for the cross­
over between 3~pkosphoglycerate and the triose phosphates#
Toews et al (29) reported a decrease in the conversion of pyruvate to 
CO^ indicating a decreased rate of flux through the Krebs cycle# This was 
associated with an elevation of acetyl CoA and a decrease in citrate, 
isocitrate,2-oxoglutarate,glutamate and malate# They suggested an 
inhibition of the Krebs cycle between acetyl CoA and citrate# Alberti et 
al (24) have shown that phenformin caused an accumulation of three-carbon 
metabolites and decreased concentrations of citrate and 2-oxoglutarate ; 
similar results are reported in this work#
Haekel and Haekel (30) have suggested that pyruvate carboxylation 
could be specifically inhibited by phenformin and this could account for 
the increase in acetyl CoA and the decrease in oxaloacetate and , 
consequently,the decrease in citrate and 2-oxoglutarate# However,they 
reported that phenformin in concentrations up to 0#8mM had no effects on 
pyruvate carboxylase activity in vitro#
Alberti et al (24) have suggested that a change in the malate/ 
oxaloacetate ratio,reflecting a more reduced state in the cell,could 
also explain the fall in citrate and 2-oxoglutarate. The results reported 
in this chapter show a rise in malate and a fall in oxaloacetate levels, 
neither of which were significant# Alberti et al (24) showed a
signii'icant elevation of malate levels in perfused livers with ImM 
phenformin,but this was not significant with 2mM phenforminithey did 
not measure oxaloacetate levels# They suggested that because of the 
shortage of acetyl CoA. acceptor (ie:oxaloacetate) for citrate synthesis, 
the acetyl CoA is diverted into ketone body synthesis and. this explains 
the enhanced ketogenesis seen with biguanides. The results reported in 
this chapter lend some support to the mode of action suggested by Alberti 
et al (24),although the change in the oxaloacetate levels was not 
significant#
Measurements of gluconeogenesis from different substrates (Chapter 5) 
suggested that phenformin might inhibit gluconeogenesis at a step in the 
pathway between pyruvate and fructose-6-phosphate# Although the 
measurement of metabolite levels has provided some evidence for an 
effect of phenformin at the glyceraldehyde-3-phosphate dehydrogenase step, 
there was no evidence to suggest an inhibition of gluconeogenesis in the 
conversion of fructose bisphosphate to fructose-6-phosphate*
The pattern of hepatic metabolites following seven days treatment 
with Wy 23675 differed markedly from that seen with phenformin treatment# 
There was a negative cross-over between malate and phosphoenolpyruvate 
with a reduction in the level of all metabolites from phosphoenolpyruvate 
to glucose# Neither lactate,pyruvate nor oxaloacetate concentration were 
significantly different from the controls,although oxaloacetate was 
elevated by 50% {the extreme lability of oxaloacetate makes precise 
measurement of this metabolite very difficult)#
The cross-over between malate and phosphoenolpyruvate suggests that 
Wy 23675 is inhibiting the enzyme phosphoenolpyruvate carboxykinase 
(PEPCK)# 3-mercaptopicolinate is a known inhibitor of this enzyme 
(13,14,36,37) and cross-over plots obtained by other wotkers with this 
drug (13,14) look similar to that reported here for Wy 23675# The present 
work and that of Goodman (14) do not show an elevation of lactate levels 
as a consequence of inhibition of PEPCK as has been shown with
3-mercaptopicolinate by other workers (13)# The finding that Wy 23675
a. very marked effect on gluconeogenesis when administered in vivo* The 
rise in malate after Wy 23675-treatment was small (132$©) compared with 
results for 3-mercaptopicolinate reported by other workers Ci.e: 908% (13)3 
and this would support the argument that Wy 23673 is not a very effective 
inhibitor of PEPCK.
There was a significant elevation in the levels of citrate following 
Wy 23673-treatment : this was probably a consequence of the inhibition 
of PEPCK-resulting in a greater availability of oxaloacetate for citrate 
as well as malate synthesis.
There was no evidence from the metabolites measured in this ig vivo 
study to suggest that Wy 23675 inhibited gluconeogenesis at the step 
controlled by fructose bisphosphatase and phosphofructokinase 
(cf. Chapter 5)*
The possibility that Wy 23675 could inhibit PEPCK was investigated by 
measurement of the activity of this enzyme dbi vitro. However,the present 
experiment failed to show any direct effect of Wy 23675 on PEPCK,while a 
clear inhibition was shown with 3-mercaptopicolinate. There are several 
possibilities which could explain this negative result-.
Liver metabolite levels were measured in freeze-clamped livers 
following seven days,twice daily,treatment in vivo with Wy 23675 ? &ud it 
may be that chronic exposure of the liver to Wy 23675 is necessary in 
order to see an effect on PEPCK.
There is also the possibility that it is a metabolite of Wy 23675* 
and not Wy 23675 itself,that is having an inhibitory effect on PEPCK.
As it is not a whole-cell preparation that is used for the assay- of 
PEPCK such a metabolite might not be formed in the cytosol - particularly 
in the short incubation period used.
However,it is also quite possible that Wy 23675 has no effect on 
PEPCK. The inhibition of the transport of metabolites in the gluconeogenic
pathway across the mitochondrial membrane can also inhibit gluconeogenesis.
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and n-butylmalonate,which inhibits malate transport (*f3)# The reason 
these compounds are effective inhibitors of gluconeogenesis is because 
pyruvate carboxylase is located within the mitochondrion,while PEPCK is 
located in the cytosol,so that inhibition of pyruvate transport prevents 
pyruvate from reaching pyruvate carboxylase and inhibition of malate 
transport prevents oxaloacetate from leaving the mitochondrion to reach 
PEPCK in the cytosol (oxaloacetate cannot readily cross the mitochondrial 
membrane and,under reduced conditions,is transported into the cytoplasm 
in the form of malate). Inhibition of malate transport could be expected 
to give a similar picture with gluconeogenic metabolite levels to that 
seen with Wy 23675 - namely,an increase din malate and a decrease in 
PEP,giving the appearance of an inhibition of PEPCK, This could provide 
an alternative explanation for the mechanism of Wy 23675-inhibition of 
gluconeogenesis.
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OVERALL DISCUSSION
Wy 23675 is a novel hypoglycaemic agent,which has been shown to 
have a number of different actions,each of which could contribute to 
its ability to lower blood glucose levels jln vivo# These actions 
include the stimulation of insulin release,an insulin-independant 
stimulation of glucose utilization,and an insulin-independant 
inhibition of hepatic gluconeogenesis#
The Relative Importance Of The Insulin-Indeoendant Effects Of Wy 23675 
On Glucose Utilization And Gluconeogenesis#
Wy 23675 has been shown to lower blood glucose levels to a large 
degree in both normal and alloxan-diabetic rats (see Table 7(i)l»so 
it appears that the insulin-independant action of Wy 23675 is significant 
in relation to its overall hypoglycaemic activity# Most of the work 
described in this thesis concerns the insulin-independant hypoglycaemic
actions of Wy 23675*
Wy 23675 has been shown to have insulin-independant effects both 
on glucose utilization and on glucose production and to lower blood 
glucose levels in both normal,fed and fasted rats. However,it is not 
possible to determine the relative contributions of the insulin- 
independant effects of Wy 23675 to the lowering of blood glucose levels 
following oral administration jLn vivo,as insulin release is stimulated 
under these circumstances. It is also difficult to distinguish 
between the relative contributions made by inhibition of glucose 
production and stimulation of glucose utilization to the hypoglycaemic 
action of the drug in the alloxan-diabetic rat,because of the 
exaggerated importance of gluconeogenesis even in the fed animal#
The results in Chapter 2 showed that Wy 23675 caused an increase in 
(^H-2)-glucose uptake from the blood stream and simultaneous measurements 
showed that the decrease in blood glucose levels occurred without a
change in plasma insulin levels in certain animal models. However,
due to the non-steady state conditions,it was not possible to calculate 
the proportion of the fall in blood glucose that was due to increased 
glucose utilization,rather than to inhibition of gluconeogenesis#
Some information on this matter may be gained from a comparison of 
the concentration of Wy 23675 required to affect glucose uptake by 
hemidiaphragm and adipocytes and that required to affect gluconeogenesis 
by hepatocytes in vitro [see Table 7(ii)]. In tissues from the normal,fed 
rat,glucose utilization was significantly increased by Wy 23675 in 
concentrations in the region of 20-200fiM and similar effects were seen 
with tissues from alloxan-diabetic rats# In contrast,the inhibitory 
effects of Wy 23675 on basal rates of gluconeogenesis were not significant 
in hepatocytes from normal rats until a drug concentration of 20mM was 
obtained - some 100-1000 fold higher than the concentration required j
for effects on glucose uptake. This contrasts markedly with glucagon- j
stimulated gluconeogenesis where Wy 23675 caused significant inhibition
at 2nM : this latter effect could provide an explanation for the more j
. 1 I
marked hypoglycaemic effect of Wy 23675 in the normal,starved rat where j
gluconeogenesis is enhanced as compared with the normal,fed rat# However, I
in hepatocytes from alloxan-diabetic rats,Wy 23675 had significant j
inhibitory effects on gluconeogenesis at 20pM - a concentration lower |
than that required for significant effects on glucose utilization in i
tissues from alloxan-diabetic rats# |
If these in vitro findings can be applied to the in vivo situation |
“ f;
(where an estimated in vivo drug concentration following an oral |
iv
hypoglycaemic dose is 10C)uM),then they suggest that,in the normal fed |
rat,Wy 23675 owes its insulin-independant hypoglycaemic activity primarily, 
to stimulation of glucose utilization with little,if any,part being 
played by inhibition of gluconeogenesis# In the alloxan-diabetic rat, 
inhibition of gluconeogenesis would appear to contribute to a much |
f
greater extent to the hypoglycaemic activity of Wy 236?5 along with the j
increase in glucose utilization. However,the maximal inhibition of I
gluconeogenesis is approximately while the maximal increase in
glucose utilization is in the region of 100-120%, so that in the alloxan- 
diabetic rat,as well as in the normal rat,a major part of the hypoglycaemic 
activity of Wy 23675 may well be attributable to stimulation of glucose 
utilization.
Wy 23675 has been compared in this thesis with the sulphonylurea, 
tolbutamide,and the biguanide,phenformin. It is clear from the results 
obtained that,as anticipated,tolbutamide is acting by stimulation of 
insulin release with a consequent increase in glucose utilization and 
decrease in elevated rates of gluconeogenesis.
The Relative Importance Of The Effects Of Phenformin On Glucose Utilization 
And On Gluconeogenesis.
Phenformin has been shown to stimulate glucose utilization and to 
decrease gluconeogenesis independant of insulin release. It has.also been 
shown to lower blood glucose levels in fasted,normal rats,but to have no 
effect in fed,normal rats Csee Table 7(iii)3« The major difference 
between these two situations is the elevated rate of gluconeogenesis in 
the fasted rat,which suggests that inhibition of gluconeogenesis by
phenformin is the mechanism by which it lowers blood glucose levels under |
I
these circumstances. Phenformin also lowered blood glucose levels in the J
glucose-loaded and alloxan-diabetic rats CTable 7(iii)]# The glucose- I
: I.
loaded rat has elevated blood glucose levels and reduced rates of f
gluconeogenesis,which suggests that phenformin has significant effects |
on glucose utilization in situations where blood glucose levels are |
■ .. ■ I
elevated. The ability of phenformin to lower blood glucose levels in the
alloxan-diabetic rat may thus be a combination of stimulation of glucose
utilization and inhibition of gluconeogenesis*
A comparison of the concentration of phenformin required to produce
different effects in vitro may shed further light on the relative |
importance of glucose utilization and gluconeogenesis in the normal |
and alloxan-diabetic rat [see Table 7(iv)J. There were no sienifican-b ' j
effects on "basal rates of either gluconeogenesis or glucose utilization 
in isolated tissues from normal rats until concentrations of phenformin 
in the region of 0,2-2mM were attained • these concentrations are well 
above those obtained with therapeutic administration of the drug {1-iOjiM.
However,phenformin significantly inhibited gluconeogenesis that 
was stimulated by glucagon in hepatocytes from normal rats in 
concentrations as low as 2pM - this effect could explain its significant 
hypoglycaemic activity in the fasted rat,while being inactive in the 
fed animal* A similar effect was seen with Wy 23675 and suggests that 
enhanced rates of gluconeogenesis are far more sensitive to the actions 
of these drugs than basal rates*
Mechanism Of Action Of Phenformin And Wy 23675 On Glucose Utilization*
For the reasons already discussed,it is proposed that a major part of 
the hypoglycaemic action of Wy 23675 is due to its effects on glucose 
utilization* This differs from the findings for phenformin,which suggest 
that inhibition of enhanced rates of gluconeogenesis may be of greater 
importance,although effects of phenformin on glucose utilization were 
observed in the alloxan-diabetic rat.
The mechanisms by which these drugs exert their effects on glucose 
utilization remain unclear* The possibility that biguanides reduce the 
negative feed-back of glucose-6-phosphate on hexokinase,which occurs 
in diabetes due to excessive oxidation of fatty acids by muscle,has been 
proposed by Frayn and Adnitt (2), They have suggested that biguanides 
increase the rate of removal of glucose-6-phosphate by increasing 
glycogen synthesis. However,the results reported in this thesis show 
a decrease in glycogen synthesis.
There is a reduction in the membrane transport of glucose in muscles 
from diabetic animals (3-6),so it is possible that biguanides could 
increase glucose utilization by increasing glucose transport. However, 
this seems very unlikely as it well established that biguanides inhibit 
glucose transport across the intestine (7— 0^),
Glycolytic flux is believed to be controlled primarily at the level 
of phosphofructokinase (11) and this enzyme is activated by a decreased 
level of ATP and increased levels of fructose bisphosphate and AMP (12). 
Biguanides have been shown to inhibit mitochondrial respiration and 
oxidative phosphorylation (13,12*,for further references,see Introduction), 
resulting in a reduction in ATP and an increase in AMP (see also results 
reported in Chapter 6). Thus,biguanides could increase glycolytic flux 
(and, eons equently,glucose_uti3d.zation) by changing the ATP/AMP ratio.
Wy 23675 has been shown to increase glucose utilization by muscle 
without a subsequent increase in lactate output (Chapter 3) and also to 
increase glucose incorporation into adipocyte lipids (Chapter *f). It has 
been proposed that activation of pyruvate dehydrogenase could account for 
these observations. However,there was no evidence that Wy 23675 activated 
pyruvate dehydrogenase in the liver (see Chapter 5,discussion),although 
there was evidence for an inhibition of gluconeogenesis without a 
subsequent elevation in blood lactate levels (see Chapter 6). No direct 
measurements of the effect of Wy 23675 on pyruvate dehydrogenase have 
been made,so it is not possible to eliminate activation of this enzyme 
as a mechanism involved in the stimulation of glucose utilization.
It is possible Wy 23675 stimulates glucose utilization by increasing 
glucose transport into the cell,but this could not explain the apparent 
increase in aerobic glycolysis unless pyruvate dehydrogenase was also 
activated.
Mechanisms Of Action Of Phenformin And Wy 23675 On Gluconeogenesis.
Both phenformin and Wy 23675 have also been shown to inhibit 
gluconeogenesis (see Chapter 5) ? and to a greater extent in the liver 
of alloxan-diabetic rats than in normal rats. Studies of liver metabolite 
levels following in vivo treatment with phenformin and Wy 23675 (see 
Chapter 6) provided some evidence for their mechanisms of action.
Phenformin—treatment resulted in a reduction in the ATP/ADP ratio 
and a more reduced state in the cell,suggesting that it was inhibiting
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gluconeogenesis,under the conditions employed in this study,by inhibiting 
mitochondrial respiration and oxidative phosphorylation# Other workers 
(15-17) have shown effects of phenformin on gluconeogenesis independant 
of any effect on oxidative phosphorylation : Schafer (18) and Davidoff (19) 
have proposed mechanisms to explain such an inhibition by the biguanides 
(these theories are discussed in the Introduction to this thesis)#
Wy 25675 has been shown to inhibit gluconeogenesis independant of 
any effects on oxidative phosphorylation (see Chapter 6) and a proposed 
mechanism of action is by inhibition of the enzyme phosphoenolpyruvate 
carboxykinase# However,direct inhibition of the enzyme in vitro by the 
drug was not demonstrated (see Chapter 6)#
Summary#
In summary,Wy 23675 has a hypoglycaemic action which contains an 
insulin-independant component. This component involves both stimulation 
of glucose utilization and inhibition of gluconeogenesis# It is proposed 
that the effects of Wy 23675 on glucose utilization make up the most 
significant part of its insulin-independant hypoglycaemic action and that 
this effect may be mediated by activation of pyruvate dehydrogenase. It 
is also proposed that Wy 23675 inhibits gluconeogenesis at a point in 
the pathway between malate and phosphoenolpyruvate,possibly by inhibiting 
the enzyme phosphoenolpyruvate carboxykinase. Further work is required 
to elucidate the mechanisms involved in these actions.
,  wv r t o a j j u  l i x o u u j o  x u h  ,
Table No. Title
7(i) Effects of Wy 23675 on Blood Glucose Levels in 24-hr Fasted,
Fed,Glucose-Loaded and Alloxan-Diabetic Rats.
7(ii) Comparison of the Concentrations of Wy 23675 Required to
Produce 'In Vitro1 Effects on Glucose Metabolism 
7 (Hi) Effects of Phenformin on Blood Glucose Levels in 2*f-hr Fasted,
Fed,Glucose-Loaded and Alloxan-Diabetic Rats.
7(iv) Comparison of the Concentration of Phenformin Required to
Produce 'In Vitro* Effects on Glucose Metabolism.
♦Table 7(i).
♦ EFFECTS OF WY 23675 ON BLOOD GLUCOSE LEVELS IN 2^-HR FASTED,FED,GLUCOSE-
LOADED AND ALLOXAN-DIABETIC RATS,
For details of methods and data,see Table 1,Chapter 1#
Animal
Treatment
% Change in Blood Glucose Levels Due to Wy 23675 (O#2mmol/kg 
p#o#) Relative to Control at the Following Times:-
1 hr 2 hr 3 hr
2^-hr
Fasted
Rats
-51%*** -86%*** -73%***
Fed
Rats -27%*** -kk%*** -3b%***
Glucose-
Loaded
Rats
-39%** -73%*** -37%***
Alloxan-
Diabetic
Rats
-30%* -60%** -37%*
Statistical significance was determined by Student*s t-Test: 
* p<0.05 ? ** P<0.01 ; *** p<0.001
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♦Table 7(ii)#
♦ COMPARISON OF THE CONCENTRATIONS OF WY 23675 REQUIRED TO PRODUCE »IN 
VITRO* EFFECTS ON GLUCOSE METABOLISM,
For details of methods and data,see Chapters and 5*
Animal
Treatment
VJy 23675 
Concentration
% Change in Glucose 
, Utilization by:-
% Change in Gluconeogenesis 
from:-
Hemi-
Diaphragm
Adipocyte I/P L/P/G
Normal 2fiM mm - - -6*f%* * *
Rat 20pM +13% +37%*** - -75%***
200pM +ko%* +172%*** -12% -80%***
2mM +97%*** +206%*** -22% -88%***
20mM - • - -55%* * -
Alloxan- 2jiM - - -29% -
Diabetic 20jiM +21% +28% -k9%** -
Rat 200jnM +85%** +9^%*** -58%** ' -
2mM +11*f%** +12k%*** - \
where I/P = 10mM lactate plus 1mM pyruvate
l/P/G = 10niM lactate plus 1mM pyruvate stimulated by 50nM glucagon
Statistical significance was determined by Student’s t-Test:
* p<0#05 ? ** p<0.01 ; *** p<0#001
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.Table 7(iii)*
.EFFECTS OF PHENFORMIN ON BLOOD GLUCOSE LEVELS IN 2*f-HR FAS TED, F5D. GLUCOSE-
LOADED AND ALLOXAN-DIABETIC RATS.—     —  - -   —
For details of methods and data,see Table 1,Chapter 1.
Animal
Treatment
% Change in Blood Glucose Levels Due to Phenformin (0.2mmol/kg 
p.o#) Relative to Control at the Folloi'ring Times
1 hr 2 hr 3 hr
2*f-hr
Fasted
Fats
-27%* * -20% -25%**
Fed
Rats
-k% -5% -12%
Glueose-
Loaded
Rats
-k5% -50%** -15%
Alloxan-
Diabetic
Rats
-28%* -35%* -18%
Statistical significance was determined by Student*s t-Test:
* P<0 .05 ; ** p<0.01 ; *** p<0.001
♦Table 7Civ)*
♦ COMPARISON OF THE CONCENTRATIONS OF PHENFORMIN REQUIRED TO PRODUCE «IN 
VITRO*EFFECTS ON GLUCOSE METABOLISM.
I
For details of methods and data,see Chapters 3*^ and 3# (
i
Animal
Treatment
Phenformin
Concentration
% Change in Glucose 
■Utilization by:-
% Change in Gluconeogenesis 
from:-
Hemi- 
Diaphragm
Adipocyte L/P I/P/G
Normal 2|aM -10% - - -4-7%**
Rat 20pM +2% - - -61%***
200|iM +35%** +8% -7% -66%***
2mM +67%*** -27%* -68%***
20raM - ' +11 h%* * * -62%*** -
Alloxan- 2p.M +21% -12% -
Diabetic 20pM +53%* +23% -if3%* -
Rat 200pM +73%** -**% -57%** -
2mM - +69%* - -
where I/P = 10mM lactate plus 1mM pyruvate 1
 .■ ; |
I/P/G = 10mM lactate plus 1mM pyruvate stimulated by 50nM glucagon
Statistical significance was determined by Student’s t-Test: |
* p<0.05 ; ** P<0.01 ; *** p<0.001 |
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